Ionizable cationic lipids and lipid nanoparticles
By adding ionizable cationic lipids and other lipid components to lipid nanoparticles, combined with targeting technology, the rapid removal and toxicity of lipid nanoparticles in the prior art are solved, and the delivery efficiency of nucleic acids is improved. Targeting, achieving more efficient intracellular release.
Patent Information
- Application Number
- CN202380032174.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-03-09
- Filing Date
- 2023-04-05
- Publication Date
- 2024-11-22
AI Technical Summary
Existing lipid preparations have problems with rapid clearance, tendency and toxicity to the lungs when used in vivo, and it is difficult to control which tissues or cells absorb lipid nanoparticles (LNPs), resulting in low nucleic acid delivery efficiency, only 2-5%. RNA can be successfully released into the cytoplasm.
Lipid nanoparticles (LNPs) containing ionizable cationic lipids were developed by adding components such as phospholipids, sterols, colipids and PEG-lipids to the LNPs and utilizing functionalized PEG-lipids to bind Partially conjugated, targeted LNP (tLNP) was prepared to improve the delivery efficiency of nucleic acids and intracellular release rate.
It significantly improves the delivery efficiency of nucleic acids, increases the orientation ability to target tissues or cells, reduces liver uptake, reduces the toxicity of lipid components, and improves the release rate of nucleic acids in the cytoplasm.
Smart Images

Figure CN119013250A_ABST
Abstract
Description
[0001] Related Applications
[0002] This application claims priority to U.S. Provisional Patent Application No. 63 / 489,381 filed on March 9, 2023, U.S. Provisional Patent Application No. 63 / 366,462 filed on June 15, 2022, and U.S. Provisional Patent Application No. 63 / 362,501 filed on April 5, 2022, the entire contents of each of which are incorporated herein by reference. Background Art
[0003] Lipid formulations have been used in the laboratory to deliver nucleic acids into cells. Early formulations based on the cationic lipid 1,2-dioleoyl-3-trimethylammonium propane (DOTAP) and the ionizable fusogenic lipid dioleoylphosphatidylethanolamine (DOPE) had large particle sizes and were problematic when used in vivo, exhibiting too rapid clearance, tropism for the lungs, and toxicity. Lipid nanoparticles (LNPs) containing ionizable cationic lipids have been developed to address these issues, achieving RNA-based products such as siRNA. and two mRNA-based SARS-CoV-2 vaccines have received regulatory approval and entered the market. Once administered, the ability to control which tissues or cells absorb LNPs is limited. Depending on the significant degree of net charge and particle size, intravenously administered LNPs are mainly absorbed in the liver, lungs, or spleen. >90% of LNPs can be directed to the liver by a combination of formulation and intravenous administration. Intramuscular administration can provide clinically useful local delivery and expression levels. By conjugating a binding moiety specific to the target tissue or cell type to the LNP, the LNP can be redirected to other tissues or cell types, for example, a polypeptide containing an antigen binding domain from an antibody is conjugated to the LNP. Nevertheless, avoiding liver uptake remains a challenge. In addition, using current systems, only a very small portion of the encapsulated nucleic acid is successfully delivered to the target cell and enters the cytoplasm. Current formulations can only release 2-5% of the administered RNA into the cytoplasm (see, e.g., Gilleron et al., Nat. Biotechnol. 31: 638-646, 2013, and Munson et al., Commun. Biol. 4: 211-224, 2021). Therefore, there are still problems of off-target delivery, low efficiency of nucleic acid release into the cytoplasm, and toxicity associated with component lipid accumulation.
[0004] Thus, the present disclosure provides ionizable lipids and lipid nanoparticles to meet the urgent needs in the art. Summary of the invention
[0005] Certain aspects of the present disclosure relate to ionizable cationic lipids having a structure selected from Formula 1, Formula 2, and Formula 3.
[0006] Other aspects of the present disclosure relate to lipid nanoparticles (LNPs), each comprising one or more ionizable cationic lipids and independently having a structure selected from Formula 1, Formula 2, and Formula 3. In certain embodiments, the LNP may further comprise one or more of a phospholipid, a sterol, a co-lipid, a PEG-lipid, or a combination thereof. Examples of the phospholipids include, but are not limited to, dioleoylphosphatidylethanolamine (DOPE), dimyristoylphosphatidylcholine (DMPC), distearoylphosphatidylcholine (DSPC), dimyristoylphosphatidylglycerol (DMPG), dipalmitoylphosphatidylcholine (DPPC), 1,2-arachidylphosphatidylcholine (DAPC), and combinations thereof. Examples of the sterols include, but are not limited to, cholesterol, campesterol, sitosterol, stigmasterol, and combinations thereof. Examples of the co-lipids include, but are not limited to, cholesterol hemisuccinate (CHEMS) and lipids containing quaternary ammonium head groups. Examples of lipids containing quaternary ammonium head groups include, but are not limited to, 1,2-dioleoyl-3-trimethylammonium propane (DOTAP), N-(1-(2,3-dioleoyloxy)propyl)-N,N,N-trimethylammonium (DOTMA), 3β-(N-(N',N'-dimethylaminoethane)carbamoyl)cholesterol (DC-Chol), and combinations thereof. Examples of PEG-lipids may include PEG moieties having a molecular weight (MW) of 1000-5000 Da, and / or PEG moieties having C 14 -C 18Examples of the PEG-lipid include, but are not limited to, DMG-PEG2000 (1,2-dimyristoyl-glycerol-3-methoxypolyethylene glycol-2000), DPG-PEG2000 (1,2-dipalmitoyl-glycerol-3-methoxypolyethylene glycol-2000), DSG-PEG2000 (1,2-distearoyl-glycerol-3-methoxypolyethylene glycol-2000), DOG-PEG2000 (1,2-dioleoyl-glycerol-3-methoxypolyethylene glycol-2000), DMPE-PEG2000 (1,2-dioleoyl-glycerol-3-methoxypolyethylene glycol-2000), and PEG-2000 (1,2-dioleoyl-glycerol-3-methoxypolyethylene glycol-2000). (1,2-dimyristoyl-glycero-3-phosphoethanolamine-3-methoxypolyethylene glycol-2000), DPPE-PEG2000 (1,2-dipalmitoyl-glycero-3-phosphoethanolamine-3-methoxypolyethylene glycol-2000), DSPE-PEG2000 (1,2-distearoyl-glycero-3-phosphoethanolamine-3-methoxypolyethylene glycol-2000), DOPE-PEG2000 (1,2-dioleoyl-glycero-3-phosphoethanolamine-3-methoxypolyethylene glycol-2000) and combinations thereof. In certain embodiments, the PEG-lipid comprises an optically pure glycerol portion. In certain embodiments, the LNP further comprises a functionalized PEG-lipid. In certain embodiments, the LNP of embodiment 28, wherein the functionalized PEG-lipid has been conjugated to a binding moiety (e.g., an antibody). In certain embodiments, the functionalized PEG-lipid comprises a C 16 -C 18 In certain embodiments, the functionalized PEG-lipid comprises a dipalmitoyl lipid or a distearoyl lipid.
[0007] In certain embodiments, the LNP comprises 40 to 60 mol% of ionizable cationic lipids. In certain embodiments, the LNP comprises 7 to 30 mol% of phospholipids. In certain embodiments, the LNP comprises 20 to 45 mol% of sterols. In certain embodiments, the LNP comprises 1 to 30 mol% of co-lipids. In certain embodiments, the LNP comprises 0 to 5 mol% of PEG-lipids. In certain embodiments, the LNP comprises 0.1 to 5 mol% of functionalized PEG-lipids.
[0008] In certain embodiments, the LNP further comprises a nucleic acid (e.g., mRNA). In certain embodiments, the weight ratio of total lipid to nucleic acid is 10:1 to 50:1.
[0009] Other aspects of the disclosure relate to methods of delivering a nucleic acid into a cell, comprising contacting the cell with one or more LNPs disclosed herein, wherein at least some of the LNPs comprise a nucleic acid. BRIEF DESCRIPTION OF THE DRAWINGS
[0010] Figures 1A to 1F A synthetic scheme for compounds having the structure of Formula 1 is described. Figure 1A The synthesis starting from readily available reagents via the intermediate I-fA is shown. Figure 1B The synthetic route from intermediate I-fA to compounds having the structure of Formula 1, Y=O, NH or N-CH3 is shown. Figure 1C The synthetic route from intermediate I-fA to the compound having the structure of Formula 1, Y=CH2 is shown. Unless otherwise indicated, all substituents are the same as defined in Formula 1. Specifically, Figure 1D The synthesis of intermediates Ic, Id, Ie and If are shown, which are embodiments of formula I-cA, I-dA, I-eA and I-fA, respectively, wherein p is 1, n is 1, and R is a C9 alkyl straight chain. Figure 1E A synthetic route from intermediate If to compound A-1 to compound A-3 is shown, wherein compound A-1 to compound A-3 are embodiments of formula 1 with Y=O, NH and N-CH3, respectively, wherein p is 1, n is 1, X is N(Me)2, and R is a C9 alkyl straight chain. Figure 1F A synthetic route from intermediate If to compound A-4 is shown, which is an embodiment of Formula 1 with Y=CH2, wherein p is 1, n is 1, X is N(Me)2, and R is a C9 alkyl straight chain.
[0011] FIG. 2A to FIG. 2F A synthetic scheme for compounds having the structure of Formula 2 is described. Figure 2A The synthesis starting from readily available reagents via intermediate II-hA is shown. Figure 2B The synthetic route from intermediate II-hA to compounds having the structure of Formula 2, Y=O, NH or N-CH3 is shown. Figure 2F The synthetic route from intermediate II-hA to the compound having the structure of Formula 2, Y=CH2 is shown. Unless otherwise indicated, all substituents are the same as defined in Formula 2. Specifically, Figure 2D The synthesis of intermediates II-c, II-d, II-e, II-f, II-g and II-h are shown, which are embodiments of formula II-cA, II-dA, II-eA, II-fA, II-gA and II-hA, respectively, wherein p is 1, n is 1, and R is a C9 alkyl straight chain when applicable. Figure 2E A synthetic route from intermediate II-h to compound A-5 to compound A-7 is shown, wherein compound A-5 to compound A-7 are embodiments of formula 2 with Y=O, NH and N-CH3, respectively, wherein p is 1, n is 1, and R is a C9 alkyl straight chain. Figure 2F A synthetic route from intermediate II-g to compound A-8 is shown, which is an embodiment of formula 2 with Y=CH2, wherein p is 1, n is 1, and R is a C9 alkyl straight chain.
[0012] FIG. 3A to FIG. 3D A synthetic scheme for compounds having the structure of Formula 3 is described. Figure 3A The synthesis of compounds having the structure of formula 3, W=C=O, starting from readily available reagents is shown. Figure 3D The synthetic route from intermediate III-cA to the compound having the structure of Formula 3, W=CH2 is shown. Unless otherwise specified, all substituents are the same as defined in Formula 3. Figure 3C The synthesis of intermediates III-a, III-b, III-c and compound A-9 starting from readily available reagents is shown, which are embodiments of formula III-aA, III-bA, III-cA and formula 3, respectively, wherein p is 1, n is 2, and when applicable R c It is a C9 alkyl straight chain. Figure 3D The synthetic routes from intermediate III-c to intermediates III-d, III-e, III-f and compound A-10 are shown, which are III-dA, III-eA, III-fA and embodiments of formula 3 with W=CH2, wherein p is 1, n is 2, and R c It is a C9 alkyl straight chain.
[0013] FIG. 4A to FIG. 4B Synthetic protocols for reagents that can be used to prepare polyethylene glycol-containing lipid head groups are described. Figure 4A The synthesis of an embodiment of XR125 wherein m is 2 and o is 3 is described (see Table 3). Figure 4B The synthesis of an embodiment of XR126 wherein o is 3 is described (see Table 3).
[0014] FIG. 5A to FIG. 5C Depicted are the viability (5A), transfection frequency (5B), and expression level (5C) as the geometric mean fluorescence intensity (gMFI) of transfected cells of HEK293F cells transfected with mCherry mRNA encapsulated in LNPs, wherein the ionizable cationic lipid is one of compounds A-2, A-11, A-12, A-13, A-14, or A-15.
[0015] Figure 6Described is the expression frequency and level of mCherry mRNA in mouse splenic T cells transfected in vitro by CD5-targeted lipid nanoparticles incorporating the indicated ionizable cationic lipids A-2, A-11, A-12, A-13, A-14 and A-15, respectively, as determined by flow cytometry. The expression level is expressed as the mean fluorescence intensity (MFI; geometric mean) of the positive peaks in the flow cytometry histogram, and the transfection rate is CD3 + The proportion of cells in the positive peak. *: 10a, 10f and 10p are described in Journal of Medicinal Chemistry 63:12992-13012,2020.
[0016] Figure 7 Described is the expression frequency and level of mCherry mRNA in mouse splenic T cells transfected in vivo by CD5-targeted lipid nanoparticles incorporating the indicated ionizable cationic lipids A-2, A-11, A-12, A-13, A-14 and A-15, respectively, as determined by flow cytometry. Expression levels are expressed as the mean fluorescence intensity (MFI; geometric mean) of positive peaks in the flow cytometry histogram, and transfection efficiency is CD3 + The proportion of cells in the positive peak. *: 10a, 10f and 10p are described in Journal of Medicinal Chemistry 63:12992-13012,2020.
[0017] Figure 8 A conceptual biodegradation scheme for compound A-11 (above the line) and the starting compounds and final products of biodegradation (below the line) are described. The disclosed ionizable cationic lipids, and in particular the compounds of Formula 1, can be biodegraded according to this conceptual scheme without being limited to any particular theory. DETAILED DESCRIPTION
[0018] The present disclosure provides ionizable cationic lipids, methods for synthesizing them, and intermediates and methods for synthesizing intermediates that can be used to synthesize these lipids. The present disclosure provides ionizable cationic lipids of the present disclosure as components of lipid nanoparticles (LNPs), which can be used to deliver nucleic acids to cells in vivo or in vitro. LNP compositions are also disclosed herein, including LNPs comprising functionalized PEG-lipids, so that a binding moiety can be conjugated to produce a target LNP (tLNP), i.e., an LNP containing a binding moiety that directs the tLNP to a desired tissue or cell type. A method for delivering nucleic acids to a cell is also disclosed herein, including contacting a cell with an LNP or tLNP of the present disclosure.
[0019] Before describing the present disclosure in more detail, it may be helpful to provide abbreviations and definitions of certain terms to be used herein. Additional definitions are set forth in the present disclosure.
[0020] abbreviation
[0021] Abbreviations used in this article include:
[0022] BF3-OEt2-boron trifluoride etherate
[0023] BOC-tert-Butyloxycarbonyl
[0024] CDI-Carbonyldiimidazole
[0025] cLogD - calculated LogD
[0026] clogP - calculated LogP (partition coefficient)
[0027] c-pKa - calculated pKa
[0028] DMF-Dimethylformamide
[0029] DMAP-4-dimethylaminopyridine
[0030] EDC-HCl-1-Ethyl-3-(3'-dimethylaminopropyl)carbodiimide·HCl
[0031] Et3N–triethylamine
[0032] MeOH - methanol
[0033] MeOTf-Methyl trifluoromethanesulfonate
[0034] Pd / C-palladium carbon
[0035] PEG-Polyethylene glycol
[0036] PPTs-Pyridinium p-toluenesulfonate
[0037] TFA-Trifluoroacetic acid
[0038] definition
[0039] As used in the specification and claims, the singular forms "a", "an", and "the" include plural references unless the context clearly dictates otherwise. It should be understood that the terms "a" and "an" as used herein refer to "one or more" of the listed components.
[0040] The use of alternatives (eg, "or") should be understood to mean one, both, or any combination of the alternatives.
[0041] As used herein, the term "about" in the context of a number refers to a range centered around that number and spanning less than 15% and greater than 15% of that number. The term "about" used in the context of a range refers to an extended range spanning less than 15% of the lowest number listed in the range and greater than 15% of the highest number listed in the range.
[0042] Throughout this disclosure, unless otherwise indicated, any concentration range, percentage range, ratio range, or integer range is understood to include the value of any integer within the range, and, where appropriate, fractions thereof (e.g., tenths and hundredths of integers). In addition, unless otherwise indicated, any numerical range of the present disclosure relating to any physical characteristic (e.g., polymer subunits, size, or thickness) is understood to include any integer within the range. Throughout this disclosure, unless otherwise specifically stated, numerical ranges include their recited endpoints.
[0043] Unless the context requires otherwise, throughout this specification and claims, the wording "comprise" and variations thereof (e.g., "comprises" and "comprising") should be interpreted in an open, inclusive sense, i.e., as "including, but not limited to." As used herein, the terms "include" and "comprises" are used synonymously.
[0044] The phrase "at least one of" when following a list of items or elements refers to an open-ended set of one or more elements in the list, which may, but does not necessarily, include more than one element.
[0045] As used herein, "derivative" refers to a chemically or biologically modified form of a compound that is structurally similar to a parent compound and (actually or theoretically) derivable from the parent compound. Generally, the difference between a "derivative" and an "analog" is that the parent compound can be the starting material for producing the "derivative", but the parent compound may not necessarily be used as the starting material for producing the "analog". A derivative may have chemical or physical properties different from the parent compound. For example, a derivative may be more hydrophilic or hydrophobic, or it may have altered reactivity compared to the parent compound.
[0046] Alkyl refers to a saturated hydrocarbon portion, i.e. an alkane lacking a hydrogen and leaving a bond connected to another portion of an organic molecule. In some embodiments, the hydrogen is unsubstituted. In other embodiments, one or more hydrogens in the alkyl group may be substituted by the same or different substituents.
[0047] Alkenyl refers to a hydrocarbon moiety having one or more carbon-carbon double bonds but otherwise being saturated. In some embodiments, hydrogen is unsubstituted. In other embodiments, one or more hydrogens in the alkenyl group may be substituted by the same or different substituents.
[0048] Alkynoic acid refers to a carboxylic acid moiety comprising one or more carbon-carbon triple bonds. In some embodiments, hydrogen is unsubstituted. In other embodiments, one or more hydrogens in the alkynoic acid group may be substituted by the same or different substituents.
[0049] Amides refer to carboxylic acid derivatives comprising a carbonyl group of a carboxylic acid bonded to an amine moiety.
[0050] Aryl refers to an aromatic or heteroaromatic ring lacking one hydrogen and leaving a bond to another part of an organic molecule. Examples of aryl include, but are not limited to, phenyl, naphthyl, pyridine, pyrimidine, pyrazine, pyrrole, furan, thiophene, imidazole, thiazole, oxazole, etc.
[0051] Aryl-alkyl refers to a moiety comprising one or more aryl rings and one or more alkyl moieties. The position of the one or more aryl rings can vary within the alkyl portion of the moiety. For example, the one or more aryl rings can be at the end of the one or more alkyl moieties, fused to the carbon chain of the one or more alkyl moieties, or replace one or more hydrogens in the one or more alkyl moieties; and the one or more alkyl moieties can replace one or more hydrogens in the one or more aryl rings. In some embodiments, there is a single ring; while in other embodiments, they are multiple rings.
[0052] Branched alkyl is a saturated alkyl moiety in which the alkyl group is not a straight chain. Alkyl moieties such as methyl, ethyl, propyl, butyl, etc. can be attached to the main alkyl chain at variable positions. In some embodiments, there is a single branch; while in other embodiments, there are multiple branches.
[0053] Branched alkenyl refers to an alkenyl group containing at least one branch branching from the main chain, which can be formed by replacing one or more hydrogens in the main chain with the same or different alkyl groups (for example, but not limited to methyl, ethyl, propyl, butyl, etc.). In some embodiments, the branched alkenyl is a single branched structure, while in other embodiments, the branched alkenyl may have multiple branches.
[0054] Straight chain alkyl groups are unbranched, non-cyclic versions of the alkyl moieties described above.
[0055] Straight chain alkenyl is an unbranched, non-cyclic version of the alkenyl moieties described above.
[0056] Cycloalkyl refers to a portion of a cycloalkyl ring of 3 to 12 carbons. In some embodiments, the cycloalkyl is a single ring structure; while in other embodiments, the cycloalkyl can have multiple rings.
[0057] Cycloalkyl-alkyl refers to a moiety containing one or more cycloalkyl rings of 3 to 12 carbons and one or more alkyl moieties. The position of the cycloalkyl rings can vary within the alkyl portion of the moiety. For example, one or more cycloalkyl rings can be at the end of one or more alkyl moieties, fused to the carbon chain of one or more alkyl moieties, or replace one or more hydrogens in one or more alkyl moieties; and the one or more alkyl moieties can replace one or more hydrogens in one or more cycloalkyl rings. In some embodiments, the cycloalkyl ring is a monocyclic structure; while in other embodiments, the cycloalkyl-alkyl can have multiple rings.
[0058] Ester refers to a carboxylic acid derivative comprising a carbonyl group bonded to an alkoxy group to form an ester bond -C(=O)-O-.
[0059] Ether refers to an oxygen atom attached to 2 identical or different carbonyl moieties.
[0060] The head group refers to the hydrophilic or polar portion of the lipid.
[0061] Imide refers to a moiety containing a nitrogen bond to two carbonyl groups.
[0062] Sterol refers to a subgroup of steroids containing at least one hydroxyl (OH) group. Examples of sterols include, but are not limited to, cholesterol, ergosterol, β-sitosterol, stigmasterol, stigmasterol, 20-hydroxycholesterol, 22-hydroxycholesterol, and the like.
[0063] Ionizable cationic lipids
[0064] Disclose ionizable cationic lipids, used as components of lipid nanoparticles for delivering nucleic acid (including DNA, mRNA or siRNA) to cells.Ionizable cationic lipids have c-pKa of 8 to 11 and cLogD of 9 to 18 or 11 to 14.These ranges can cause the pKa measured in LNP or tLNP to be 6 to 7, thereby promoting ionization in endosomes.In some embodiments, slightly larger alkalinity may be required, and ionizable cationic lipids with c-pKa and cLogD in the range may be obtained.In some embodiments, c-pKa is about 8, about 9, about 10 or about 11, or in the range of any one pair of limits defined by these values.In some embodiments, cLogD is about 9, about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, or in the range of any one pair of limits defined by these values.
[0065] In certain aspects, the ionizable cationic lipid has the structure of Formula 1,
[0066]
[0067] wherein Y is O, NH, N-CH3 or CH2,
[0068] n is an integer from 0 to 4,
[0069] X is
[0070]
[0071] m is an integer from 1 to 3,
[0072] o is an integer from 1 to 4,
[0073] p is an integer from 1 to 4,
[0074] When p=1, each R is independently C6 to C 16 Straight chain alkyl; C6 to C 16 Branched alkyl; C6 to C 16 Straight chain alkenyl; C6 to C 16 Branched alkenyl; C9 to C 16 Cycloalkyl-alkyl, wherein the cycloalkyl is a C3 to C8 cycloalkyl located at the end of the alkyl chain or within the alkyl chain; or a C8 to C 18 Aryl-alkyl, wherein the aryl group is phenyl or naphthyl and is located at the end of the alkyl chain or within the alkyl chain,
[0075] When p=2, each R is independently C6 to C 14 Straight chain alkyl; C6 to C 14 Straight chain alkenyl; C6 to C 14 Branched alkyl; C6 to C 14 Branched alkenyl; C9 to C 14 Cycloalkyl-alkyl, wherein the cycloalkyl is a C3 to C8 cycloalkyl located at the end of the alkyl chain or within the alkyl chain; or a C8 to C 16 Aryl-alkyl, wherein the aryl group is phenyl or naphthyl and is located at the end of the alkyl chain or within the alkyl chain,
[0076] When p=3, each R is independently C6 to C 12 Straight chain alkyl; C6 to C 12 Straight chain alkenyl; C6 to C 12 Branched alkyl; C6 to C 12 Branched alkenyl; C9 to C 12 Cycloalkyl-alkyl, wherein the cycloalkyl is a C3 to C8 cycloalkyl located at the end of the alkyl chain or within the alkyl chain; or a C8 to C 14Aryl-alkyl, wherein the aryl group is phenyl or naphthyl and is located at the end of the alkyl chain or within the alkyl chain, and
[0077] When p=4, each R is independently C6 to C 10 Straight chain alkyl; C6 to C 10 Straight chain alkenyl; C6 to C 10 Branched alkyl; C6 to C 10 Branched alkenyl; C9 to C 10 Cycloalkyl-alkyl, wherein the cycloalkyl is a C3 to C8 cycloalkyl located at the end of the alkyl or within the alkyl; or a C8 to C 12 Aryl-alkyl, wherein the aryl group is phenyl or naphthyl and is located at the end of the alkyl chain or within the alkyl chain.
[0078] Some embodiments specifically include one or more species or subgenera based on specific selections of R, X, Y, m, n, o, p and / or carbon chain length, structure or saturation. Other embodiments specifically exclude one or more species or subgenera based on specific selections of R, X, Y, m, n, o, p and / or carbon chain length, structure or saturation. In some embodiments, when p is 1, each R is independently C8 to C 12 , C 13 or C 14 Straight chain alkyl. In some embodiments, each R from the nearest common branch point is the same. In some embodiments, each R is the same.
[0079] In some embodiments, the ionizable cationic lipid has the structure of Formula 1a
[0080]
[0081] Where each R is independently C6 to C 16 Straight chain alkyl; C6 to C 16 Straight chain alkenyl; C6 to C 16 Branched alkyl; C6 to C 16 Branched alkenyl; C9 to C 16 Cycloalkyl-alkyl, wherein the cycloalkyl is a C3 to C8 cycloalkyl located at the end of the alkyl chain or within the alkyl chain; or a C8 to C 18 Aryl-alkyl, wherein the aryl group is phenyl or naphthyl and is located at the end of the alkyl chain or within the alkyl chain,
[0082] Y is O, NH, N-CH3 or CH2,
[0083] n is an integer from 0 to 4,
[0084] X is
[0085]
[0086] m is an integer from 1 to 3, and
[0087] o is an integer from 1 to 4.
[0088] In other aspects, the ionizable cationic lipid has the structure of Formula 2,
[0089]
[0090] wherein Y is O, NH, N-CH3 or CH2,
[0091] n is an integer from 0 to 4,
[0092] X is
[0093]
[0094] m is an integer from 1 to 3,
[0095] o is an integer from 1 to 4,
[0096] p is an integer from 1 to 4,
[0097] When p=1, each R is independently C6 to C 16 Straight chain alkyl; C6 to C 16 Straight chain alkenyl; C6 to C 16 Branched alkyl; C6 to C 16 Branched alkenyl; C9 to C 16 Cycloalkyl-alkyl, wherein the cycloalkyl is a C3 to C8 cycloalkyl located at the end of the alkyl chain or within the alkyl chain; or a C8 to C 18 Aryl-alkyl, wherein the aryl group is phenyl or naphthyl and is located at the end of the alkyl chain or within the alkyl chain,
[0098] When p=2, each R is independently C6 to C 14 Straight chain alkyl; C6 to C 14 Straight chain alkenyl; C6 to C 14 Branched alkyl; C6 to C 14 Branched alkenyl; C9 to C 14 Cycloalkyl-alkyl, wherein the cycloalkyl is a C3 to C8 cycloalkyl located at the end of the alkyl chain or within the alkyl chain; or a C8 to C 16 Aryl-alkyl, wherein the aryl group is phenyl or naphthyl and is located at the end of the alkyl chain or within the alkyl chain,
[0099] When p=3, each R is independently C6 to C 12 Straight chain alkyl; C6 to C 12 Straight chain alkenyl; C6 to C 12 Branched alkyl; branched C6 to C12 Alkenyl; C9 to C 12 Cycloalkyl-alkyl, wherein the cycloalkyl is a C3 to C8 cycloalkyl located at the end of the alkyl chain or within the alkyl chain; or a C8 to C 14 Aryl-alkyl, wherein the aryl group is phenyl or naphthyl and is located at the end of the alkyl chain or within the alkyl chain, and
[0100] When p=4, each R is independently C6 to C 10 Straight chain alkyl; Straight chain C6 to C 10 Alkenyl; C6 to C 10 Branched alkyl; C6 to C 10 Branched alkenyl; C9 to C 10 Cycloalkyl-alkyl, wherein the cycloalkyl is a C3 to C8 cycloalkyl located at the end of the alkyl or within the alkyl; or a C8 to C 12 Aryl-alkyl, wherein the aryl group is phenyl or naphthyl and is located at the end of the alkyl chain or within the alkyl chain.
[0101] Some embodiments include one or more species or subgenus based on the specific selection of R, X, Y, m, n, o, p and / or carbon chain length, structure or saturation. Other embodiments specifically exclude one or more species or subgenus based on the specific selection of R, X, Y, m, n, o, p and / or carbon chain length, structure or saturation. In some embodiments, each R from the nearest shared branch point is the same. In some embodiments, each R is the same.
[0102] In some embodiments, the ionizable cationic lipid has the structure of Formula 2a
[0103]
[0104] Where R is C6 to C 16 Straight chain alkyl; C6 to C 16 Straight chain alkenyl; C6 to C 16 Branched alkyl; branched C6 to C 16 Alkenyl; C9 to C 16 Cycloalkyl-alkyl, wherein the cycloalkyl is a C3 to C8 cycloalkyl located at the end of the alkyl chain or within the alkyl chain; or a C8 to C 18 Aryl-alkyl, wherein the aryl group is phenyl or naphthyl and is located at the end of the alkyl chain or within the alkyl chain,
[0105] Y is O, NH, N-CH3 or CH2,
[0106] n is an integer from 0 to 4,
[0107] X is
[0108]
[0109] m is an integer from 1 to 3, and
[0110] o is an integer from 1 to 4.
[0111] In a further aspect, the ionizable cationic lipid has the structure of Formula 3,
[0112]
[0113] Wherein W is C=O or CH2,
[0114] n is an integer from 0 to 4,
[0115] X is
[0116]
[0117] m is an integer from 1 to 3,
[0118] o is an integer from 1 to 4,
[0119] p is an integer from 1 to 4,
[0120] When p = 1, each R c Independently C8 to C 18 Straight chain alkyl; C8 to C 18 Straight chain alkenyl; C8 to C 18 Branched alkyl; C8 to C 18 Branched alkenyl; C 11 To C 18 Cycloalkyl-alkyl, wherein the cycloalkyl is a C3 to C8 cycloalkyl located at the end of the alkyl chain or within the alkyl chain; or C 10 To C 20 Aryl-alkyl, wherein the aryl group is phenyl or naphthyl and is located at the end of the alkyl chain or within the alkyl chain,
[0121] When p = 2, each R c Independently C8 to C 16 Straight chain alkyl; C8 to C 16 Straight chain alkenyl; C8 to C 16 Branched alkyl; C8 to C 16 Branched alkenyl; C 11 To C 16 Cycloalkyl-alkyl, wherein the cycloalkyl is a C3 to C8 cycloalkyl located at the end of the alkyl chain or within the alkyl chain; or C 10 To C 18 Aryl-alkyl, wherein the aryl group is phenyl or naphthyl and is located at the end of the alkyl chain or within the alkyl chain,
[0122] When p = 3, each R cIndependently C8 to C 14 Straight chain alkyl; C8 to C 14 Straight chain alkenyl; C8 to C 14 Branched alkyl; C8 to C 14 Branched alkenyl; C 11 To C 14 Cycloalkyl-alkyl, wherein the cycloalkyl is a C3 to C8 cycloalkyl located at the end of the alkyl chain or within the alkyl chain; or C 10 To C 16 Aryl-alkyl, wherein the aryl group is phenyl or naphthyl and is located at the end of the alkyl chain or within the alkyl chain, and
[0123] When p = 4, each R c Independently C8 to C 12 Straight chain alkyl; C8 to C 12 Straight chain alkenyl; C8 to C 12 Branched alkyl; C8 to C 12 Branched alkenyl; C 11 To C 12 Cycloalkyl-alkyl, wherein the cycloalkyl is a C3 to C8 cycloalkyl located at the end of the alkyl or within the alkyl; or C 10 To C 14 Aryl-alkyl, wherein the aryl group is phenyl or naphthyl and is located at the end of the alkyl chain or within the alkyl chain.
[0124] Some embodiments include R-based c , W, X, m, n, o, p and / or one or more species or subgenera specifically selected for carbon chain length, structure or saturation. Other embodiments specifically exclude the use of c , W, X, m, n, o, p and / or one or more species or subgenera specifically selected for carbon chain length, structure or saturation. In some embodiments, each R from the nearest common branch point c In some embodiments, each R c are the same.
[0125] In some embodiments, the ionizable cationic lipid has the structure of Formula 3a
[0126]
[0127] Where R c C8 to C 18 Straight chain alkyl; C8 to C 18 Straight chain alkenyl; C8 to C 18 Branched alkyl; C8 to C 18 Branched alkenyl; C 11 To C 18Cycloalkyl-alkyl, wherein the cycloalkyl is a C3 to C8 cycloalkyl located at the end of the alkyl chain or within the alkyl chain; or C 10 To C 20 Aryl-alkyl, wherein the aryl group is phenyl or naphthyl and is located at the end of the alkyl chain or within the alkyl chain,
[0128] W is C=O or CH2,
[0129] n is an integer from 0 to 4,
[0130] X is
[0131]
[0132] m is an integer from 1 to 3, and
[0133] o is an integer from 1 to 4.
[0134] With respect to each of the foregoing aspects, in some embodiments, all four R groups are the same. In other embodiments, the two R groups derived from the first branch point are c The groups are identical to each other and the two R from the second branch point c The groups are identical to each other, but the R originating from the first branch point c The group is different from the R group originating from the second branch point.
[0135] With respect to each of the foregoing aspects, where applicable, some embodiments are limited to R c , W, X, Y, m, n, o and / or p. Other embodiments specifically exclude R c , W, X, Y, m, n, o, p and / or one or a subset of the alternatives for carbon chain length, structure or saturation. Each range of carbon chain lengths is intended to convey embodiments of all individual lengths and subranges therein.
[0136] With respect to each of the foregoing aspects and embodiments, in some cases, R c is a straight chain alkyl group, and in a further case, the chain is unsubstituted. In a further case, R c Is C8 or C9 or C 10 To C 12 .
[0137] With respect to each of the foregoing aspects and embodiments, in some cases, X is With respect to each of the foregoing aspects and embodiments, in some instances Y is O, and in other instances Y is NH or N—CH 3 .
[0138] cLogD is a calculated measure of the lipophilicity of the ionization state of a molecule at a specific pH, predicting the distribution of lipids between water and octanol as a function of pH. More specifically, cLogD is calculated at a specified pH based on clogP and c-pKa. (LogP is the partition coefficient of a molecule between an aqueous phase and a lipophilic phase (generally considered to be octanol and water).) When an ionizable lipid of higher basicity is required, it should be balanced by a larger lipophilicity represented by a higher cLogD value. The balance of basicity and lipophilicity is used herein to maximize LNP function, including the stability of LNP and the release of cargo (cargo) (e.g., nucleic acids) after being taken up by cells. Therefore, as m, n or p increases, the overall lipophilicity represented by cLogD of an ionizable cationic lipid disclosed herein can be balanced by a shorter chain length of R. Some embodiments of the ionizable cationic lipid species encompassed by Formula 1-3 have a cLogD in the range of about 9 to about 18 or about 9 to about 22 calculated using ACD Labs Structure Designer v 12.0, cLogP calculated using ACD Labs Version B; cLogD calculated at pH 7.4.
[0139] The pKa measured for the LNP carrying nucleic acid load is 6 to 7, which ensures that the ionizable cationic lipid in LNP remains neutral in the bloodstream and interstitial space, but ionizes with endosome acidification after being taken into the cell. After the endosomal space is acidified, lipid becomes protonated, and more strongly combines with the phosphate backbone of nucleic acid, which makes the structure of LNP destabilize and promotes nucleic acid to be released into the cytoplasm (also referred to as endosome escape) from LNP. Therefore, the ionizable cationic lipid disclosed herein constitutes a means (when ionized) for destabilizing the LNP structure or a means for promoting nucleic acid release or endosome escape.
[0140] The ionizable cationic lipids of the present disclosure have a branched structure to give the lipids a conical rather than a cylindrical shape, and this structure helps promote endosomal lytic activity. The greater the endosomal lytic activity, the more efficient the release of the nucleotide cargo.
[0141] In order to promote the biodegradability of the present disclosure and minimize the accumulation of ionizable cationic lipids, the fatty acid tails are designed to contain esters in positions that minimize the steric hindrance of ester cleavage. For example, although a single fatty acid tail will tend to extend away from the ester carbonyl, the presence of two tails causes the tails to extend in opposite directions because this is an energetically favorable conformation. This means that one of the tails can extend toward the carbonyl and sterically hinder the cleavage of the ester. Therefore, large side chains directly adjacent to the ester carbonyl are avoided. When positioning the ester in the lipid, potential degradation products are also considered to avoid the production of toxic compounds, such as formaldehyde.
[0142] Another consideration that potentially contributes to lipid tolerance is the extent to which ester cleavage or other catabolism produces fragments or byproducts, and whether these fragments or byproducts can be eliminated from the body without involving oxidative degradation in the liver. It is expected that the ionizable cationic lipids of the present disclosure are readily biodegradable and the fragments are readily cleared. For example, Figure 8 It is described that esterase cleavage or other hydrolysis of compound A-11 will be predicted to produce tetraol B and 4 equivalents of nonanoic acid. Cyclization should then result in the production of 2 equivalents of butyrolactone C and 1 equivalent of diol D. Esterase hydrolysis of C will result in the production of 2 equivalents of diol-acid E. The products of biodegradation of A-11 are collectively shown in Figure 8 All of these entities are small and polar and are expected to be cleared from the body without the need for hepatic oxidation or conjugation. These considerations are important if tLNPs of LNPs are to be used in chronic dosing regimens.
[0143] The advantage of relying at least in part on the ionizable cationic lipids of the present invention is that it avoids the toxicity associated with quaternary ammonium cationic lipids. Some LNPs based on this lipid are actually permanent cations and have shown fatal hyperacute toxicity in experimental animals. By using the ionizable cationic lipids of the present invention in LNP, the use of quaternary ammonium cationic lipids can significantly reduce or avoid toxicity. In certain embodiments, LNPs or tLNPs of the present invention are used to cause no more than mild toxicity to cells or in individuals. In certain embodiments, LNPs or tLNPs of the present invention are used to cause no more than mild toxicity to cells or in individuals, i.e., asymptomatic or only induce mild symptoms that do not require intervention. In certain embodiments, LNPs or tLNPs of the present invention are used to cause no more than moderate toxicity to cells or in individuals, which may impair the activities of daily life, and it only requires minimal, local or non-invasive intervention.
[0144] The relationship between the efficacy and toxicity of a drug is usually represented by a therapeutic window and a therapeutic index. The therapeutic window is a dosage range from the lowest dose showing a detectable therapeutic effect to the maximum tolerated dose (MTD); the highest dose that achieves the desired therapeutic effect without producing unacceptable toxicity. The most typical therapeutic index is calculated as the ratio of LD50:ED50 (when based on animal studies) and TD50:ED50 (when based on human studies) (although the calculation can also be derived from animal studies and is sometimes referred to as a protection index), wherein LD50, TD50, and ED50 are lethal, toxic, and effective doses in 50% of the test population, respectively. These concepts can be applied to whether toxicity is based on the active agent itself or some other components of the drug product, such as LNP or its components. For any inherent toxicity level of the disclosed lipid or LNP itself, the improvement of the efficiency of nucleic acid delivery to the cytoplasm will improve the therapeutic window or index, because the nucleic acid of an effective amount will be delivered with a smaller dose of LNP (and its component lipid).
[0145] Sometimes toxicity and adverse events are graded according to a 5-point scale. Grade 1 or mild toxicity is asymptomatic or induces only mild symptoms; can be characterized only by clinical or diagnostic observations; and no intervention is indicated. Grade 2 or moderate toxicity may impair activities of daily life (e.g., preparing meals, shopping, managing money, using the phone, etc.), but only minimal, local or non-invasive intervention is indicated. Grade 3 toxicity is medically significant, but not immediately life-threatening; indicates hospitalization or extended hospitalization; may impair activities of daily life related to self-care (e.g., bathing, dressing and undressing, feeding oneself, using the toilet, taking medication, rather than being bedridden). Grade 4 toxicity is life-threatening and indicates emergency intervention. Grade 5 toxicity produces death associated with adverse events. Therefore, in various embodiments, by using disclosed LNPs and tLNPs, toxicity is limited to observations of grade 2 or lower, grade 1 or lower, or no toxicity.
[0146] In some cases, the LNPs and tLNPs of the present disclosure are used according to a specified regimen, provided at a specific dose, or administered via a specific route of administration.
[0147] Method for preparing ionizable cationic lipids
[0148] Structural symmetry and convergent rather than linear synthetic pathways can be exploited to simplify the synthesis of ionizable lipids.
[0149] In certain aspects, the present disclosure provides methods for synthesizing an ionizable cationic lipid of Formula 1. In some embodiments, the method includes converting an intermediate having an I-fA structure into an ionizable cationic lipid of Formula 1. In some embodiments, the method further includes synthesizing an intermediate having an I-fA structure (e.g., Figure 1A ).
[0150] In certain embodiments of the method for synthesizing an ionizable cationic lipid of formula 1, Y=O, NH or N-CH3, and the method further comprises reacting I-fA with carbonyl diimidazole to provide I-gA. In certain embodiments, the method further comprises reacting I-gA and X-(CH2) n+2 -YH coupling. In certain embodiments, I-gA and X-(CH2) n+2 The coupling reaction of -YH is carried out in the presence of an alkylating agent. In certain embodiments, the alkylating agent is MeOTf, such as Figure 1B In certain embodiments, the coupling reaction comprises reacting an intermediate having a structure of I-hA with X-(CH2) n+2 -YH is coupled to provide an ionizable cationic lipid of Formula 1, wherein Y = O, NH or N-CH3. In certain embodiments, I-hA is coupled to X-(CH2) n+2 The coupling reaction of -YH is carried out in the presence of a base (such as, but not limited to, NaH or Et3N).
[0151] In certain embodiments of the method for synthesizing an ionizable cationic lipid of formula 1, Y=CH2, the method comprises reacting an intermediate having a structure of I-fA with X-(CH2) n+3 -COOH coupling to provide an ionizable cationic lipid of Formula 1. In certain embodiments, the coupling method is carried out in the presence of DMAP and Et3N, for example, Figure 1C Displayed in.
[0152] In certain embodiments of the method for synthesizing I-fA, the method comprises reacting an intermediate of I-dA with (HO-CH2-(CH2) p )2-N-PG coupling to provide an amine protected derivative of I-fA, wherein PG is an amine protecting group. In certain embodiments, PG is Figure 1A In certain embodiments of the method for synthesizing I-fA, the amine-protected derivative of I-fA is deprotected to provide I-fA. For example, Figure 1A As shown in , the deprotecting agent can be TFA in dimethyl chloride. In certain embodiments, the method further comprises the synthesis of I-dA.
[0153] In certain embodiments of the method for synthesizing I-dA, a carboxylic acid derivative of I-dA is prepared, wherein the carboxylic acid moiety of I-dA is protected with a protecting group that can be selectively deprotected upon hydrolysis of the R-COO- moiety. In certain embodiments, the carboxylic acid derivative of I-dA is I-cA, which is the tert-butyl ester of I-dA, e.g., see Figure 1AIn certain embodiments, the carboxylic acid derivative of I-dA is prepared by reacting the desired diol carboxylic acid derivative (e.g., Ib, wherein the carboxylic acid derivative is a tert-butyl ester, in other embodiments, the derivative may be in other forms) with R-COOH. In certain embodiments, the diol carboxylic acid derivative is prepared by hydrogenation of an alkenyl diol carboxylic acid derivative (e.g., Ia, wherein the carboxylic acid derivative is a tert-butyl ester, in other embodiments, the derivative may be in other forms). In certain embodiments, the alkenyl diol carboxylic acid derivative is prepared by reacting dihydroxyacetone with an alkoxycarbonylmethylenetriphenylphosphine (e.g., the alkyl group may be, for example, Figure 1A Prepared by reaction of the tert-butyl group shown in FIG.
[0154] In some embodiments, the method for synthesizing the ionizable cationic lipid of Formula 1 is according to Figures 1D to 1F . In some embodiments, the method for synthesizing an ionizable cationic lipid of Formula 1 is carried out according to Examples 5 to 16 and 24 (e.g., Compound A-11 to Compound A-15), Examples 17 to 23 (e.g., Compound A-2), or Examples 25 to 33 (e.g., Compound A-16); analogs of these compounds having different m, n, o, p, R, X, and / or Y can be prepared by substituting the reactants as described herein. In some embodiments, the method is a method for synthesizing an ionizable cationic lipid of Formula 1a. In some cases, the method is a method for synthesizing Compound A-1, Compound A-2, Compound A-3, Compound A-4, Compound A-11, Compound A-12, Compound A-13, Compound A-14, Compound A-15, or Compound A-16. In some embodiments, the method specifies only Figures 1D to 1F Or individual steps or subsets of steps described in Examples 5 to 16 and 24, 17 to 23 or 25 to 33 to obtain the final product.
[0155] Other aspects are Figures 1A to 1F , intermediates I-cA, I-dA, I-eA, I-fA, I-gA, I-hA, Id, I-d2, Ie, I-e2, If, I-f2, Ig, I-g2, Ih and I-h2 of the synthetic schemes of Examples 8 to 12 and Examples 18 to 22, wherein the substituents are the same as defined in Formula 1 unless otherwise stated.
[0156] Another aspect is synthesis Figures 1D to 1F In some embodiments, the method only specifies the production of an intermediate of a synthetic scheme of Figures 1D to 1FIn other embodiments, the method specifies that Figures 1D to 1F Other embodiments relate to analogs of intermediates Id, Ie, If, Ig or Ih (e.g., I-d2, I-e2, I-f2, I-g2 or I-h2 as shown in Examples 8 to 12 and 18 to 22), which are suitable for final products with different X, n or p, e.g., I-eA or I-gA.
[0157] exist Figures 1D to 1F In the synthetic scheme described in , the value of p is 1, obtained by coupling intermediate Id with BOC-terminated diethanolamine. Compounds where p is 2 to 4 can be synthesized by substituting BOC-terminated dialkylamino alcohols of appropriate size; i.e., 3,3'-azanediylbis(propan-1-ol), 4,4'-azanediylbis(butan-1-ol), and 5,5'-azanediylbis(pentan-1-ol), respectively.
[0158] exist Figures 1D to 1F In the synthesis scheme described in, the value of n is 1, and the intermediate Ih is reacted with 3-dimethylamino-1-propanol, N,N-dimethyl-1,3-propylenediamine, N,N,N'-trimethyl-1,3-propylenediamine in the presence of a base to produce compounds A-1 to A-3, wherein Y is O, NH or N-CH3, respectively. Compounds wherein n is 0 or 2 to 4 can be synthesized by replacing the propylenediamine moiety with a similar C2, C4, C5 or C6 moiety. Compound A-4 wherein Y is CH2 is obtained by reacting a salt of the intermediate If with 5-dimethylamino-pentanoic acid. Compounds wherein n is 0 or 2 to 4 can be synthesized by replacing the pentanoic acid moiety with a similar C4, C6, C7 or C8 moiety.
[0159] exist Figures 1D to 1F In the synthetic scheme described in , R is C9, obtained by using decanoic acid in the conversion of intermediate Ib to intermediate Ic. Substitution of ω-acids with corresponding chain lengths and structures can be used as appropriate to obtain C6-C8 or C 10 -C 18 R.
[0160] exist Figures 1D to 1FIn the synthesis scheme described in , X is N(CH3)2. Compounds according to Formula 1 with the optional definition of X can be synthesized by reacting the optional head group fragments from Tables 1 to 3 with Ih to obtain analogs of Compounds A-1 to Compound A-3, respectively, or reacting the optional head group fragments from Table 4 with If to obtain analogs of Compound A-4, as disclosed in Example 1 (below). The synthesis of head group fragments not previously disclosed in the art can be carried out similarly to their shorter homologs, or for head group fragments containing polyethylene glycol, can be synthesized according to FIG. 4A to FIG. 4B The synthetic schemes shown in and disclosed in Example 4 can be carried out, or as described in Examples 25 to 32 (below).
[0161] The synthesis of the polyethylene glycol-containing head group fragment requires polyethylene glycol amine and related reagents not previously described. Thus, some aspects are intermediates V-5, V-5a, V-6, V-6A, V-7, V-7a, V-8, V-8a, V-12, V-13, V-14 or V-15, and according to FIG. 4A to FIG. 4B Methods for synthesizing them are shown in and disclosed in Example 4 or as described in Examples 25 to 32.
[0162] Synthesis of intermediate Ie and its analogs having the structure of I-eA:
[0163]
[0164] wherein p is an integer from 1 to 4, and R is the same as defined in Formula 1, dihydroxyacetone reacts with tert-butyloxycarbonylmethylenetriphenylphosphine to give olefin Ia. For example, hydrogenation in ethyl acetate in the presence of Pd / C gives Ib ( Figure 1D ). Ib was coupled with the appropriate carboxylic acid of the desired R in the presence of EDC-HCl and DMAP in dichloromethane to give triester Ic ( Figure 1D ) or its analogues with different R, as shown in I-cA. The tert-butyl ester is hydrolyzed with TFA in dichloromethane to give the key monoacid Id ( Figure 1D ) or its analogs with different R. Id or its analogs are reacted with commercially available BOC-capped diethanolamine ( Figure 1D ) or a BOC-terminated dialkylamino alcohol (n=2 to 4) of appropriate size in dichloromethane to give compounds having structure I-eA.
[0165] Synthetic intermediate Ig and its analogs with different R and / or p, i.e., intermediates having the following structure:
[0166]
[0167] wherein p is an integer from 1 to 4 and R is as defined in Formula 1, the intermediate having the structure of I-eA is treated with TFA in dichloromethane to remove the BOC protecting group to give the If salt ( Figure 1D ) or its analogs having different R and / or p (e.g., Figure 1A The intermediate with the structure of I-fA is shown in FIG. 1 ). The product is then converted to the acyl-imidazole lactone Ig ( Figure 1E ) or an acyl-imidazolide having an I-gA structure ( Figure 1B ).
[0168] In order to complete the synthesis of compounds A-1 to A-3 and analogs thereof having different R and / or p, the desired reactive intermediate is reacted with methyl triflate to produce acyl-imidazolium salt Ih ( Figure 1E ) or its analogs with different R, such as I-h2 (Example 12) or I-hA ( Figure 1B ). For p=1 and n=1, the acyl-imidazolium salt intermediate is then reacted with 3-dimethylamino-1-propanol in the presence of triethylamine to provide compound A-1 ( Figure 1E ) or analogs with different p (e.g., Figure 1B ); react with N,N-dimethyl-1,3-propylenediamine and triethylamine to provide compound A-2 ( Figure 1E ; see also Example 23) or analogs with different p (e.g., Figure 1B ); or react with N,N,N'-trimethyl-1,3-propylenediamine and triethylamine to obtain compound A-3 ( Figure 1E ), in each case in dichloromethane, or analogs with different p ( Figure 1B ).
[0169] In order to complete compound A-4 ( Figure 1F ) or its analogues with different R and / or p, so that the salt of If ( Figure 1C ) or its analogs with different R and / or p are reacted with 5-dimethylamino-pentanoic acid in the presence of EDC-HCl, DMAP and triethylamine in dichloromethane to provide compound A-4 ( Figure 1F ) or its analogs having different R and / or p ( Figure 1C ).
[0170] The reagent substitution for obtaining analogs of Compound A-1 to Compound A-4 with different X, Y and / or n is as described above, and is applicable to the aforementioned synthesis of analogs of Compound A-1 to Compound A-4 with different R and / or p ( Figures 1A to 1C ).
[0171] Such analogs include compounds A-11 to A-15, wherein R is a linear C8 instead of a linear C9 as in compounds A-1 to A-4. In addition, A-11 differs from A-1 in that n=0 instead of n=1. A-12 differs from A-1 only in R. A-13 also differs from A-2 in that n=0 instead of n=1. A-14 also differs from A-3 in that n=0 instead of n=1. A-15 differs from A-3 only in R.
[0172] To complete the synthesis of compound A-11, acyl-imidazolium salt I-h2 was reacted with 2-dimethylamino-ethanol in the presence of tetramethylethylenediamine as described in Example 13. Analogs of compound A-11 retaining p=1 but having other R were prepared by substituting the acyl-imidazolium salt generated from the appropriate species of I-gA.
[0173] To complete the synthesis of compound A-12, acyl-imidazolium salt I-h2 was reacted with 3-dimethylamino-propanol in the presence of tetramethylethylenediamine as described in Example 14. Analogs of compound A-12 retaining p=1 but with other R were prepared by substituting the acyl-imidazolium salt generated from the appropriate species of I-gA.
[0174] To complete the synthesis of compound A-13, acyl-imidazolium salt I-h2 was reacted with 2-dimethylamino-ethanol in the presence of triethylamine as described in Example 15. Analogs of compound A-13 retaining p=1 but with other R were prepared by substituting the acyl-imidazolium salt generated from the appropriate species of I-gA.
[0175] To complete the synthesis of compound A-14, acyl-imidazolium salt I-h2 is reacted with N,N,N'-trimethylethylenediamine in the presence of triethylamine as in Example 16. Analogs of compound A-14 retaining p=1 but having other R are prepared by substituting the acyl-imidazolium salt generated from the appropriate species of I-gA.
[0176] To complete the synthesis of compound A-15, acyl-imidazolium salt I-h2 was reacted with N,N,N'-trimethylpropylenediamine in the presence of triethylamine as described in Example 24. Analogs of compound A-15 retaining p=1 but with other R were prepared by substituting the acyl-imidazolium salt generated from the appropriate species of I-gA.
[0177] In compound A-16 (i.e., in formula 1a, Y is N-CH3, X is n is 1, m is 2, and o is 1), the head group fragment terminates in a small polyethylene glycol moiety. Compound A-16 can be prepared according to the synthetic scheme presented in Example 4, and is also synthesized as shown in Examples 25 to 33. In these latter examples, final I-d2 is reacted with V-15 in the presence of DMAP and EDC-HCl in dichloromethane. Analogs of I-d2 with different hydrocarbon tails (e.g., Figure 1A I-dA) in (A-16) can be used to generate analogs of compound A-16 with different R.
[0178] In order to synthesize V-15, can start from (3-hydroxypropyl) (methyl) tert-butyl carbamate, by adding the cooling suspension of the NaH in THF wherein.Slowly add the methanesulfonic acid 2-methoxyethyl ester solution in THF subsequently, and the mixture is stirred for a period of time at high temperature.After being cooled to room temperature, by carefully adding saturated NH the Cl aqueous solution quenching reaction.Mixture is poured in ethyl acetate, separate organic phase, with ethyl acetate extraction aqueous phase, and the organic phase merged is washed with salt water and through Na sO dry.Concentrated filtrate, produces thick V-5a, is dissolved in dichloromethane, and is dried on silica gel.Silica gel is positioned in post and uses dichloromethane wash-out V-5a and is condensed into yellow oil.
[0179] To synthesize V-6a, a solution of V-5a in dioxane is slowly exposed to an added acid, such as HCl, stirred for several hours, and the solvent is removed. Crude V-6a is dissolved in dichloromethane and tert-butyl (3-oxopropyl) carbamate is added. After stirring and incubating, NaBH(OAc)3 is added several times over a period of time and further incubated. Water is then added, and the pH is adjusted to 8 with Na2CO3. The mixture is extracted with dichloromethane, the organic phases are combined, dried over Na2SO4, and the solids are removed by filtration. Silica gel is added to the filtrate and concentrated to dryness. Silica gel is then added to the column, and V-7a is eluted with a gradient of dichloromethane: methanol, and dried to a yellow oil. V-7a is dissolved in dioxane and exposed to slowly added acid, such as HCl. After incubation, the solvent is removed to obtain crude V-8a as a white solid.
[0180] To synthesize V-12, imidazole was added to a solution of diethanolamine in dichloromethane, stirred, and a solution of tert-butyldimethylsilyl chloride was slowly added. The resulting solution was incubated and then quenched by adding 10% NH4OH aqueous solution. The organic phase was separated and the aqueous phase was extracted with dichloromethane. The combined organic phases were washed with saturated NH4Cl and brine, and dried. Filtered and concentrated to obtain V-12 as a clear colorless oil.
[0181] CDI and Et3N were added to a dichloromethane solution of V-12, the resulting solution was incubated under stirring, and then poured into water. The organic phase was separated, and the aqueous phase was extracted with dichloromethane. The combined organic phases were washed with saturated NH4Cl and 5% NaHCO3 water in turn, and dried. Filtered and concentrated to obtain V-13 as a clear light yellow oil.
[0182] MeOTf is slowly added to the dichloromethane solution of cold V-13. After the stirred cold incubation, Et3N and the dichloromethane solution of V-8a are slowly added. When the addition is complete, the solution is heated and incubated for several hours. Then the reaction mixture is poured into water and the organic layer is removed. The aqueous layer is extracted with dichloromethane and the organic phase merged is concentrated. The gained crude V-14 is dissolved in heptane, and the solution is extracted with MeOH / H2O. The aqueous phase merged is then extracted with heptane, and the organic phase merged is washed with salt water, and dried over MgSO4. After filtration, silica gel is added to the filtrate, and the mixture is concentrated to dryness. Then silica gel is added to the post, and with the gradient elution V-14 of dichloromethane: methanol, the cut containing V-14 is concentrated, to obtain V-14, which is a yellow oil.
[0183] To complete the synthesis of V-15, BF3-OEt2 was slowly added to a THF solution of V-14. The mixture was incubated under stirring for several hours and poured into water. The pH was adjusted to 8.0 with saturated NaHCO3 aqueous solution and the solvent was removed to about one-fifth of its original volume. The remaining solution was purified by flash chromatography using a water: acetonitrile gradient. The fractions containing V-14 were combined and concentrated to give V-14 as an off-white oil.
[0184] In certain aspects, the present disclosure provides methods for synthesizing an ionizable cationic lipid of Formula 2. In some embodiments, the method comprises converting an intermediate having a structure of II-gA into an ionizable cationic lipid of Formula 2. In some embodiments, the method further comprises synthesizing an intermediate having a structure of II-gA ( Figure 2A ).
[0185] In certain embodiments of the method for synthesizing an ionizable cationic lipid of Formula 2 wherein Y=O, NH or N-CH3, and the method further comprises reacting II-gA with carbonyldiimidazole to provide II-hA. In certain embodiments, the method further comprises reacting II-hA and X-(CH2) n+2 -YH coupling. In certain embodiments, II-hA and X-(CH2) n+2 The coupling reaction of -YH is carried out in the presence of an alkylating agent. In certain embodiments, the alkylating agent is MeOTf, such as Figure 2BIn certain embodiments, the coupling reaction comprises reacting an intermediate having a structure of II-iA with X-(CH2) n+2 -YH is coupled to provide an ionizable cationic lipid of Formula 2, wherein Y = O, NH or N-CH3. In certain embodiments, II-iA is coupled to X-(CH2) n+2 The coupling reaction of -YH is carried out in the presence of a base (such as, but not limited to, NaH or Et3N). Figure 2B .
[0186] In certain embodiments of the method for synthesizing an ionizable cationic lipid wherein Y=CH2 of Formula 2, the method comprises reacting an intermediate having a structure of II-gA with X-(CH2) n+3 -COOH coupling to provide an ionizable cationic lipid of Formula 2. In certain embodiments, the coupling method is carried out in the presence of DMAP and Et3N, for example, Figure 2C Displayed in.
[0187] In certain embodiments of the method for the synthesis of II-gA, the method comprises coupling an intermediate of II-eA with R-COOH to provide an amine protected derivative of II-gA, also referred to as II-fA. In certain embodiments, the amine protecting group is such as Figure 2A In certain embodiments of the synthesis of II-gA and II-fA, the amine-protected derivative of II-gA is deprotected to provide II-gA. For example, Figure 2A As shown in , the deprotecting agent can be TFA in dimethyl chloride. In certain embodiments, the method further comprises the synthesis of II-eA.
[0188] In certain embodiments of the method for synthesizing II-eA, a derivative of II-eA is prepared, wherein the hydroxyl group of II-eA is protected (i.e., OH-protected II-eA). Figure 2A It is shown that OH-protected II-eA can be II-cA, which can be obtained by making BOC-N((CH2) p+1 In another example, the sodium salt of CH2-OH)2 is reacted with II-a. Figure 2A It is shown that OH-protected II-eA can be II-dA, which can be obtained by reacting BOC-N((CH2) p+1 Prepared by reacting the sodium salt of CH2-OH)2 with II-b.
[0189] In some embodiments, the method for synthesizing the ionizable cationic lipid of Formula 2 is according to FIG. 2A to FIG. 2FIn some embodiments, the method is a method for synthesizing an ionizable cationic lipid of Formula 2a. In some cases, the method is a method for synthesizing Compound A-5, Compound A-6, Compound A-7, or Compound A-8. In some embodiments, the method only specifies FIG. 2A to FIG. 2F A single step or a subset of steps described in .
[0190] In a further aspect, the present disclosure provides synthesis FIG. 2D to FIG. 2F In some embodiments, the method comprises only producing an intermediate of a synthetic scheme of FIG. 2D to FIG. 2F In other embodiments, the method comprises the following steps: FIG. 2D to FIG. 2F All or a subset of the steps described in to reach the intermediate.
[0191] exist FIG. 2D to FIG. 2F In the synthetic scheme described in , the value of p is 1, which is obtained by reacting BOC-terminated diethanolamine with intermediate II-a or II-b to form intermediate II-c or II-d, respectively. Compounds where p is 2 to 4 can be synthesized by substituting BOC-terminated dialkylamino alcohols of appropriate size; i.e., 3,3'-azanediylbis(propan-1-ol), 4,4'-azanediylbis(butan-1-ol), and 5,5'-azanediylbis(pentan-1-ol), respectively.
[0192] exist FIG. 2D to FIG. 2F In the synthesis scheme described in, the value of n is 1, and intermediate II-i is reacted with the sodium salt of 3-dimethylamino-1-propanol, N,N-dimethyl-1,3-propylenediamine, N,N,N'-trimethyl-1,3-propylenediamine to produce compounds A-5 to A-7, wherein Y is O, NH or N-CH3, respectively. Compounds wherein n is 0 or 2 to 4 can be synthesized by replacing the propylenediamine moiety with a similar C2, C4, C5 or C6 moiety. Compound A-8 wherein Y is CH2 is obtained by reacting a salt of intermediate II-g with 5-dimethylamino-pentanoic acid. Compounds wherein n is 0 or 2 to 4 can be synthesized by replacing the pentanoic acid moiety with a similar C4, C6, C7 or C8 moiety.
[0193] exist FIG. 2D to FIG. 2F In the synthetic scheme described in , R is C9, obtained by using decanoic acid in the conversion of intermediate II-e to intermediate II-f. Substitution of ω-acids with corresponding chain lengths and structures can be used as appropriate to obtain C6-C8 or C 10 -C 18 R.
[0194] exist FIG. 2D to FIG. 2FIn the synthesis scheme described in , X is N(CH3)2. Compounds according to Formula 2 with the optional definition of X can be synthesized by reacting the optional head group fragments from Tables 1 to 3 with II-i to obtain analogs of Compounds A-5 to Compound A-7, respectively, or reacting the optional head group fragments from Table 4 with Ig to obtain analogs of Compound A-8, as disclosed in Example 2 (below). The synthesis of head group fragments not previously disclosed in the art can be carried out similarly to their shorter homologs, or for head group fragments containing polyethylene glycol, can be synthesized according to FIG. 4A to FIG. 4B The synthesis schemes shown in and disclosed in Example 4 are followed, or as described in Examples 25 to 32 (below).
[0195] Synthetic intermediate II-f and its analogs with different R and / or p, i.e., intermediates having the following structures:
[0196]
[0197] Wherein p is an integer from 1 to 4 and R is defined as in Formula 2, the sodium salt of BOC-terminated diethanolamine or a dialkylamino alcohol of appropriate size (p = 2 to 4) is reacted with 5-(2-bromoethyl)-2,2-dimethyl-1,3-dioxane (II-a) or 5-(2-bromoethyl)-2-phenyl-1,3-dioxane (II-b), respectively, in DMF to produce II-c and II-d ( Figure 2D ) or its analogs having p=2 to 4 ( Figure 2A II-c and its analogs can be deblocked with weak acid in MeOH in the presence of PPTs to produce diol II-e ( Figure 2D ) and its analogs with p=2 to 4 ( Figure 2A Alternatively, benzylidene acetal II-d and its analogs can be deblocked with hydrogen and Pd / C in ethyl acetate to also yield II-e ( Figure 2D ) or its analogs having p=2 to 4 ( Figure 2A ). II-e is coupled with the appropriate carboxylic acid of the desired R in the presence of EDC-HCl and DMAP in dichloromethane to yield II-f ( Figure 2D ) or its analogs having different R and / or p ( Figure 2A ).
[0198] Synthetic intermediate II-h and its analogs with different R and / or p, i.e., intermediates having the following structures:
[0199]
[0200] wherein p is an integer from 1 to 4 and R is as defined in Formula 2, the intermediate having the structure of II-fA is treated with TFA in dichloromethane to remove the BOC blocking group to give the amine salt II-g ( Figure 2D ) or its analogs having different R and / or p ( Figure 2A ). The amine salt II-g or its analog is reacted with carbonyldiimidazole and triethylamine in dichloromethane to obtain acyl imidazole II-h or its analog II-hA ( Figure 2A ).
[0201] In order to complete the synthesis of compounds A-5 to A-7 and their analogs having different R and / or p, the desired reactive intermediate is reacted with methyl triflate to produce acyl-imidazolium salt II-i ( Figure 2E ) or its analogs having different R and / or p ( Figure 2B ). The acyl-imidazolium salt intermediate is then reacted with 3-dimethylamino-1-propanol in the presence of triethylamine to obtain compound A-5 ( Figure 2E ) or analogs with different R and / or p ( Figure 2B ); react with N,N-dimethyl-1,3-propylenediamine and triethylamine to provide compound A-6 ( Figure 2E ) or analogs with different R and / or p ( Figure 2B ); or react with N,N,N'-trimethyl-1,3-propylenediamine and triethylamine to obtain compound A-7 ( Figure 2E ), in each case in dichloromethane, or analogs with different R and / or p ( Figure 2B ).
[0202] In order to complete the synthesis of compound A-8 or its analogs having different R and / or p, salt II-g ( Figure 2F ) or its analogs having different R and / or p ( Figure 2C ) is reacted with 4-dimethylamino-butyric acid in the presence of EDC-HCl, DMAP and triethylamine in dichloromethane to provide compound A-8 ( Figure 2F ) or its analogs having different R and / or p ( Figure 2C ).
[0203] The reagent substitutions used to obtain analogs of Compound A-5 to Compound A-8 with different X, Y and / or n are as described above and are applicable to the aforementioned syntheses to obtain analogs of Compound A-5 to Compound A-8 with different R and / or p.
[0204] In certain aspects, the present disclosure provides methods for synthesizing an ionizable cationic lipid of Formula 3. In some embodiments, the method comprises converting an intermediate having a structure of III-cA into an ionizable cationic lipid of Formula 3. In some embodiments, the method further comprises synthesizing an intermediate having a structure of III-cA.
[0205] In certain embodiments of the method for synthesizing the ionizable cationic lipid of Formula 3, W=C=O, and the method further comprises reacting III-cA with I-dA to provide the ionizable cationic lipid of Formula 3. See, e.g. Figure 3A .
[0206] In certain embodiments of the method for synthesizing an ionizable cationic lipid of Formula 3, W = CH2, and the method further comprises converting III-cA to III-fA, and reacting III-fA with R-COOH to provide an ionizable cationic lipid of Formula 3. See, e.g. Figure 3B In certain embodiments, the method further comprises preparing a derivative of III-fA, wherein the hydroxyl group of III-fA is protected (ie, OH-protected III-fA). Figure 3B As shown in FIG. 1 , OH-protected III-fA can be III-dA, which can be prepared by reacting the sodium salt of III-cA with II-a. In another example, Figure 3B It is shown in Figure 1 that OH-protected III-fA can be III-eA, which can be prepared by reacting the sodium salt of III-cA with II-b.
[0207] In certain embodiments, III-cA is prepared by reduction of the carbonyl group of III-bA, for example by Figure 3A In certain embodiments, the reduction of LiAlH4 is carried out by reacting III-aA with HN((CH2) p -CH2OH)2 reaction to prepare III-bA. In certain embodiments, III-aA and HN((CH2) p -CH2OH)2 is carried out in the presence of 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride, for example Figure 3A Embodiments of III-aA in which n=2 can be prepared by reacting glutaric anhydride with dimethylamine, for example, as Figure 3A Displayed in.
[0208] In some embodiments, the method for synthesizing the ionizable cationic lipid of Formula 3 is according to Figure 3AIn some embodiments, the method is a method for synthesizing an ionizable cationic lipid of formula 3a. In some cases, the method is a method for synthesizing compound A-9 or compound A-10. In some embodiments, the method only comprises FIG. 3A to FIG. 3D A single step or a subset of steps described in .
[0209] A further aspect is FIG. 3A to FIG. 3D The intermediates III-aA, III-bA, III-cA, III-dA, III-eA, III-fA, III-d, III-e and III-f of the synthetic scheme and the method for synthesizing each of the intermediates III-d, III-e and III-f. Other embodiments relate to analogs of intermediates III-d, III-e and III-f suitable for final products with different X, n or p.
[0210] In another aspect, there is provided a synthesis FIG. 3C to FIG. 3D In some embodiments, the method only specifies the production of an intermediate of a synthetic scheme of FIG. 3C to FIG. 3D In other embodiments, the method specifies that FIG. 3C to FIG. 3D All or a subset of the steps described in to reach the intermediate.
[0211] exist FIG. 3C to FIG. 3D In the synthetic scheme described in , the value of p is 1, obtained by the reaction of glutaric anhydride with dimethylamine to form III-a which reacts with diethanolamine. Compounds where p is 2 to 4 can be synthesized by substituting dialkylamino alcohols of appropriate size; i.e., 3,3'-azanediylbis(propan-1-ol), 4,4'-azanediylbis(butan-1-ol), and 5,5'-azanediylbis(pentan-1-ol), respectively.
[0212] exist FIG. 3C to FIG. 3D In the synthesis scheme described in , the value of n is 2, obtained by coupling intermediate III-a with diethanolamine (4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride) and subsequent reduction. Compounds in which n is 0 to 1 or 3 to 4 can be synthesized by substituting dimethylamine for malonic acid, maleic anhydride, 1,6-hexanoic acid, 1,7-pimelic acid in the coupling reaction and subsequently adding the amide acid with an amino alcohol.
[0213] exist Figure 3C In the synthesis of compound A-9 described in , W is C=O. Figure 3D In the synthesis of compound A-10 described in , W is CH2.
[0214] exist FIG. 3C to FIG. 3DIn the synthetic scheme described in , R c is C9, obtained by using decanoic acid in the conversion of intermediate III-c or intermediate III-f to compound 9 or compound 10, respectively. Substitution of ω-acids with corresponding chain lengths and structures can be used as appropriate to obtain C6-C8 or C 10 -C 20 R c .
[0215] exist FIG. 3C to FIG. 3D In the synthetic scheme described in , X is N(CH3)2. Compounds according to Formula 3 with the optional definition of X can be synthesized by reacting alternative head group fragments from Table 4 (instead of III-a) with diethanolamine to obtain analogs of Compound A-9 and Compound A-10, as disclosed in Example 3 (below). The synthesis of head group fragments not previously disclosed in the art can be carried out similarly to their shorter homologs, or for head group fragments containing polyethylene glycol, can be prepared according to FIG. 4A to FIG. 4B The synthesis schemes shown in and disclosed in Example 4 are followed, or as described in Examples 25 to 32 (below).
[0216] To complete the synthesis of compound A-9 and its analogs with different R and p as defined in Formula 3, glutaric anhydride is first reacted with dimethylamine in THF to give 5-(dimethylamino)-5-oxopentanoic acid III-a. Coupling of III-a with diethanolamine or a dialkylamino alcohol of appropriate size (p=2 to 4) in the presence of (4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride) gives N1,N1-bis(2-hydroxyethyl)-N5,N5-dimethyl-glutaramide III-b ( Figure 3C ) or its analogs ( Figure 3A ), and reduction with LiAlH4 in THF provides diol III-c ( Figure 3C ) or its analogs having p=2 to 4 ( Figure 3A Then intermediate Id or its analogs with different R (whose synthesis is described above) is coupled with III-c in dichloromethane to give compound A-9 ( Figure 3C ) and their different R c and / or analogs of p( Figure 3A ).
[0217] To complete the synthesis of compound A-10 and its analogs with different R and p as defined in formula 3, the sodium salt of III-c or its analogs with p=2 to 4 is reacted with bromide II-a or II-b in the presence of NaH in DMF to give diamines III-d and III-e ( Figure 3D ) or its analogs having p=2 to 4 ( Figure 3B ). Deprotection of III-d with PPTs in methanol or deprotection of III-e with hydrogen and Pd / C in ethyl acetate affords tetraol III-f or its analogs with p=2 to 4. Coupling of tetraol III-f with decanoic acid or other carboxylic acids suitable for producing analogs with different R in dichloromethane in the presence of EDC-HCl and DMAP yields compound A-10 ( Figure 3D ) or its analogs having different R and / or p ( Figure 3B ).
[0218] The reagent substitutions used to obtain analogs of Compound A-9 to Compound A-10 having different X and / or n are as described above and are applicable to the aforementioned syntheses to obtain analogs of Compound A-9 to Compound A-10 having different R and / or p.
[0219] The synthesis is described using a specific solvent, but in all cases, optional solvents will be known to those skilled in the art. THF can be replaced by, for example, but not limited to, DMF, diethyl ether, methyl tert-butyl ether, dioxane or 2-methyl THF. Ethyl acetate can be replaced by, for example, but not limited to, isopropyl acetate, THF, 2-methyl THF, dioxane or methyl tert-butyl ether. Methylene chloride can be replaced by, for example, but not limited to, ethyl acetate, isopropyl acetate, THF, methyl tert-butyl ether, 2-methyl THF, dioxane or heptane. Methanol can be replaced by, for example, but not limited to, ethanol or the THF aqueous solution.
[0220] Lipid Nanoparticles (LNP) and Targeted LNP (tLNP)
[0221] As used herein, "lipid nanoparticle" (LNP) means a solid particle other than a liposome having an aqueous cavity. The core of the LNP (such as the cavity of a liposome) is surrounded by a lipid layer, which may be, but not necessarily, a continuous lipid monolayer, a bilayer found in a liposome, or a multilayer having three or more lipid layers.
[0222] In certain aspects, the disclosure provides lipid nanoparticles (LNPs) comprising ionizable cationic lipids of Formula 1, Formula 2, or Formula 3, or a combination thereof. In some embodiments, the LNP comprises an ionizable cationic lipid of Formula 1, Formula 2, or Formula 3, or a combination thereof, and a phospholipid, a sterol, a co-lipid, or a PEGylated lipid, or a combination thereof. In certain embodiments, the PEG-lipid is not a functionalized PEG-lipid. In certain embodiments, the LNP comprises at least one functionalized PEG-lipid and at least one PEG-lipid that is not a functionalized PEG-lipid.
[0223] In a further aspect, the present disclosure provides targeting lipid nanoparticles (tLNP) comprising ionizable cationic lipids of formula 1, formula 2 or formula 3 or a combination thereof. In some embodiments, the above-mentioned tLNP may also include one or more of phospholipids, sterols, co-lipids and PEG-lipids or a combination thereof and functionalized PEG-lipids. As used herein, "functionalized PEG-lipids" refer to PEG-lipids, wherein the PEG moiety has been derivatized with a chemically reactive group that can be used to conjugate the targeting moiety to the PEG-lipid. After LNP is formed, the functionalized PEG-lipid can react with the binding moiety so that the binding moiety is conjugated to the PEG moiety of the lipid. Therefore, the conjugated binding moiety can be used as the targeting moiety of tLNP.
[0224] About LNP or tLNP of the present disclosure, in various embodiments, phospholipid comprises dioleoylphosphatidylethanolamine (DOPE), dimyristoylphosphatidylcholine (DMPC), distearoylphosphatidylcholine (DSPC), dimyristoylphosphatidylglycerol (DMPG), dipalmitoylphosphatidylcholine (DPPC) or 1,2-arachidonylphosphatidylcholine (DAPC) or its combination. Phospholipid can contribute to the formation of monolayer, bilayer or multilayer membrane around LNP or tLNP core. In addition, phospholipid such as DSPC, DMPC, DPPC, DAPC imparts membrane structure stability and rigidity. Phospholipid, such as DOPE, imparts fusogenicity. Other phospholipids, such as DMPG, that obtain negative charge at physiological pH promote charge regulation. Therefore, phospholipid constitutes the means for promoting membrane formation, the means for imparting membrane stability and rigidity, the means for imparting fusogenicity and the means for charge regulation.
[0225] About LNP or tLNP of the present disclosure, in various embodiments, sterol is cholesterol, 20-hydroxy cholesterol, 22-hydroxy cholesterol or plant sterol. In further embodiments, plant sterol comprises campesterol, sitosterol or stigmasterol or its combination. In preferred embodiments, cholesterol is not of animal origin, but is obtained by using plant sterol as starting point synthesis. It has been reported that LNP incorporating C-24 alkyl (such as methyl or ethyl) plant sterol provides enhanced gene transfection. The length of alkyl tail, the flexibility of sterol ring and the polarity associated with the C-3-OH group retained are important for obtaining high transfection efficiency. Although beta-sitosterol and stigmasterol perform well, vitamin D2, D3 and calcipotriol (analogs lacking complete cholesterol bodies) and betulin, lupeol ursolic acid and oleanolic acid (comprising the 5th ring) should be avoided. Sterol is used to fill the space between other lipids in LNP or tLNP and affect LNP or tLNP shape. Sterol also controls the fluidity of lipid composition and reduces temperature dependence. Thus, sterols such as cholesterol, 20-hydroxycholesterol, 22-hydroxycholesterol, campesterol, fucoxanthinol, β-sitosterol and stigmasterol constitute a means for controlling the shape and fluidity of LNPs, or a sterol means for increasing transfection efficiency.
[0226] About LNP or tLNP of the present disclosure, in some embodiments, co-lipid does not exist or comprises ionizable lipid, anion or cation.Co-lipid can be used to adjust various properties of LNP or tLNP, such as surface charge, mobility, rigidity, size, stability, etc. In some embodiments, co-lipid is ionizable lipid, such as cholesterol hemisuccinate (CHEMS) or ionizable lipid of the present disclosure. In some embodiments, co-lipid is charged lipid, such as lipid containing quaternary ammonium head group. In some cases, lipid containing quaternary ammonium head group comprises 1,2-dioleoyl-3-trimethylammonium propane (DOTAP), N-(1-(2,3-dioleoyloxy) propyl)-N,N,N-trimethylammonium (DOTMA) or 3β-(N-(N',N'-dimethylaminoethane) carbamoyl) cholesterol (DC-Chol) or its combination. In certain embodiments, these compounds are chloride, bromide, mesylate or tosylate.
[0227] When the disclosed ionizable lipids of Formula 1, Formula 2 and Formula 3 have a measured pKa of 6 to 7, they can contribute to significant endosomal release activity for LNPs or tLNPs containing ionizable lipids. The more acidic or basic ionizable lipids of Formula 1, Formula 2 and Formula 3 can contribute to the surface charge and are therefore used as the co-lipids just described above. In this case, it may be advantageous to incorporate another lipid with fusion activity into the LNP or tLNP of the present disclosure. It is known that the surface charge affects the tissue tropism of LNP or tLNP; for example, positively charged LNP or tLNP has been shown to be tropistic to the spleen and lung.
[0228] With respect to the LNPs or tLNPs of the present disclosure, in some embodiments, the PEG-lipid (i.e., a lipid conjugated to polyethylene glycol (PEG)) is a C 14 -C 20 Lipids. They have fatty acid chains shorter than C 14 PEG-lipids are lost too quickly from (t)LNPs, while chain lengths greater than C 20Those of PEG are difficult to formulate. In some embodiments, PEG is 500-5000 or 1000-5000Da molecular weight (MW). In some embodiments, the PEG unit has a MW of 2000Da. In some cases, MW2000PEG-lipids include DMG-PEG2000 (1,2-dimyristoyl-glycerol-3-methoxypolyethylene glycol-2000), DPG-PEG2000 (1,2-dipalmitoyl-glycerol-3-methoxypolyethylene glycol-2000), DSG-PEG2000 (1,2-distearoyl-glycerol-3-methoxypolyethylene glycol-2000), DOG-PEG2000 (1,2-dioleoyl-glycerol-3-methoxypolyethylene glycol-2000), DMPE-PEG2 00 (1,2-dimyristoyl-glycero-3-phosphoethanolamine-3-methoxypolyethylene glycol-2000), DPPE-PEG2000 (1,2-dipalmitoyl-glycero-3-phosphoethanolamine-3-methoxypolyethylene glycol-2000), DSPE-PEG2000 (1,2-distearoyl-glycero-3-phosphoethanolamine-3-methoxypolyethylene glycol-2000), DOPE-PEG2000 (1,2-dioleoyl-glycero-3-phosphoethanolamine-3-methoxypolyethylene glycol-2000) or a combination thereof. In some embodiments, the PEG unit has a MW of 2000 Da. In some cases, MW 2000 PEG-lipids include DMRG-PEG2000 (1,2-dimyristoyl-rac-glycerol-3-methoxypolyethylene glycol-2000), DPRG-PEG2000 (1,2-dipalmitoyl-rac-glycerol-3-methoxypolyethylene glycol-2000), DSrG-PEG2000 (1,2-distearoyl-rac-glycerol-3-methoxypolyethylene glycol-2000), DORG-PEG2000 (1,2-dioleoyl-glycerol-3-methoxypolyethylene glycol-2000), DMPER-PEG2000 (1,2-dipalmitoyl-rac-glycerol-3-methoxypolyethylene glycol-2000). 00 (1,2-dimyristoyl-glycero-3-phosphoethanolamine-3-methoxypolyethylene glycol-2000), DPPER-PEG2000 (1,2-dipalmitoyl-glycero-3-phosphoethanolamine-3-methoxypolyethylene glycol-2000), DSPEr-PEG2000 (1,2-distearoyl-rac-glycero-3-phosphoethanolamine-3-methoxypolyethylene glycol-2000), DOPEr-PEG2000 (1,2-dioleoyl-rac-glycero-3-phosphoethanolamine-3-methoxypolyethylene glycol-2000), or a combination thereof. Alternatively, an optically pure enantiomer of the glycerol portion may be used, i.e., the glycerol portion is homochiral. As used herein with respect to the glycerol portion, optical purity means ≥95% of a single enantiomer (D or L).In some embodiments, the enantiomeric excess is ≥98%. In some embodiments, the enantiomeric excess is ≥99%. Additional PEG-lipids are disclosed in U.S. Provisional Application No. 63 / 362,502 filed on April 5, 2022 and PCT Application (Atty. Docket No. 146758-8002.WO00) filed on April 5, 2023, including non-chiral PEG-lipids constructed on symmetrical dihydroxyacetone scaffolds, symmetrical 2-(hydroxymethyl) butane-1,4-diol or symmetrical glycerol scaffolds, both of which are entitled PEG-Lipids and LipidNanoparticles, the entire contents of which are incorporated herein by reference.
[0229] The PEG-part provides a hydrophilic surface on the LNP, which suppresses the aggregation or merging of the LNP, thereby contributing to their stability and reducing polydispersity. In addition, the PEG part may hinder the combination of LNP, including the combination with plasma proteins. These plasma proteins include apoE, which is understood to mediate the uptake of LNP by the liver, so that the inhibition of combination can cause the ratio of LNP arriving in other tissues to increase. These plasma proteins also include opsonins, so that the inhibition of combination reduces the recognition of the reticuloendothelial system. The PEG-part can also be functionalized to serve as the attachment point of the targeting moiety. Cell or tissue specific binding moiety is conjugated to the PEG-part so that tLNP can avoid the liver and be attached to its target tissue or cell type, thereby greatly increasing the ratio of LNP arriving at the target tissue or cell type. Therefore, PEG-lipid can be used as the means for suppressing the combination of LNP, and the PEG-lipid conjugated to the binding moiety can be used as the means of LNP targeting.
[0230] In some embodiments, a "binding moiety" or "targeting moiety" refers to a protein, polypeptide, oligopeptide, peptide, carbohydrate, nucleic acid, or combination thereof that is capable of specifically binding to a target or multiple targets. Binding domains include any naturally occurring, synthetic, semisynthetic, or recombinantly produced binding partner for a target of a biological molecule or another target. Exemplary binding moieties of the present disclosure include antibodies, Fab', F(ab')2, Fab, Fv, rIgG, scFv, hcAbs (heavy chain antibodies), single domain antibodies, VHH, VNAR, sdAbs, nanobodies, receptor extracellular domains or their ligand binding portions, or ligands (e.g., cytokines, chemokines). "Fab" (fragment antigen binding) is a portion of an antibody that binds to an antigen and includes a variable region and CH1 of a heavy chain connected to a light chain via an interchain disulfide bond. A variety of assays are known for identifying binding moieties of the present disclosure that specifically bind to a particular target, including Western blots, ELISAs, and Binding moieties, such as those comprising immunoglobulin light and heavy chain variable regions (e.g., scFv), can be incorporated into various protein scaffolds or structures as described herein, such as antibodies or antigen-binding fragments thereof, scFv-Fc fusion proteins, or fusion proteins comprising two or more such immunoglobulin binding regions.
[0231] If the antibody or other binding moiety (or its fusion protein) is equal to or greater than 10 5 M -1 An antibody or other binding moiety (or fusion protein thereof) "specifically binds" a target if it binds to the target with an affinity or Ka (i.e., equilibrium association constant of a specific binding interaction with 1 / M units) of at least 10 Å, without significantly binding to other components present in the test sample. Binding domains (or fusion proteins thereof) can be classified as "high affinity" binding domains (or fusion proteins thereof) and "low affinity" binding domains (or fusion proteins thereof). "High affinity" binding domains are those that have at least 10 8 M -1 , at least 10 9 M -1 , at least 10 10 M -1 , at least 10 11 M -1 , at least 10 12 M -1 or at least 10 13 M -1 , preferably at least 10 8 M -1 or at least 10 9 M -1 "Low affinity" binding domains are those with a maximum affinity of 10 8 M -1 , up to 10 7 M -1 , up to 10 6 M -1 , up to 10 5 M -1 Alternatively, affinity can be defined as the unit of specific binding interaction with M (e.g., 10 -5 M to 10 -13 The affinity of the binding domain polypeptides and fusion proteins according to the present disclosure can be readily determined using conventional techniques (see, e.g., Scatchard et al., Ann. NY Acad. Sci. 51:660, 1949; and U.S. Pat. Nos. 5,283,173, 5,468,614, or their equivalents).
[0232] Some embodiments of disclosed ionizable cationic lipids have the head group with little (<250Da) PEG part.These lipids are not the implication of the term PEG-lipid as used herein.These little PEG parts are usually too little to hinder the combination with the degree similar to the larger PEG part of PEG-lipid described above, although they will affect the lipophilicity of ionizable cationic lipid.In addition, PEG-lipid is understood to be mainly located in the thin sheet facing the outer layer, and most of ionizable cationic lipid is located at the inside of LNP.
[0233] In various embodiments, the binding portion of tLNP comprises an antigen binding domain of an antibody, an antigen, a ligand binding domain of a receptor, or a receptor ligand. In some embodiments, the binding portion comprising the antigen binding domain of an antibody comprises a complete antibody, F(ab)2, Fab, a small antibody, a single-chain Fv (scFv), a double antibody, a VH domain, or a nanobody, such as a VHH or a single domain antibody. In some embodiments, the receptor ligand is a carbohydrate, such as a carbohydrate comprising a terminal galactose or N-acetylgalactosamine unit, which is bound by an asialoglycoprotein receptor. These binding portions constitute the means of LNP targeting. Some embodiments specifically include one or more of these binding portions. Other embodiments specifically exclude one or more of these binding portions.
[0234] As used herein, "antibody" refers to a protein comprising an immunoglobulin domain having a hypervariable region that determines the specificity of the antibody binding antigen; the so-called complementary determining region (CDR). Therefore, the term antibody can refer to a complete or entire antibody and an antibody fragment and construct comprising the antigen-binding portion of the entire antibody. Although typical natural antibodies have a pair of heavy and light chains, camelids (camels, alpacas, llamas, etc.) produce antibodies with typical structures and antibodies containing only heavy chains. The variable region of antibodies with only camelid heavy chains has a different structure, with an elongated CDR3 called VHH, or when produced as a fragment, with nanobodies. Antigen-binding fragments and constructs of antibodies include F(ab)2, F(ab), small antibodies, Fv, single-chain Fv (scFv), double antibodies and VH. Such elements can be combined to produce bispecific and multispecific agents, such as BiTE. The term "monoclonal antibody" comes from hybridoma technology, but is now used to refer to any single molecule species of antibodies, regardless of how it originates or is produced. Antibodies can be obtained by immunization, selection (for example, by phage display) from natural or immune libraries, changes in isolated antibody coding sequences, or any combination thereof. A variety of antibodies that can be used as binding moieties are known in the art. An excellent source (including sequence information) for information about antibodies for which international nonproprietary names (INNs) have been proposed or recommended is Wilkinson & Hale, MAbs 14 (1): 2123299, 2022, including its supplementary tables, which are incorporated herein by reference because they teach all the contents of individual antibody forms and various antibody forms that can be constructed. US11,326,182, and especially its Table 9 cancer, inflammation and immune system antibodies are sources of sequences and other information including many antibodies without INNs, and they teach all the contents of single antibodies, incorporated herein by reference.
[0235] The functionalized PEG-lipid of the tLNP comprises one or more fatty acid tails, each of which is no shorter than C for straight chain fatty acids. 16 No longer than C 20 For branched chain fatty acids, no shorter than C 14 Fatty acids or no longer than C 20 In some embodiments, the fatty acid tail is C 16 In some embodiments, the fatty acid tail is C 18. In some embodiments, the functionalized PEG-lipid comprises a dipalmitoyl lipid. In some embodiments, the functionalized PEG-lipid comprises a distearoyl lipid. The fatty acid tail is used as a means of anchoring the PEG-lipid in the tLNP to reduce or eliminate the PEG-lipid from the tLNP. This is a useful property for the PEG-lipid, whether it is functionalized or not, but has greater importance for the functionalized PEG-lipid because it will have a targeting moiety attached to it, and if the PEG-lipid (with the conjugated binding moiety) falls off from the tLNP, the targeting function may be impaired.
[0236] Any suitable chemical method can be used to conjugate the binding moiety to the PEG of the PEG-lipid, including maleimide (see Parhiz et al., Journal of Controlled Release 291: 106-115, 2018) and click (see Kolb et al., Angewandte Chemie International Edition 40 (11): 2004-2021, 2001; and Evans, Australian Journal of Chemistry 60 (6): 384-395, 2007) chemistry. Reagents used for this reaction include lipid-PEG-maleimide, lipid-PEG-cysteine, lipid-PEG-alkyne, lipid, PEG-dibenzocyclooctyne (DBCO) and lipid-PEG-azide. Further conjugation reactions utilize lipid-PEG-bromomaleimide, lipid-PEG-alkyne acid amide, PEG-alkyne acid imide and lipid-PEG-alkyne reactions, such as U.S. Provisional Application No. 63 / 362,502 filed on April 5, 2022 and PCT Application (Atty.Docket No.146758-8002.WO00) filed on April 5, 2023, both of which are entitled PEG-Lipids and Lipid Nanoparticles, the entire contents of which are incorporated herein by reference. On the binding part side of the reaction, existing cysteine sulfhydryls can be used, or by adding, for example, sulfur-containing carboxylic acids to the epsilon amino group of lysine to react with maleimide, bromomaleimide, chain alkyne acid amide or alkyne acid imide to derivatize the protein. Alternatively, alkynes can be added to the sulfhydryl or epsilon amino group of lysine to participate in click chemistry reactions.
[0237] About LNP or tLNP of the present disclosure, in some embodiments, the molar ratio of lipid is about 40 to about 60mol% ionizable cationic lipid. In some embodiments of LNP or tLNP, the molar ratio of lipid is about 7 to about 30mol% phospholipid. In some embodiments of LNP or tLNP, the molar ratio of lipid is about 20 to about 45mol% sterol. In some embodiments of LNP or tLNP, the molar ratio of lipid is 1 to 30mol% total lipid. In some embodiments of LNP or tLNP, the molar ratio of lipid is 0 to 5mol% PEG-lipid. In some embodiments of LNP or tLNP, the molar ratio of lipid is 0.1 to 5mol% functionalized PEG-lipid. In some embodiments, functionalized PEG-lipid is conjugated to binding moiety.
[0238] Due to the physiology and manufacturing restrictions of the LNP or tLNP used in vivo, it is necessary to have a particle with a hydrodynamic diameter of about 50 to about 150nm. Therefore, in some embodiments, LNP or tLNP have a hydrodynamic diameter of 50 to 150nm, and in some cases, the hydrodynamic diameter is ≤120nm, ≤110nm, ≤100nm or ≤90nm. The uniformity of particle size is also desirable, and polydispersity index (PDI) ≤0.2 (on a scale of 0 to 1) is acceptable. Both hydrodynamic diameter and polydispersity index are measured by dynamic light scattering (DLS). The particle diameter assessed by cryo-transmission electron microscopy (Cryo-TEM) can be less than the value measured by DLS.
[0239] LNP or tLNP of the present disclosure also include nucleic acid.In various embodiments, nucleic acid is mRNA, self-replicating RNA, siRNA, miRNA, DNA, gene editing assembly (for example, guide RNA, tracr RNA, sgRNA), gene writing assembly, mRNA encoding gene or base editing protein, zinc finger nuclease, Talen, CRISPR nuclease (for example Cas9, insert or use as the DNA molecule of the template of repair), etc., or its combination.In some embodiments, mRNA encodes chimeric antigen receptor (CAR).In other embodiments, mRNA encodes gene editing or base editing or gene writing protein.In some embodiments, nucleic acid is guide RNA.In some embodiments, LNP or tLNP include gene editing or base editing or gene writing protein encoding mRNA and one or more guide RNA.CRISPR nuclease can have the activity of change, for example, modifying nuclease so that it is nickase, instead of double-stranded cutting, or making it bind to the sequence specified by guide RNA, but without enzymatic activity. Base editing proteins are typically fusion proteins containing a deaminase domain and a sequence-specific DNA binding domain (e.g., an inactive CRISPR nuclease).
[0240] With respect to the LNPs or tLNPs of the present disclosure, in some embodiments, the ratio of total lipid to nucleic acid is from about 10: 1 to about 50: 1 by weight. In some embodiments, the ratio of total lipid to nucleic acid is from about 10: 1, about 20: 1, about 30: 1, or about 40: 1 to about 50: 1, or 10: 1 to 20: 1, 30: 1, 40: 1 or 50: 1, or any range defined by a pair of these ratios.
[0241] In some aspects, the present disclosure provides a method for preparing LNP or tLNP, including mixing an aqueous solution of nucleic acid with an alcohol solution of lipid. In a specific embodiment, mixing is fast. The aqueous solution is buffered to pH about 3 to about 5, such as but not limited to citrate or acetate. In various embodiments, alcohol can be ethanol, isopropanol, tert-butyl alcohol or a combination thereof. In some embodiments, rapid mixing is achieved by pumping two solutions through a T-joint or with an impact jet mixer. Microfluidic mixing by staggered herringbone mixers (SHM) or fluid dynamic mixers (microfluidic dynamic focusing), microfluidic bifurcated mixers and microfluidic baffle mixers can also be used. After forming LNP, they are diluted with buffer (such as phosphate, HEPES or Tris) in a pH range of 6 to 8.5 to reduce alcohol (ethanol) concentration. The diluted LNP is purified by dialysis or ultrafiltration or using tangential flow filtration (TFF) in a buffer (such as phosphate, HEPES or Tris) in a pH range of 6 to 8.5 to remove alcohol. Alternatively, size exclusion chromatography can be used. Once alcohol is completely removed, the buffer is exchanged with a similar buffer containing a cryoprotectant (e.g., glycerol or sugar, such as sucrose, trehalose or mannose). LNP is concentrated to a desired concentration, then filtered at 0.2 μm through, for example, polyethersulfone (PES) or a modified PES filter, and filled into a glass vial, plugged, capped, and stored frozen. In an optional embodiment, a lyophilized LNP is stored instead of as a frozen liquid using a lyophilized protective agent. Other methods for preparing LNP can be found in, for example, US20200297634, US20130115274, and WO2017 / 048770, each of which is incorporated herein by reference to obtain all contents of the production of LNPs taught therein.
[0242] One aspect is the method for preparing tLNP, as disclosed for LNP, including the rapid mixing of the aqueous solution of nucleic acid with the alcohol solution of lipid.In some embodiments, lipid mixture includes functionalized PEG-lipid, for being conjugated to targeting moiety subsequently.As used herein, functionalized PEG-lipid refers to the PEG-lipid that wherein PEG part has been derived with chemically reactive group (for example, maleimide, NHO ester, Cys, azide, alkyne etc.), and described chemically reactive group can be used for being conjugated to targeting moiety to PEG-lipid, and therefore being conjugated to the LNP comprising PEG-lipid.In other embodiments, after LNP is initially formed by other components, functionalized PEG-lipid is inserted in LNP.In the embodiment of either type, after forming the LNP containing functionalized PEG-lipid, targeting moiety is conjugated to functionalized PEG-lipid. For conjugation protocols, see, for example, Parhiz et al. J. Controlled Release 291: 106-115, 2018 and Tombachz et al., Molecular Therapy 29 (11): 3293-3304, 2021, each of which is incorporated herein by reference to obtain all of the contents of the PEG lipid conjugated to the binding moiety taught therein. Alternatively, the targeting moiety can be conjugated to the PEG-lipid before insertion into the preformed LNP.
[0243] In certain embodiments of the method of preparing tLNP, the method comprises:
[0244] i). forming an initial LNP by mixing all components of the tLNP except one or more functionalized PEG-lipids and one or more targeting moieties;
[0245] ii). forming pre-conjugated tLNPs by mixing the initial LNPs with one or more functionalized PEG-lipids; and
[0246] iii). Forming tLNPs by conjugating pre-conjugated tLNPs to one or more targeting moieties.
[0247] In certain embodiments of the method of preparing tLNP, the method comprises:
[0248] i). forming a pre-conjugated tLNP by mixing all components of the tLNP except the one or more targeting moieties (including the one or more functionalized PEG-lipids); and
[0249] ii). Forming tLNPs by conjugating pre-conjugated tLNPs to one or more targeting moieties.
[0250] In certain embodiments of the method of preparing tLNP, the method comprises:
[0251] i). forming one or more conjugated functionalized PEG-lipids by conjugating one or more functionalized PEG-lipids to one or more targeting moieties; and
[0252] ii) forming the tLNP by mixing all components of the tLNP, including the one or more conjugated functionalized PEG-lipids.
[0253] In certain embodiments of the method of preparing tLNP, the method comprises:
[0254] i). forming one or more conjugated functionalized PEG-lipids by conjugating one or more functionalized PEG-lipids to one or more targeting moieties;
[0255] ii) forming the LNP by mixing all components of the tLNP except the one or more conjugated functionalized PEG-lipids; and
[0256] iii) Forming tLNPs by mixing the initial LNPs with one or more conjugated functionalized PEG-lipids.
[0257] After conjugation, tLNPs are purified by dialysis, tangential flow filtration, or size exclusion chromatography and stored as disclosed above for LNPs.
[0258] The encapsulation efficiency of the nucleic acid by LNP or tLNP is usually determined by adding nucleic acid-binding fluorescent dye to the complete and cracked aliquots of the final LNP or tLNP preparation to measure the amount of unencapsulated and total nucleic acid respectively. Encapsulation efficiency is usually expressed as a percentage, and is calculated as 100 × (TU) / T, where T is the total amount of nucleic acid, and U is the amount of unencapsulated nucleic acid. In various embodiments, the encapsulation efficiency is ≥80%, ≥85%, ≥90% or ≥95%.
[0259] In other aspects, disclosed herein are methods of delivering nucleic acids to cells, comprising contacting the cells with the LNP or tLNP of any of the foregoing aspects. In some embodiments, the contact is performed ex vivo. In some embodiments, the contact is performed in vivo. In some cases, in vivo contact includes intravenous, intramuscular, subcutaneous, intranodal or intralymphatic administration. In some embodiments, as described above, toxicity is limited (or largely limited to) to 0 or 1 or 2 grades.
[0260] The following examples are intended to illustrate various embodiments of the present invention. Therefore, the specific embodiments discussed do not constitute a limitation to the scope of the invention. It is apparent to those skilled in the art that various equivalents, changes and modifications may be made without departing from the scope of the present invention, and it is understood that these equivalent embodiments will be included herein. In addition, all references cited in this disclosure are incorporated herein by reference in their entirety, as if fully described herein to the extent that they are not inconsistent with this disclosure.
[0261] Example
[0262] Example 1: Synthesis of a compound having the structure of Formula 1
[0263] Dihydroxyacetone can be reacted with (tert-butoxycarbonylmethylene)triphenylphosphine to provide the olefin Ia. Hydrogenation of Ia provides Ib, and coupling of Ib with decanoic acid (EDC-HCl, DMAP) produces the triester Ic. Hydrolysis of the tert-butyl ester (CF3CO2H, CH2Cl2) produces the monoacid Id. Coupling of Id with BOC-terminated diethanolamine gives Ie. Removal of BOC (CF3CO2H, CH2Cl2) provides the salt If (see Figure 1D ), which is converted to an acyl-imidazolide Ig when reacted with carbonyldiimidazole. Reaction of Ig with methyl trifluoromethanesulfonate produces an acyl-imidazolium salt Ih, which is an intermediate to be converted into compounds A-1 to A-3. Reaction of Ih with 3-dimethylamino-1-propanol in the presence of a base produces carbamate compound A-1, reaction of Ih with N,N-dimethyl-1,3-propylenediamine provides NH-urea compound A-2, and reaction of Ih with N,N,N'-trimethyl-1,3-propylenediamine produces compound A-3 (see Figure 1E ).
[0264] Compound A-4 (see Figure 1F ).
[0265] The head group in compound A-1, i.e., X in Formula 1, is derived from 3-dimethylamino-1-propanol. To obtain analogs of compound A-1 with the disclosed optional head group X and various n values, the compounds of Table 1 can be used to replace 3-dimethylamino-1-propanol in the transformation of Ih.
[0266] Table 1. Optional head groups of compound A-1
[0267]
[0268]
[0269]
[0270]
[0271] Reagents XR1 to XR9, XR12 to XR18, XR21 to XR27, XR30 to XR38 and XR41 to 49 are known in the art, e.g., from the Chemical Abstracts Society. As reported, among them XR1 to XR5, XR7, XR12 to XR15, XR21 to XR25, XR30 to XR31, XR33 and XR41 are commercially available. Polyethylene glycol containing reagents can be synthesized as described in Example 4, as shown below.
[0272] The head group in compound A-2, i.e., X in Formula 1, is derived from N,N-dimethyl-1,3-propanediamine. To obtain analogs of compound A-2 with the disclosed optional head group X and various values of n, the compounds of Table 2 can be used to replace N,N-dimethyl-1,3-propanediamine in the transformation of Ih.
[0273] Table 2. Optional head groups of compound A-2
[0274]
[0275]
[0276]
[0277]
[0278] Reagents XR52 to XR60, XR63 to XR70, XR73 to XR81, XR84 to XR92 and XR95 to XR103 are known in the art, as described in the Chemical Abstracts Society As reported, among them XR52 to XR57, XR63 to XR66, XR73 to XR77, XR84, XR86 to XR87 and XR95 are commercially available. Polyethylene glycol containing reagents can be synthesized as described in Example 4, as shown below.
[0279] The head group in compound A-3, i.e., X in Formula 1, is derived from N,N,N'-trimethyl-1,3-propanediamine. To obtain analogs of compound A-3 with the disclosed optional head group X and various n values, the compounds of Table 3 can be used to replace N,N,N'-trimethyl-1,3-propanediamine in the transformation of Ih.
[0280] Table 3. Alternative head groups of compound A-3
[0281]
[0282]
[0283]
[0284]
[0285] Agents XR106 to XR114, XR117 to XR124, XR127 to XR131, XR134, XR138 to XR142, XR149 to XR153 and XR156 are known in the art, as described in the Chemical Abstracts Society. As reported, XR106 to XR110, XR117 to XR120 and XR127 are commercially available. XR132 to XR133, XR135, XR143 to XR146, XR154 to XR154 and XR156 are prepared similarly to their shorter homologues. Polyethylene glycol-containing reagents are synthesized as disclosed in Example 4, as shown below.
[0286] The head group in compound A-4, ie, X in Formula 1, is derived from 4-dimethylaminobutyric acid. To obtain analogs of compound A-4 with the disclosed optional head group X and various n values, the compounds of Table 4 can be used to replace 4-dimethylaminobutyric acid in the conversion of If.
[0287] Table 4. Alternative head groups of compound A-4
[0288]
[0289]
[0290]
[0291]
[0292] Agents XR160 to XR168, XR171 to XR178, XR181 to XR189, XR192 to XR196 and XR203 to XR206 are known in the art, as described in the Chemical Abstracts Society As reported, XR160, XR162 to XR164 and XR181 are commercially available. XR196 to XR199 and XR207 to XR211 can be prepared similarly to their shorter homologues. Polyethylene glycol-containing reagents can be synthesized as described in Example 4, as shown below.
[0293] Example 2: Synthesis of a compound having the structure of Formula 2
[0294] Reaction of the sodium salt of BOC-terminated diethanolamine with 5-(2-bromoethyl)-2,2-dimethyl-1,3-dioxane II-a or 5-(2-bromoethyl)-2-phenyl-1,3-dioxane II-b affords II-c and II-d, respectively. Different deprotection options are available, for example, as exemplified by II-c and II-d, respectively. II-c can be deprotected with a weak acid (PPTs, MeOH) to afford the diol II-e. The benzylidene acetal II-d can be deprotected with hydrogen and Pd / C to provide II-e. Coupling of II-e with decanoic acid (EDC-HCl, DMAP) affords II-f, which upon deprotection of the BOC-protected amine exposed to CF3CO2H affords the amine salt II-g. The reaction of amine salt II-g with carbonyldiimidazole produces II-h, followed by the reaction of acyl imidazole II-h with methyl trifluoromethanesulfonate to provide the intermediate acyl imidazole salt II-i ( Figure 2D ). In the presence of a base, the reaction of II-i with 3-dimethylamino-1-propanol produces carbamate compound A-5, the reaction of II-i with N,N-dimethyl-1,3-propylenediamine provides NH-urea compound A-6, and the reaction of II-i with N,N,N'-trimethyl-1,3-propylenediamine produces compound A-7 ( Figure 2E ).
[0295] Amide compound A-8 was obtained from the reaction of salt II-g with 4-dimethylamino-butyric acid (EDC-HCl, DMAP, Et3N) ( Figure 2F ).
[0296] The head group in compound A-5, i.e., X in Formula 2, is derived from 3-dimethylamino-1-propanol. To obtain analogs of compound A-5 with the disclosed optional head group X and various n values, the compounds of Table 1 (above) can be used to replace 3-dimethylamino-1-propanol in the transformation of II-i.
[0297] The head group in compound A-6, i.e., X in Formula 2, is derived from N,N-dimethyl-1,3-propanediamine. To obtain analogs of compound A-6 with the disclosed optional head group X and various values of n, the compounds of Table 2 (above) can be used to replace N,N-dimethyl-1,3-propanediamine in the transformation of II-i.
[0298] The head group in compound A-7, i.e., X in Formula 2, is derived from N,N,N'-trimethyl-1,3-propanediamine. To obtain analogs of compound A-7 with the disclosed optional head group X and various values of n, the compounds of Table 3 (above) can be used to replace N,N,N'-trimethyl-1,3-propanediamine in the transformation of II-i.
[0299] The head group in compound A-8, i.e., X in Formula 2, is derived from 4-dimethylamino-butyric acid. To obtain analogs of compound A-8 with the disclosed optional head group X and various n values, the compounds of Table 4 (above) can be used to replace 4-dimethylamino-butyric acid in the transformation of II-g.
[0300] Polyethylene glycol-containing reagents were synthesized as disclosed in Example 4 below.
[0301] Example 3: Synthesis of a compound having the structure of Formula 3
[0302] The reaction of glutaric anhydride and dimethylamine gives 5-(dimethylamino)-5-oxopentanoic acid III-a. In the presence of (4-(4,6-dimethoxy-1,3,5-triazine-2-yl)-4-methylmorpholinium chloride), coupling of III-a with diethanolamine gives N1,N1-bis(2-hydroxyethyl)-N5,N5-dimethyl-glutaramide III-b, and reduction (LiAlH4) gives diol III-c. Diol III-c is then coupled with acid Id to give compound A-9 ( Figure 3C ).
[0303] The sodium salt of III-c (NaH, DMF) reacts with bromide II-a or II-b to give diamines III-d and III-e. Deprotection of III-d with PPTs in methanol or deprotection of III-e with hydrogen and palladium / carbon gives tetraol III-f. Coupling of tetraol III-f with decanoic acid (EDC-HCl, DMAP) produces compound A-10.
[0304] The head group in compounds A-9 and A-10, ie, X in Formula 3, is derived from 5-(dimethylamino)-5-oxopentanoic acid (III-a) reacted with diethanolamine. To obtain analogs of compounds A-9 and A-10 with the disclosed optional head group X and various n values, the carboxylic acids of Table 4 can be used to replace 5-(dimethylamino)-5-oxopentanoic acid (III-a) according to the following scheme:
[0305]
[0306] and, as the case may be, according to FIG. 3C to FIG. 3D Complete the reaction.
[0307] Polyethylene glycol-containing reagents were synthesized as disclosed in Example 4 below.
[0308] Example 4. Synthesis of Polyethylene Glycol-Containing Head Group
[0309] Commercially available sodium salt (NaH, DMF) of 1,1-dimethylethyl N-(3-hydroxypropyl)-N-methylcarbamate was reacted with the mesylate of 2-(2-(2-methoxyethoxy)ethoxy)ethyl methanesulfonate to provide V-5, which subsequently afforded amine V-6 after BOC removal (TFA) and neutralization. Reductive amination using commercially available 1,1-dimethylethyl N-methyl-N-(3-oxopropyl)carbamate then afforded BOC-protected amine V-7. The target PEG-containing head group fragment V-8 (XR125 in Table 3) was then obtained after BOC removal (TFA) and amine neutralization. See Figure 4A .
[0310] Similarly, the sodium salt (NaH, DMF) of commercially available BOC-terminated 4-hydroxypiperidine was reacted with commercially available 2-(2-(2-methoxyethoxy)ethoxy)ethyl methanesulfonate to provide V-1, which subsequently afforded amine V-2 after BOC removal (TFA) and neutralization. Reductive amination using commercially available 1,1-dimethylethyl N-methyl-N-(3-oxopropyl)carbamate then afforded BOC-protected amine V-3. The target PEG-containing head group fragment V-4 (XR126 in Table 3) was then obtained after BOC removal (TFA) and amine neutralization. See Figure 4B .
[0311] Shorter chain PEG containing head group entities can be obtained by replacing the 2-(2-(2-methoxyethoxy)ethoxy)ethyl methanesulfonate used in the above scheme with known / commercially available shorter chain mesylates V-9 (known) and V-10 (commercially available).
[0312]
[0313] To synthesize V-4 variants with different n values or alternative definitions of Y, appropriate analogs of 1,1-dimethylethyl N-methyl-N-(3-oxopropyl)carbamate were used to generate the desired PEG-containing head group fragments. For variants of V-8, appropriate analogs of 1,1-dimethylethyl N-(3-hydroxypropyl)-N-methylcarbamate were used to generate different m values and analogs of 1,1-dimethylethyl N-methyl-N-(3-oxopropyl)carbamate were used to generate different n values or definitions of Y to generate the desired PEG-containing head group fragments.
[0314] Example 5.
[0315] Synthesis of 1,1-dimethylethyl 4-hydroxy-3-(hydroxymethyl)-2-butenoate (Ia)
[0316]
[0317] Under nitrogen, tert-butoxycarbonylmethylene-triphenylphosphine (627 g, 1.67 mol) was added in batches to a solution of dihydroxyacetone (150.0 g, 1.67 mol) in anhydrous dichloromethane (3.0 L) over 1 hour. The mixture was stirred at room temperature for 18 hours, then silica gel (750 g, type: ZCX-2, 100-200 mesh) was added to the solution, and the solvent was removed in vacuo to obtain the crude product 1 impregnated on silica gel. The dried silica gel was placed on a gravity column of silica gel (3700 g, type: ZCX-2, 100-200 mesh, filled with petroleum ether), and the resulting column was eluted with a gradient of petroleum ether: ethyl acetate (100:0 to 50:50). Compound Ia was eluted with petroleum ether:ethyl acetate 50:50 and fractions of Ia were concentrated in vacuo to afford 1 (235.0 g) containing Ph 3 PO (73.8% purity by HNMR, 55% yield of Ia).
[0318] 1 H NMR (400MHz, DMSO-d6, ppm): δ5.77(m,1H),5.00(t,J=5.6Hz,1H),4.80(t,J=5.7Hz,1H) ,4.49(dd,J=5.8,1.5Hz,2H),4.17(dd,J=5.6,2.0Hz,2H),1.42(s,9H); LCMS(+ mode):C9H 16 O4+H + Calculated value: 189.11, measured value: 189.10.
[0319] Example 6.
[0320] Synthesis of tert-butyl 4-hydroxy-3-(hydroxymethyl)butyrate (Ib)
[0321]
[0322] To a solution of Ia (100.00 g, 73.8% purity, 0.53 mol) in anhydrous EtOH (1.0 L) was added Et3N (8.10 g, 0.080 mol) followed by 10% Pd / C (20.0 g) in a 2.0 L round bottom flask under nitrogen. The mixture was placed under a hydrogen balloon at room temperature for 16 hours. HPLC analysis indicated that hydrogenation was not complete and the hydrogen balloon was refilled and the reaction continued for an additional 16 hours. The mixture was stirred for 1 h by evaporation. The mixture was filtered through a pad of Celite®, the filter cake was rinsed with anhydrous EtOH (200 mL), and the combined filtrates were concentrated in vacuo to afford Ib (198.0 g) containing P3PO (67.5% purity by HNMR, 66% yield of Ib) as a yellow oil.
[0323] 1 H NMR (400MHz, DMSO-D6, ppm): d 4.47 (t, J = 5.10Hz, 2H), 3.44-3.29 (5H), 2.17 (d, J = 7.00Hz, 2H), 1.93 (m, 1H), 1.39 (s, 9H).
[0324] Example 7.
[0325] Synthesis of 2-(2-(tert-Butoxy)-2-oxoethyl)propane-1,3-diyldinonanoate (I-c2)
[0326]
[0327] To a solution of Ib (120.00 g, 67.5% purity, 0.63 mol) in CH2Cl2 (1.2 L) was added nonanoic acid (199.60 g, 1.26 mol, 2.0 equiv) and DMAP (77.10 g, 0.63 mol) in a 4 L flask under nitrogen. The mixture was stirred at room temperature for 10 min, and then EDCl (266.8 g, 1.39 mol, 2.20 equiv) was added in one portion. The mixture was stirred at room temperature for 16 hours, and then the solvent was removed in vacuo to provide the crude product I-c2 as a viscous yellow oil. The crude product I-c2 was dissolved in heptane / methyl tert-butyl ether (MTBE) (9:1, 2.0 L), and the solution was washed with 10% aqueous citric acid solution (2×1.2 L). The organic phase was washed with brine (2.0 L), MeOH: H2O (5: 1, 3 × 1.20 L), and then dried over anhydrous Na2SO4. The solid was removed by filtration and silica gel (400 g, type: ZCX-2, 100-200 mesh) was added to the solution. The solvent was removed in vacuo to obtain the crude product I-c2 impregnated on silica gel. The dried silica gel was placed on a gravity column of silica gel (4000 g, type: ZCX-2, 100-200 mesh, filled with petroleum ether), and the resulting column was eluted with a gradient of petroleum ether: THF (100: 0 to 95: 5). Compound I-c2 was eluted with petroleum ether: THF (98: 2) and the fractions of I-c2 were concentrated in vacuo to provide I-c2 as a colorless oil (208.0 g, HPLC purity 97.2%, 68% yield).
[0328] 1 H NMR (400MHz, CDCl3, ppm): d 4.11 (m, 4H), 2.52 (m, 1H), 2.31 (t, J = 7.40Hz, 4H), 1.62 (m, 4H), 1.46 (s, 9H), 1.35-1.27 (20H), 0.87 (m, 6H).
[0329] When used to synthesize lipids conforming to Formula 1 or Formula 3 according to the synthetic schemes disclosed herein, I-c2 produces lipids in which R is a linear C8, while Ic produces lipids in which R is a linear C9.
[0330] Example 8.
[0331] Synthesis of 4-(nonanoyloxy)-3-((nonanoyloxy)methyl)butanoic acid (I-d2)
[0332]
[0333] To a solution of I-c2 (110.0 g, 0.234 mol) in CH2Cl2 (1.0 L) was added trifluoroacetic acid (TFA) (330 mL, 4.31 mol) at room temperature under nitrogen over 30 min. The resulting solution was stirred at room temperature for 16 h and then concentrated in vacuo to provide the crude product I-d2 as a yellow oil. The crude product I-d2 was dissolved in CH2Cl2 (1.10 L) and the solution was washed with water (2×0.50 L). The combined aqueous phases were extracted with CH2Cl2 (0.5 L) and the combined organic layers were dried over anhydrous MgSO4. Filtration and concentration in vacuo gave I-d2 as a light brown oil (96.0 g, 0.232 mol, 99%, HPLC purity 98.5%).
[0334] 1 H NMR (400MHz, CDCl3, ppm):d 4.13 (m, 4H), 2.58 (m, 1H), 2.49 (d, II = 6.90Hz, 2H), 2.33 (t, J = 7.60Hz, 4H), 1.63 (m, 4H), 1.36-1.22 (20H), 0.89 (t, J = 6.60Hz, 6H); LCMS (+ mode): C 23 H 42 O6+H + Calculated value: 415.31. Measured value: 415.30.
[0335] When used to synthesize lipids conforming to Formula 1 or Formula 3 according to the synthetic schemes disclosed herein, I-d2 produces lipids in which R is a linear C8, while Id produces lipids in which R is a linear C9.
[0336] Example 9.
[0337] Synthesis of ((((((tert-Butoxycarbonyl)azanediyl)bis(ethane-2,1-diyl))bis(oxy))bis(2-oxoethane-2,1-diyl))bis(propane-2,1,3-triyl)tetrapelargonate (I-e2)
[0338]
[0339] To a solution of I-d2 (142.8 g, 0.344 mol) in CH2Cl2 (1.0 L) was added tert-butyl bis(2-hydroxyethyl)carbamate (33.6 g, 0.164 mol) and DMAP (20.0 g, 0.164 mol) at room temperature under nitrogen. The mixture was stirred for 10 min, then EDCl (78.7 g, 0.410 mol) was added over 10 min, and the resulting solution was stirred at room temperature for 16 hours. The reaction mixture was washed with water (2×1.2 L), the aqueous phase was extracted with CH2Cl2 (2×1.2 L), and the combined organic phases were dried over anhydrous MgSO4. After filtering to remove the solids, the solution was concentrated in vacuo to a volume of about 1.5 L and silica gel (350 g, type: ZCX-2, 100-200 mesh) was added and the mixture was concentrated in vacuo to dryness. The dried silica gel was placed on a gravity column of silica gel (2100 g, type: ZCX-2, 100-200 mesh, packed with heptane), and the resulting column was eluted with a gradient of heptane:THF (100:0 to 90:10). Compound I-e2 was eluted with heptane:THF (95:5) and the fractions of I-e2 were concentrated in vacuo to provide I-e2 as a yellow oil (143.5 g, HPLC purity 96.3%, 83% yield).
[0340] 1 H NMR (400MHz, CDCl3, ppm):d 4.21(m,4H),4.11(m,8H),3.49(m,4H),2.58(m,2H),2.43(d,J=6.90Hz,4H),2.31(t,J =7.60Hz,8H),1.66-1.59(8H),1.48(s,9H),1.20-1.39(40H),0.89(t,J=6.60Hz,12H).
[0341] When used to synthesize lipids conforming to Formula 1 or Formula 3 according to the synthetic schemes disclosed herein, I-e2 produces lipids in which R is a linear C8, while Ie produces lipids in which R is a linear C9.
[0342] Example 10.
[0343] Synthesis of bis(2-((4-(nonanoyloxy)-3-((nonanoyloxy)methyl)butanoyl)oxy)ethyl)amine trifluoroacetate (I-f2)
[0344]
[0345] To a solution of I-e2 (143.0 g, 0.137 mol) in CH2Cl2 (850 mL) was added TFA (286 mL, 3.74 mol) at room temperature under nitrogen over 30 min. After the addition was complete, the mixture was stirred for 5 h, then the solution was poured into 10% aqueous K2HPO4 (1.40 L) and water (0.70 L). The organic phase was dried (MgSO4), filtered and concentrated in vacuo to give the ammonium salt 6 as a yellow oil (140.5 g, HPLC purity 89%, 87% yield).
[0346] 1 H NMR (400MHz, CDCl3, ppm):d 4.79(m,4H),4.20(m,4H),4.10(m,4H),3.46(m,4H),2.55(m,2H),2.42(d,J=7.10Hz,4 H), 2.34 (t, J = 7.60Hz, 8H), 1.62 (m, 8H), 1.21-1.38 (40H), 0.90 (m, 12H); LCMS (+ mode): C 50 H 92 NO 12 Calculated value: 898.66. Measured value: 899.0.
[0347] When used to synthesize lipids conforming to Formula 1 or Formula 3 according to the synthetic schemes disclosed herein, I-e2 produces lipids in which R is a linear C8, while Ie produces lipids in which R is a linear C9.
[0348] Example 11.
[0349] Synthesis of ((((((1H-imidazole-1-carbonyl)azanediyl)bis(ethane-2,1-diyl))bis(oxy))bis(2-oxoethane-2,1-diyl))bis(propane-2,1,3-triyl)tetrapelargonate (I-g2)
[0350]
[0351] At room temperature under nitrogen, carbonyl diimidazole (CDI) (79.8 g, 0.493 mol) and EtN (25.2 g, 0.246 mol) were added to a solution of I-f2 (130.0 g, 0.123 mol) in CHCl (1.30 L) in sequence. The resulting solution was stirred at room temperature for 3 hours. HPLC analysis showed that the reaction was not complete, and additional CDI (39.9 g, 0.246 mol) and EtN (14.6 g, 0.123 mol) were added. The solution was stirred at room temperature for 14 hours, and then the mixture was poured into an aqueous solution of HCl (0.8 M, 1.30 L). The organic phase was separated, and the aqueous phase was extracted with CHCl (1.30 L). The combined organic phases were concentrated in vacuo to obtain the crude product I-g2 as a yellow oil, which was dissolved in heptane (1.30 L). The heptane solution was washed with MeOH-H2O (5:1, 2 x 0.65 L) and brine (0.65 L). The heptane solution was dried (MgSO4), the solids were removed by filtration, and the filtrate was concentrated in vacuo to give 7 (122.0 g, HPLC purity 83.3%, 83% yield) as a viscous yellow oil.
[0352] 1 H NMR (400MHz, CDCl3, ppm):d 7.99(s,1H),7.31(s,1H),7.14(s,1H),4.32(m,4H),4.12(m,8H),3.77(m,4H),2.55(m,2H),2 .42(d,J=6.90Hz,4H),2.31(m,8H),1.62(m,8H),1.21-1.33(40H),0.90(m,12H); LCMS(+ mode):C 54 H 93 N3O 13 Calculated value: 991.67. Measured value: 993.0.
[0353] Example 12.
[0354] Synthesis of 1-(bis(2-((4-(nonanoyloxy)-3-((nonanoyloxy)methyl)butanoyl)oxy)ethyl)carbamoyl)-3-methyl-1H-imidazol-3-ium trifluoromethanesulfonate (I-h2)
[0355]
[0356] Acyl-imidazole I-g2 (18.0 g, 18.2 mmol) was dissolved in CH2Cl2 (270 mL) under nitrogen and cooled in an ice-water bath. Methyl trifluoromethanesulfonate (MeOTf) (3.30 g, 20.0 mmol) was added to the cooled I-g2 solution within 15 min. The resulting solution was stirred at 0°C for 1 hour and then proceeded to obtain the target lipid (see below). HPLC and LCMS showed that I-g2 was completely consumed.
[0357] Example 13. Synthesis of Compound A-11
[0358]
[0359] To the I-h2 solution cooled in an ice-water bath under nitrogen prepared by I-g2 (20.2mmol) as described above, tetramethylethylenediamine (11.70g, 100.8mmol) and 2-dimethylamino-ethanol (3.60g, 40.3mmol) were added successively. The mixture was stirred at 0°C for 1 hour, then warmed to room temperature and stirred for 18 hours. The solution was concentrated in vacuo, and the residue was dissolved in ethyl acetate (300mL). The solution was washed with 10% citric acid aqueous solution (2×300mL), the organic phase was separated, and the aqueous phase was extracted with ethyl acetate (300mL). The organic phases merged were washed with 5% NaHCO3 aqueous solution (300mL), brine (300mL) and dried (MgSO4). The solid was removed by filtration and silica gel (40g, type: ZCX-2, 100-200 mesh) was added to the solution, and the mixture was concentrated to dryness in vacuo. The dried silica gel was placed on a gravity column of silica gel (200 g, type: ZCX-2, 100-200 mesh, filled with CH2Cl2), and the resulting column was eluted with a gradient of CH2Cl2: MeOH (100:0 to 90:10). Compound A-11 was eluted with CH2Cl2: MeOH 95:5, and the fractions of compound A-11 were concentrated in vacuo to provide compound A-11 as a yellow oil (12.0 g, HPLC purity 88%). Compound A-11 was further purified by reverse phase flash chromatography (WelFlash XSelect CSH Prep C18, 5 mm OBD, Regular 30×150 mm column; solvent: A: 0.1% formic acid in water, B: acetonitrile, gradient 50-80%, 20 min, flow rate 55 ml / min). The cut containing compound A-11 is merged, and concentrated in vacuum, and the residue is dissolved in heptane (150mL). The heptane solution is washed with MeOH / water (75:25, 100mL) and salt solution (100mL). The organic phase is dried (Na2SO4), the solid is removed by filtration, and the filtrate is concentrated in vacuum to obtain compound A-11 (10.15g, HPLC purity 97.8%, 49% yield), which is a yellow oil.
[0360] 1 H NMR (400MHz, CDCl3, ppm):d 4.20(m,6H),4.09(m,8H),3.54(m,4H),2.55(m,4H),2.41(d,J=6.90Hz,4H),2.25 -2.32(14H),1.61(m,8H),1.20-1.34(40H),0.88(t,J=6.70Hz,12H); LCMS(+ mode):C 55 H 100 N2O14 +H + Calculated value: 1013.72. Found: 1013.80 [M+H + ].
[0361] Example 14. Synthesis of Compound A-12
[0362]
[0363] To the I-h2 solution cooled in an ice-water bath under nitrogen prepared by I-g2 (18.2mmol) as described above, tetramethylethylenediamine (6.30g, 54.4mmol) and 3-dimethylamino-propanol (2.20g, 21.8mmol) were added successively. The mixture was stirred at 0°C for 1 hour, then warmed to room temperature and stirred for 18 hours. The solution was concentrated in vacuo, and the residue was dissolved in ethyl acetate (300mL). The solution was washed with 10% citric acid aqueous solution (2×300mL), the organic phase was separated, and the aqueous phase was extracted with ethyl acetate (300mL). The organic phases merged were washed with 5% NaHCO3 aqueous solution (300mL), brine (300mL) and dried (MgSO4). The solid was removed by filtration and silica gel (36g, type: ZCX-2, 100-200 mesh) was added to the solution, and the mixture was concentrated to dryness in vacuo. The dried silica gel was placed on a gravity column of silica gel (180 g, type: ZCX-2, 100-200 mesh, filled with CH2Cl2), and the resulting column was eluted with a gradient of CH2Cl2: MeOH (100:0 to 90:10). Compound A-12 was eluted with CH2Cl2: MeOH 95:5, and the fractions of compound A-12 were concentrated in vacuo to provide compound A-12 as a yellow oil (11.2 g, HPLC purity 85%). Compound A-12 was further purified by reverse phase flash chromatography (WelFlashXSelect CSH Prep C18, 5 mm OBD, Regular 30×150 mm column; solvent: A: 0.1% formic acid in water, B: acetonitrile, gradient 50-80%, 20 min, flow rate 55 ml / min). The cut containing compound A-12 is merged, and concentrated in vacuum, and the residue is dissolved in heptane (150mL). By heptane solution 5% NaCO aqueous solution (100mL), MeOH / water (75:25, 100mL) and salt solution (100mL) washing. Organic phase is dried (NaSO), solids are removed by filtration, and the filtrate is concentrated in vacuum to obtain compound A-12 (10.22g, HPLC purity 96.8%, 48% yield), which is a yellow oil.
[0364] 1H NMR (400MHz, CDCl3, ppm):d 4.06-4.23(14H),3.53(m,4H),2.55(m,2H),2.41(d,J=6.90Hz,6H),2.27-2.32(14H), 1.85(m,2H),1.57-1.62(8H),1.20-1.35(40H),0.88(t,J=6.80Hz,12H); LCMS(+ mode):C 56 H 102 N2O 14 +H + Calculated value: 1027.74. Found: 1027.90 [M+H + ].
[0365] Example 15. Synthesis of Compound A-13
[0366]
[0367] To the I-h2 solution cooled in an ice-water bath under nitrogen prepared by I-g2 (22.0mmol) as described above, triethylamine (6.72g, 66.0mmol) and 2-dimethylamino-ethylamine (2.34g, 26.0mmol) were added successively. The mixture was stirred at 0°C for 1 hour, then warmed to room temperature and stirred for 18 hours. The solution was concentrated in vacuo, and the residue was dissolved in ethyl acetate (600mL). The solution was washed with 5% Na2CO3 aqueous solution (2×300mL), salt solution (300mL) and dried (MgSO4). The solid was removed by filtration and silica gel (40g, type: ZCX-2, 100-200 mesh) was added to the solution, and the mixture was concentrated to dryness in vacuo. The dried silica gel was placed on a gravity column of silica gel (250 g, type: ZCX-2, 100-200 mesh, filled with CH2Cl2), and the resulting column was eluted with a gradient of CH2Cl2: MeOH (100:0 to 90:10). Compound A-13 was eluted with CH2Cl2: MeOH 97:3, and the fractions of compound A-13 were concentrated in vacuo to provide compound A-13 as a yellow oil (18.0 g, HPLC purity 83%). Compound A-13 was further purified by reverse phase flash chromatography (WelFlash XSelect CSHPrep C18, 5 mm OBD, Regular 30×150 mm column; solvent: A: 0.1% formic acid in water, B: acetonitrile, gradient 50-80%, 20 min, flow rate 55 ml / min). The fractions containing compound A-13 are combined and concentrated in vacuo, and the residue is dissolved in heptane (150 mL). The heptane solution is washed with saturated NaHO aqueous solution (200 mL), MeOH / water (80:20, 2 × 200 mL) and saline (200 mL). The organic phase is dried (Na2SO4), the solid is removed by filtration, and the filtrate is concentrated in vacuo to obtain compound A-13 (10.58 g, HPLC purity 95.5%, 47% yield), which is a yellow oil.
[0368] 1 H NMR (300MHz, CDCl3, ppm):d 5.50(brs,1H),4.22(t,J=6.00Hz,4H),4.03-4.20(8H),3.52(m,4H),3.30(m,2H),2.56(m,2H), 2.32-2.46(6H),2.20-2.32(14H),2.50-2.65(8H),1.15-1.32(40H),0.88(m,12H); LCMS(+ mode):C 54 H 101 N3O 13+H + Calculated value: 1012.74. Found: 1012.80 [M+H + ].
[0369] Example 16. Synthesis of Compound A-14
[0370]
[0371] To the I-h2 solution cooled in an ice-water bath under nitrogen prepared by I-g2 (22.0mmol) as described above, triethylamine (6.72g, 66.0mmol) and N,N,N'-trimethylethylenediamine (2.71g, 26.0mmol) were added successively. The mixture was stirred at 0°C for 1 hour, then warmed to room temperature and stirred for 18 hours. The solution was concentrated in vacuo, and the residue was dissolved in ethyl acetate (600mL). The solution was washed with 10% citric acid aqueous solution (2×300mL), 5% Na2CO3 aqueous solution (2×300mL), brine (300mL) and dried (MgSO4). The solid was removed by filtration and silica gel (40g, type: ZCX-2, 100-200 mesh) was added to the solution, and the mixture was concentrated to dryness in vacuo. The dried silica gel was placed on a gravity column of silica gel (250 g, type: ZCX-2, 100-200 mesh, filled with CH2Cl2), and the resulting column was eluted with a gradient of CH2Cl2: MeOH (100:0 to 90:10). Compound A-14 was eluted with CH2Cl2: MeOH 97:3, and the fractions of compound A-14 were concentrated in vacuo to provide compound A-14 as a yellow oil (18.0 g, HPLC purity 88%). Compound A-14 was further purified by reverse phase flash chromatography (WelFlash XSelect CSH Prep C18, 5 mm OBD, Regular 30×150 mm column; solvent: A: 0.1% formic acid in water, B: acetonitrile, gradient 50-80%, 20 min, flow rate 55 ml / min). The fractions containing compound A-14 are merged, and concentrated in vacuo, and the residue is dissolved in heptane (500mL). The heptane solution is washed with saturated NaHO aqueous solution (500mL), MeOH / water (80:20, 2×200mL) and saline (200mL). The organic phase is dried (Na 2 SO 4 ), the solid is removed by filtration, and the filtrate is concentrated in vacuo to obtain compound A-14 (10.37 g, HPLC purity 96.6%, 46% yield), which is a yellow oil.
[0372] 1H NMR (300MHz, CDCl3, ppm):d 4.21(t,J=6.00Hz,4H),4.04-4.17(8H),3.42(t,J=6.00Hz,4H),3.30(t,J=6.90Hz,2H),2.87(s,3H),2 .30-2.60(8H),2.10-2.27(14H),1.59(m,8H),1.14-1.30(40H),0.88(t,J=6.90Hz,12H); LCMS(+ mode):C 56 H 103 N3O 13 +H + Calculated value: 1026.76. Found: 1027.00 [M+H + ].
[0373] Example 17.
[0374] Synthesis of 2-(2-(tert-Butoxy)-2-oxoethyl)propane-1,3-diylbis(decanoate) (Ic)
[0375]
[0376] To a solution of Ib (30.0 g, 0.16 mol) in CH2Cl2 (300 mL) was added capric acid (54.3 g, 0.32 mol) and DMAP (77.10 g, 0.63 mol) in sequence under nitrogen. The mixture was stirred at room temperature for 10 min, and then EDCl (66.7 g, 0.36 mol) was added in one portion. The mixture was stirred at room temperature for 16 hours, and then the solvent was removed in vacuo to provide the crude product Ic as a viscous yellow oil. The crude product Ic was dissolved in MTBE (450 mL), and the organic phase was extracted with 1% aqueous citric acid solution (2×300 mL). The combined aqueous phases were extracted with MTBE (2×300 mL), and the combined organic phases were washed with brine (450 mL) and dried (Na2SO4). The solids were removed by filtration, and the filtrate was concentrated in vacuo to give the crude product Ic as a yellow oil. The crude product Ic is dissolved in ethyl acetate (250mL), and silica gel (90g, type: ZCX-2, 100-200 mesh) is added to the solution. The solvent is removed in vacuo to obtain the crude product Ic impregnated on silica gel. The dried silica gel is placed on a gravity column of silica gel (900g, type: ZCX-2, 100-200 mesh, filled with petroleum ether), and the resulting column is eluted with a gradient of petroleum ether: ethyl acetate (100:0 to 95:5). Compound Ic is eluted with petroleum ether: ethyl acetate (98:2) and the fractions of Ic are concentrated in vacuo to provide Ic as a light pink oil (49.8g, HPLC purity 98.6%, 92% yield).
[0377] 1 H NMR (400MHz, CDCl3, ppm): d 4.11(m,4H),2.53(m,1H),2.32(m,6H),1.63(m,4H),1.49(s,9H),1.20-1.30(24H),0.90(m,6H).
[0378] Example 18.
[0379] Synthesis of 4-(Decanyloxy)-3-((Decanyloxy)methyl)butanoic acid Id
[0380]
[0381] To a solution of Ic (49.0 g, 98.2 mmol) in CHCl (400 mL) was added trifluoroacetic acid (TFA) (147 mL, 1.92 mol) at room temperature under nitrogen over 30 min. The resulting solution was stirred at room temperature for 16 h and then concentrated in vacuo to provide the crude product Id as a yellow oil. The crude product Id was dissolved in CHCl (500 mL) and the solution was washed with water (2×0.250 L). The combined aqueous phases were extracted with CHCl (0.25 L) and the combined organic layers were washed with 2% aqueous NaHCO (250 mL) and dried over anhydrous MgSO. Filtration and concentration in vacuo gave Id as a milky white solid (42.0 g, 95.6 mol, 99% yield, HPLC purity 98.5%).
[0382] 1 H NMR (400MHz, CDCl3, ppm):d 4.13(m,4H),2.58(m,1H),2.49(d,J=6.90Hz,2H),2.32(t,J=7.60Hz,4H),1.63(m,4H),1.36-1.22(24H),0.89(t,J=6.70Hz,6H); LCMS (+ mode): C 25 H 46 O6+H + Calculated value: 443.34. Measured value: 443.30.
[0383] Example 19.
[0384] Synthesis of ((((((tert-Butoxycarbonyl)azanediyl)bis(ethane-2,1-diyl))bis(oxy))bis(2-oxoethane-2,1-diyl))bis(propane-2,1,3-triyl)tetrakis(decanoate) Ie
[0385]
[0386] To a solution of tert-butyl bis(2-hydroxyethyl)carbamate (7.50 g, 36.6 mmol) in CH2Cl2 (225 mL) was added Id (34.00 g, 76.8 mmol) and DMAP (4.50 g, 36.6 mmol) in sequence at room temperature under nitrogen. The mixture was stirred for 10 min, then EDCl (17.60 g, 91.5 mmol) was added over 10 min, and the resulting solution was stirred at room temperature for 16 h. The reaction mixture was washed with water (2×300 mL), the aqueous phase was extracted with CH2Cl2 (2×300 mL), and the combined organic phases were dried over anhydrous MgSO4. After filtering to remove the solids, silica gel (187.5 g, type: ZCX-2, 100-200 mesh) was added to the filtrate, and the mixture was concentrated to dryness in vacuo. The dried silica gel was placed on a gravity column of silica gel (1125 g, type: ZCX-2, 100-200 mesh, packed with heptane), and the resulting column was eluted with a gradient of heptane:THF (100:0 to 90:10). Compound Ie was eluted with heptane:THF (95:5) and the fractions of Ie were concentrated in vacuo to provide Ie as a yellow oil (25.50 g, HPLC purity 91%, 60% yield).
[0387] 1 H NMR (400MHz, CDCl3, ppm):d 4.20(m,4H),4.12(m,8H),3.49(m,4H),2.58(m,2H),2.43(d,J=7.00Hz,4H),2.31 (t,J=7.60Hz,8H),1.66-1.59(8H),1.48(s,9H),1.21-1.39(48H),0.89(m,12H).
[0388] Example 20. Synthesis of bis(2-((4-(decanoyloxy)-3-((decanoyloxy)methyl)butanoyl)oxy)ethyl)ammonium trifluoroacetate (If)
[0389]
[0390] To a solution of Ie (27.00 g, 23.3 mmol) in CH2Cl2 (150 mL) was added TFA (54.0 mL, 0.71 mol) at room temperature under nitrogen over 30 min. After the addition was complete, the mixture was stirred for 5 h, then the solution was washed with 10% aqueous K2HPO4 (270 mL) and water (2×135 mL). The organic phase was dried (MgSO4), filtered and concentrated in vacuo to give the ammonium salt If as a yellow oil (25.50 g, HPLC purity 88%, 90% yield).
[0391] 1 H NMR (400MHz, CDCl3, ppm):d 4.43(m,4H),4.12(m,8H),3.40(m,4H),2.54(m,2H),2.42(m,4H),2.32(m, 8H), 1.61 (m, 8H), 1.20-1.37 (48H), 0.89 (t, J = 6.70Hz, 12H); LCMS (+ mode): C 54 H 100 NO 12 Calculated value: 954.72. Measured value: 955.00.
[0392] Example 21.
[0393] Synthesis of ((((((1H-imidazole-1-carbonyl)azanediyl)bis(ethane-2,1-diyl))bis(oxy))bis(2-oxoethane-2,1-diyl))bis(propane-2,1,3-triyl)tetra(decanoate) Ig
[0394]
[0395] To a solution of If (25.00 g, 22.1 mmol) in CH2Cl2 (250 mL) was added carbonyldiimidazole (CDI) (14.40 g, 88.6 mol) and Et3N (4.50 g, 44.3 mol) at room temperature under nitrogen. The resulting solution was stirred at room temperature for 3 hours. HPLC analysis showed that the reaction was not complete, and additional CDI (14.4 g, 88.6 mmol) and Et3N (4.50 g, 44.3 mol) were added. The solution was stirred at room temperature for 14 hours, and then the mixture was poured into an aqueous solution of HCl (0.8 M, 250 mL). The organic phase was separated and the aqueous phase was extracted with CH2Cl2 (250 mL). The combined organic phases were concentrated in vacuo to give the crude product 1 g as a yellow oil, which was dissolved in heptane (250 mL). The heptane solution was washed with MeOH-H2O (5:1, 2 x 125 mL) and brine (125 mL). The heptane solution was dried (MgSO4), the solids were removed by filtration, and the filtrate was concentrated in vacuo to give 1 g (23.40 g, HPLC purity 79.8%, 80% yield) as a viscous light yellow oil.
[0396] 1H NMR (400MHz, CDCl3, ppm):d 7.98(s,1H),7.30(s,1H),7.13(s,1H),4.32(m,4H),4.11(m,8H),3.76(m,4H),2.54(m,2H),2 .41(d,J=6.90Hz,4H),2.30(m,8H),1.60(m,8H),1.18-1.32(48H),0.89(m,12H); LCMS(+ mode):C 58 H 101 N3O 13 +H + Calculated value: 1048.74. Measured value: 1049.10.
[0397] Example 22. Synthesis of 1-(bis(2-((4-(decanoyloxy)-3-((decanoyloxy)methyl)butanoyl)oxy)ethyl)carbamoyl)-3-methyl-1H-imidazol-3-ium trifluoromethanesulfonate (Ih)
[0398]
[0399] Acyl-imidazole Ig (20.0 g, 18.2 mmol) was dissolved in CH2Cl2 (300 mL) under nitrogen and cooled in an ice-water bath. MeOTf (4.50 g, 27.3 mmol) was added to the cooled Ig solution over 15 min. The resulting solution was stirred at 0°C for 1 hour and then carried out to obtain the target lipid (see below). HPLC and LCMS showed complete consumption of Ig.
[0400] LCMS (+ mode): C 59 H 104 N3O 13 Calculated value: 1062.76. Measured value: 1063.00.
[0401] Example 23. Synthesis of Compound A-2
[0402]
[0403] Triethylamine (5.50g, 54.7mmol) and 3-dimethylaminopropylamine (2.80g, 27.3mmol) are added successively to the 1h solution cooled in an ice-water bath under nitrogen prepared by 1g (18.2mmol) as described above. The mixture is stirred at 0°C for 1 hour, then warmed to room temperature and stirred for 18 hours. The solution is concentrated in vacuo, and the residue is dissolved in heptane (600mL). The solution is washed with MeOH / H2O (80:20, 2×150mL), brine (150mL) and dried (MgSO4). The solid is removed by filtration, and the filtrate is concentrated in vacuo to provide a crude product compound A-2, which is a viscous yellow oil. The crude product is dissolved in ethyl acetate (300mL) and washed with 5% Na2CO3 aqueous solution (2×300mL), brine (300mL) and dried (MgSO4). Solids are removed by filtration and silica gel (40g, type: ZCX-2, 100-200 mesh) is added to the solution, and the mixture is concentrated to dryness in vacuum. Dry silica gel is placed on the gravity column (200g, type: ZCX-2, 100-200 mesh, is filled with CH2Cl2) of silica gel, and the gradient elution of gained column CH2Cl2: MeOH (100:0 to 90:10). Use CH2Cl2: MeOH 95:5 wash-out compound A-2, and the cut of compound A-2 is concentrated in vacuum, to provide compound A-2, is yellow oil (12.5g). Compound A-2 is dissolved in heptane (150mL), washed with MeOH / H2O (80:20, 2 × 150mL), brine (150mL) and dried (MgSO4). The solids were removed by filtration and the filtrate was concentrated in vacuo to provide compound A-2 as a light yellow oil (11.96 g, HPLC purity 94%, 57% yield).
[0404] 1 H NMR (400MHz, CDCl3, ppm):d 6.61(m,1H),4.20(t,J=6,.40Hz,4H),4.10(m,8H),3.49(t,J=6.00Hz,4H),3.32(m,2H),2.46-2.56(4H ),2.41(m,4H),2.23-2.32(14H),1.73(m,2H),1.59(m,8H),1.19-1.34(48H),0.89(t,J=6.70Hz,12H60 LCMS(+mode):C 56 H 111 N3O 13 +H + Calculated value: 1082.82. Found: 1083.00 [M+H + ].
[0405] Example 24. Synthesis of Compound A-15
[0406]
[0407] To the I-h2 solution cooled in an ice-water bath under nitrogen prepared by I-g2 (15.12mmol) as described above, triethylamine (4.60g, 45.36mmol) and N,N,N'-trimethylpropylenediamine (2.63g, 22.68mmol) were added successively. The mixture was stirred at 0°C for 1 hour, then warmed to room temperature and stirred for 18 hours. The mixture was poured into water (750mL) and the organic phase was separated. The aqueous phase was extracted with CH2Cl2 (2×300mL), and the combined organic phase was washed with brine (300mL) and dried (Na2SO4). The solid was removed by filtration and silica gel (30g, type: ZCX-2, 100-200 mesh) was added to the filtrate, and the mixture was concentrated to dryness in vacuo. The dried silica gel is placed on a gravity column of silica gel (150 g, type: ZCX-2, 100-200 mesh, filled with heptane), and the resulting column is eluted with a gradient of heptane: ethyl acetate (100:0 to 0:100). Compound A-15 is eluted with heptane: ethyl acetate 70:30 and the fractions of compound A-15 are concentrated in vacuo to provide compound A-15 as a yellow oil (12.0 g, HPLC purity 88%). Compound A-15 is further purified by reverse phase flash chromatography (WelFlash XSelect CSHPrep C18, 5 mm OBD, Regular 30×150 mm column; solvent: A: 0.05% formic acid in water, B: acetonitrile, gradient 50-80%, 20 min, flow rate 55 ml / min). The fractions containing compound A-15 are combined and concentrated in vacuo, and the residue is dissolved in heptane (150 mL). The heptane solution was washed with MeOH / water (80:20, 2×100 mL) and brine (100 mL). The organic phase was dried (MgSO ), the solids were removed by filtration, and the filtrate was concentrated in vacuo to give compound A-15 (10.33 g, HPLC purity 93%, 66% yield) as a light yellow oil.
[0408] 1H NMR (300MHz, CDCl3, ppm):d 4.20(t,J=6.00Hz,4H),4.04-4.14(8H),3.41(t,J=6.00Hz,4H),3.20(t,J=7.20Hz,2H),2.83(s,3H), 2.52(m,2H),2.20-2.40(20H),1.74(m,2H),1.60(m,8H),1.14-1.32(40H),0.90(m,12H); LCMS(+ mode):C 57 H 105 N3O 13 +H + Calculated value: 1040.77. Found: 1040.90 [M+H + ].
[0409] Example 25.
[0410] Synthesis of tert-butyl (3-(2-methoxyethoxy)propyl)(methyl)carbamate (V-5a)
[0411]
[0412] To THF (160mL) suspension of NaH (62%, in oil, 10.1g, 6.22g, 0.259mol) cooled in ice-water bath under nitrogen, THF (160mL) solution of (3-hydroxypropyl) (methyl) tert-butyl carbamate (40.0g, 0.216mol) was added in 1 hour. After addition was completed, the mixture was stirred for 1 hour, then THF (280ml) solution of 2-methoxyethyl methanesulfonate (39.10g, 0.254mol) was added in 1 hour. After addition was completed, the mixture was heated to 80 ℃ and stirred for 18 hours. Then the mixture was cooled to room temperature and quenched by carefully adding saturated NH in 1 hour Cl (500mL) aqueous solution. The mixture was poured into ethyl acetate (500mL), separated organic phase. The aqueous phase is extracted with ethyl acetate (2×500mL), and the organic phase combined is washed with salt water (1.5L) and dried (Na2SO4). Filter and vacuum concentrate the filtrate to obtain crude product V-5a (27.0g), which is a yellow liquid. The crude product is dissolved in CH2Cl2 (200mL) and silica gel (50g, type: ZCX-2, 100-200 mesh) is added to the filtrate, and the mixture is vacuum concentrated to dryness. Dry silica gel is placed on a silica gel gravity column (500g, type: ZCX-2, 100-200 mesh, filled and eluted with CH2Cl2). The fraction containing V-5a is concentrated in a vacuum to provide V-5a, which is a yellow oil (10.0g, 41.0mmol, 19%).
[0413] 1 H NMR (400 MHz, CD3OD, ppm): d 3.33-3.73 (6H), 3.39 (s, 3H), 3.29 (t, J=7.00 Hz, 2H), 2.85 (s, 3H), 1.82 (m, 2H), 1.46 (s, 9H); LCMS (+ mode): C 12 H 25 NO4+H + Calculated value: 248.19. Found: 248.20 [M+H + ].
[0414] Example 26.
[0415] Synthesis of 3-(2-methoxyethoxy)-N-methylpropane-1-ammonium chloride (V-6a)
[0416]
[0417] To a solution of V-5a (17.0 g, 68.7 mmol) in dioxane (350 mL) was added a solution of HCl in dioxane (2 M, 350 mL) under nitrogen at room temperature over 30 min. The solution was stirred at room temperature for 10 hours, and then the solvent was removed in vacuo to provide the crude product V-6a (13.0 g) as a yellow oil. The crude product V-6a was used without purification.
[0418] LCMS (+ mode): Calculated value for C7185NO2: 148.13. Found: 148.30.
[0419] Example 27. Synthesis of tert-butyl (3-((3-(2-methoxyethoxy)propyl)(methyl)amino)propyl)(methyl)carbamate (V-7a)
[0420]
[0421] Under nitrogen, methyl (3-oxopropyl) carbamic acid tert-butyl ester (20.99g, 112mmol) was added once to a solution of V-6a (15.00g, 81.7mmol) in dichloromethane (180mL). The mixture was stirred at room temperature for 30min, and then NaBH (OAc) (43.26g, 204mmol) was added in batches within 20min. The solution was stirred at room temperature for 2 hours, and then water (200mL) was added, and the pH of the solution was adjusted to pH=8 by adding saturated NaCO aqueous solution. The mixture was extracted with CHCl (3×200mL) and the combined organic phase was dried (NaSO). The solid was removed by filtration and silica gel (40g, type: ZCX-2, 100-200 mesh) was added to the filtrate, and the mixture was concentrated to dryness in vacuo. The dried silica gel was placed on a gravity column of silica gel (500 g, type: ZCX-2, 100-200 mesh, packed with CH2Cl2, eluted with a gradient of CH2Cl2:MeOH 100:0 to 90:10). The fractions containing V-7a were concentrated in vacuo (CH2Cl2:MeOH 95:5) to provide V-7a as a yellow oil (8.0 g, 25.1 mmol, 31%).
[0422] 1 H NMR (400 MHz, CDCl3, ppm): d 3.20-3.65 (14H), 2.86 (m, 4H), 1.62-1.85 (6H), 1.48 (s, 9H); LCMS (+ mode): C 16 H 34 N2O4+H + Calculated value: 319.26. Found: 319.40 [M+H + ].
[0423] Example 28. Synthesis of 3-((3-(2-methoxyethoxy)propyl)(methyl)amino)-N-methylpropane-1-ammonium chloride (V-8a)
[0424]
[0425] To a solution of V-7a (1.00 g, 3.14 mmol) in dioxane (20 mL) was added a solution of HCl in dioxane (2M, 20 mL) at room temperature under nitrogen over 5 min. The resulting solution was stirred at room temperature for 10 h, and then the solvent was removed in vacuo to give the crude product V-8a (800 mg) as a white solid. The crude product 18 was used without further purification.
[0426] 1H NMR (400MHz, CDCl3, ppm): d 10.92(brs,1H),9.75(brs,2H),3.00-3.62(15H),2.94(brs,3H),2.76(brs,3H),2.53(brm,2H),2.17(brm,2H); LCMS(+ mode):C 11 H 27 Calculated value of N2O2: 219.21. Measured value: 219.20.
[0427] Example 29. Synthesis of bis(2-((tert-butyldimethylsilyl)oxy)ethyl)amine (V-12)
[0428]
[0429] To a solution of diethanolamine (100.00 g, 0.952 mol) in dichloromethane (1.0 L) was added imidazole (194.0 g, 2.86 mol) at room temperature under nitrogen, and the resulting solution was stirred for 5 min. To the mixture was added a solution of tert-butyldimethylsilyl chloride (316.3 g, 2.10 mol) in dichloromethane (1.0 L) over 30 min. The resulting solution was stirred at room temperature for 2 hours, then the reaction was quenched by the addition of 10% aqueous NH4OH (400 mL). The organic phase was separated, the aqueous phase was extracted with dichloromethane (2×600 mL), and the combined organic phases were washed with saturated aqueous NH4Cl (5×800 mL), brine (800 mL) and dried (Na2SO4). Filtration and concentration in vacuo afforded V-12 (300.0 g, 0.899 mol, 94%) as a clear, colorless oil.
[0430] 1 H NMR (400MHz, CDCl3, ppm): d 3.75 (t, J = 5.30Hz, 4H), 2.74 (t, J = 5.30Hz, 4H), 2.03 (brs, 1H), 0.91 (s, 18H), 0.07 (s, 12H); LCMS (+ mode): C 16 H 19 NO2Si2+H + Calculated value: 334.26. Measured value: 334.40.
[0431] Example 30. Synthesis of N,N-bis(2-((tert-butyldimethylsilyl)oxy)ethyl)-1H-imidazole-1-carboxamide (V-13)
[0432]
[0433] To a solution of V-12 (230.0 g, 0.690 mol) in dichloromethane (2.30 L) was added CDI (446.20 g, 2.75 mol) and Et3N (139.10 g, 1.38 mol) in sequence at room temperature under nitrogen. The resulting solution was stirred at room temperature for 16 hours, and then the mixture was poured into water (2.30 L). The organic phase was separated, the aqueous layer was extracted with dichloromethane (1.15 L), and the combined organic phases were washed with saturated aqueous NH4Cl solution (2×4.6 L), 5% aqueous NaHCO3 solution (4.6 L) and dried (Na2SO4). Filtration and concentration in vacuo gave the crude product V-13 as a yellow oil, which was dissolved in heptane (250 mL). The solution was washed with MeOH / H2O (80:20, 1.15 L) and dried (MgSO4). Filtration and concentration in vacuo afforded V-13 (270.0 g, 0.631 mol, 91%) as a light yellow oil.
[0434] 1 H NMR (400MHz, CDCl3, ppm):d 8.06(t,J=1.10Hz,1H),7.42(t,J=1.40Hz,1H),7.07(dd,J=1.40,1.10Hz,1H),3.85 (t, J=5.30Hz, 4H), 3.64 (t, J=5.30Hz, 4H), 0.89 (s, 18H), 0.08 (s, 12H); LCMS (+ mode): C 20 H 41 N3O3Si2+H + Calculated value: 428.28. Measured value: 428.30.
[0435] Example 31. 1,1-bis(2-((tert-butyldimethylsilyl)oxy)ethyl)-3-(3-
[0436] Synthesis of ((3-(2-methoxyethoxy)propyl)(methyl)amino)propyl)-3-methylurea (V-14)
[0437]
[0438] To a solution of V-13 (20.0 g, 48 mmol) in dichloromethane (200 mL) cooled in an ice-water bath under nitrogen, MeOTf (8.40 g, 51.0 mmol) was added within 5 min. The resulting mixture was stirred at 0 ° C for 1 hour, and then a solution of Et3N (14.0 g, 140 mmol) and V-8a (17.80 g, 70 mmol) in dichloromethane (200 mL) was added to the solution within 30 min. After the addition was complete, the mixture was warmed to room temperature and stirred for 16 hours. The reaction mixture was poured into water (200 mL) and the organic phase was removed. The aqueous layer was extracted with dichloromethane (2×200 mL) and the combined organic phases were concentrated in vacuo. The resulting crude product V-14 was dissolved in heptane (300 mL), and the solution was extracted with MeOH / H2O (75:25, 2×100 ml). The aqueous phase merged is extracted with heptane (6 × 200mL), and the organic phase merged is washed with brine (400mL). The organic phase is dried (MgSO4). After filtration, silica gel (60g, type: ZCX-2, 100-200 mesh) is added in the filtrate, and the mixture is concentrated in vacuo to dryness. Dry silica gel is placed on the gravity column of silica gel (330g, type: ZCX-2, 100-200 mesh, filled with CH2Cl2, with CH2Cl2 / MeOH 100:0 to 90:10 gradient elution). The cut containing V-14 (CH2Cl2 / MeOH 93:7) is concentrated in vacuo to provide V-14, which is a yellow oil (11.15g, 22.0mmol, 46%).
[0439] 1 H NMR (400MHz, CDCl3, ppm):d 3.72(t,J=6.20Hz,4H),3.48-3.60(6H),3.40(s,3H),3.33(t,J=6.20Hz,4H),3.17(t,J=7.50Hz,2H),2 .83(s,3H),2.31-2.50(4H),2.26(brs,3H),1.70-1.83(4H),0.90(s,18H),0.06(s,12H); LCMS(+ mode):C 28 H 63 N3O5Si2+H + Calculated value: 578.44. Measured value: 578.30.
[0440] Example 32.1,1-bis(2-hydroxyethyl)-3-(3-((3-(2-methoxyethoxy)propyl)
[0441] Synthesis of (methyl)amino)propyl)-3-methylurea (V-15)
[0442]
[0443] To a solution of V-14 (11.15 g, 22.0 mmol) in THF (125 mL) was added BF3-OEt2 (8.20 mL, 9.40 g, 66.0 mmol) under nitrogen at room temperature over 10 min. The mixture was stirred at room temperature for 16 hours and then poured into water (100 mL). The pH of the solution was adjusted to pH = 8.0 by adding saturated aqueous NaHCO3, and the solvent was removed in vacuo to a volume of about 25 ml. The retained solution was purified by reverse phase flash chromatography (WelFlash AQ-C18 gel, Regular 120 g, A: water, B: acetonitrile, gradient 0-30% over 15 min, flow rate: 80 ml / min). The target V-15 was eluted in 30% acetonitrile and the fractions containing V-15 were combined and concentrated in vacuo to provide V-15 as an off-white oil (7.38 g, 21.12 mmol, 96% yield).
[0444] 1 H NMR (400MHz, CDCl3, ppm):d 4.50(brs,2H),3.72(m,4H),3.41-3.57(6H),3.28-3.38(9H),2.82(s,3H),2. 48(m,2H),2.39(t,J=6.60Hz,2H),2.25(s,3H),1.70-1.85(4H); LCMS(+ mode):C 16 H 35 N3O5+H + Calculated value: 350.27. Measured value: 350.40.
[0445] Example 33. Synthesis of Compound A-16
[0446]
[0447] Under nitrogen at room temperature, I-d2 (17.00g, 40.9mmol), DMAP (2.30g, 18.6mmol) and EDCl (8.20g, 42.7mmol) were added successively to a solution of V-15 (6.50g, 18.6mmol) in dichloromethane (130mL). The resulting solution was stirred at room temperature for 16 hours and then poured into water (100mL). The organic phase was separated, the aqueous phase was extracted with dichloromethane (2×100ml), and the combined organic phase was concentrated in vacuo. The resulting crude compound A-16 was dissolved in heptane (150mL), and the resulting solution was washed with MeOH / water (80:20, 100mL), brine (100mL) and dried (Na2SO4). The solid was removed by filtration and silica gel (25g, type: ZCX-2, 100-200 mesh) was added to the filtrate, and the mixture was concentrated to dryness in vacuo. The dried silica gel is placed on a gravity column of silica gel (175 g, type: ZCX-2, 100-200 mesh, filled with CH2Cl2, eluted with a gradient of CH2Cl2 / MeOH 100:0 to 90:10). The fraction containing compound A-16 (CH2Cl2 / MeOH 95:5) is concentrated in vacuo to provide compound A-16 (HPLC purity is 94%) as a yellow oil. Compound A-16 is further purified by reverse phase flash chromatography (WelFlashXSelect CSH Prep C18, 5mm OBD, Regular 30×150mm column; solvent: A: 0.1% formic acid in water, B: acetonitrile, gradient 50-80%, 20min, flow rate 55ml / min). The fractions containing compound A-16 are combined and concentrated in vacuo, and the residue is dissolved in heptane (150mL). The heptane solution was washed with 5% aqueous NaCO (2×100 mL), MeOH / water (75:25, 2×100 mL), and brine (100 mL). The organic phase was dried (Na 2 SO 4 ), the solids were removed by filtration, and the filtrate was concentrated in vacuo to give compound A-16 (12.08 g, HPLC purity 96.4%, 51% yield) as a yellow oil.
[0448] 1H NMR (400MHz, CDCl3, ppm):d 4.19(t,J=6.00Hz,4H),4.08(m,8H),3-46-3.60(6H),3.41(t,J=6.00Hz,4H),3.37(s,3H),3.17(m,2H),2.82(s,3H),2.53(m,2H ),2.35-2.42(6H),2.24-2.33(10H),2.19(s,3H),1.66-1.80(4H),1.54-1.65(8H),1.20-1.36(40H),0.89(m,12H); LCMS(+ mode):C 62 H 115 N3O 15 +H + Calculated value: 1142.84. Measured value: 1142.90.
[0449] Example 34. Biophysical and biochemical characteristics
[0450] The biophysical and biochemical characteristics of clogD, c-pKa, pKa, and in vitro stability in mouse plasma of compounds A-2 and A-11 to A-15 and three benchmark lipids known to successfully deliver nucleic acids to cells 10a, 10f, and 10p were determined (see Journal of Medicinal Chemistry 63: 12992-13012, 2020).
[0451] Table 5
[0452]
[0453] *Calculated using ACD Labs Structure Designer v12.0. ClogP component of cLogD calculated using ACD Labs version B; cLogD calculated at pH = 7.4.
[0454] *Difference between calculated and measured pKa
[0455] #Journal of Medicinal Chemistry 63:12992-13012, 2020, the entire contents of which are incorporated herein by reference, teach ionizable cationic lipids and LNPs comprising them, which are not contradictory or inconsistent with the present disclosure.
[0456] cLogD and c-pKa were calculated as described above.The measured pKa of lipids as formulated in lipid nanoparticles was determined using the TNS assay as described in the Examples below.
[0457] Past experience leads to the expectation that the difference between the c-pKa and the measured pKa in LNPs (ΔpKa) will be 2 to 3 units; however, surprisingly, all compounds A-2 and A-11 to A-15 have a ΔpKa of less than 2. The activity of ionizable amino lipids for promoting endosomal escape of nucleic acid cargoes is generally greatest for lipids with pKas of 6 to 7. Of the disclosed lipids tested in this example, only compound A-11 had a pKa observed in this range. One way to reduce the measured basicity of these lipids to a preferred range for good endosomal escape activity is to increase the chain length of the fatty acid tail (R of Formula I) by 1 to 4 carbons each. Table 6 shows the structures of analogs of compounds A-2 and A-12 to A-15 and their analogs with extended R groups (C of compound A-2). 10 -C 13 and C9-C 12 ) calculated cLogD and c-pKa. In each case, the increase in cLogD reflects the increase in lipophilicity as the R length increases, but the c-pKa remains the same. However, when incorporated into LNPs, the increased lipophilicity will result in a decrease in the measured pKa of the lipid and an increase in ΔpKa.
[0458] Table 6
[0459]
[0460]
[0461]
[0462]
[0463]
[0464]
[0465]
[0466] In order to determine the stability of the disclosed lipids in mouse plasma, lipid stock solutions were prepared by dissolving the lipids in isopropanol at a concentration of 5 mg / mL. The lipid-isopropanol solution of the required volume was then diluted to a concentration of 100 μM with a total volume of 1.0 mL using 50:50 (v / v) ethanol / water. 10 microliters of this 100 μM solution were added to 1.0 mL of mouse plasma (BioIVT, Lot MSE394920, CD-1 mice, anticoagulant: heparin sodium, unfiltered), which was preheated to 37 ° C and stirred at 50 rpm with a magnetic stirring bar. Therefore, the initial concentration of lipids in plasma was 1 μM. Aliquots (50 μL) were taken out after 0, 15, 30, 45, 60 and 120 min, transferred to microcentrifuge tubes and quenched with three volumes (150 μL) of ice-cold acetonitrile / methanol (4:1). The positive control incubation used the same plasma, using Benflurex (1 μM) as a substrate and Labetalol (1.0 μg l) as in situ disappearance. The quenched solution was vortexed, centrifuged at 13,000 rpm for 5 min, and the supernatant (100 μL) was transferred to a 96-well plate and diluted with water (200 μL, 0.1% FA). After filtering through a 0.45 μm 96-well filter plate, the filtrate was analyzed by LC-MS (Waters AQUITY I-class UPLC system, ThermoScientific Vanquish UPLC system (consisting of a binary pump, an autosampler, and a column chamber), a Waters Xevo G2-XSQTof mass spectrometer; Phenomenex F5, 1.7 μm, 2.1×50 mm column). Mobile phase A was an aqueous solution of 0.1% formic acid, and mobile phase B was an acetonitrile solution of 0.1% formic acid. The flow rate was 0.6 mL / min. The elution gradient was as follows: time, 0.5 min: 20% B; 0.5-2 min: 20-100% B; 2-4.8 min: 100% B; 4.8-5.45 min: 100-20% B. The mass spectrometer was in positive scan mode from 600 to 1100 m / z. The molecular ion peaks of lipids were integrated in the extracted ion chromatogram (XIC) using Xcalibur software (Thermo Fisher). After normalization by the peak area of the internal standard, the relative peak area compared to T=0 was used as the percentage of lipid remaining at each time point. T was calculated using the first-order decay model. 1 / 2 value.
[0467] All compounds A-2 and A-11 to A-15 were significantly degraded in mouse plasma, comparable to the benchmark 10f, but different from the rapidly degrading 10a and the extremely stable 10p. Even compound A-11 (the slowest degradation of the tested compounds) had a half-life of <10 hours, indicating that it can be administered several times a week without problematic accumulation. Although these data only record the disappearance of the initial compound, these lipids are designed to have multiple ester bonds to promote further degradation into species that can be easily eliminated from the body without the need for oxidative metabolism in the liver.
[0468] Example 35. LNP Encapsulation of mRNA
[0469] The ability of various published ionizable cationic lipids to be incorporated into LNPs to encapsulate mRNA was evaluated using mRNA encoding the fluorescent marker mCherry.
[0470] mCherry mRNA was synthesized by T7 RNA polymerase-mediated in vitro transcription (IVT) of a linearized DNA template, using N1-methyl pseudouridine to completely replace uridine. A Cap1 structure was co-transcriptionally added to the 5' end of the mRNA, and the 3' polyadenosine tail was encoded by the DNA template. After IVT, the mRNA was purified using a two-step chromatography method using OligoDT affinity chemistry for bulk capture and ion-pair reverse phase chemistry to remove residual impurities.
[0471] The mRNA was encapsulated in LNP using a self-assembly method, wherein an mRNA aqueous solution of pH=3.5 was rapidly mixed with a lipid solution dissolved in ethanol, followed by dilution with phosphate and Tris buffer and tangential flow filtration (TFF) purification. The LNP composition in this study was: ionizable cationic lipid / distearylphosphatidylcholine / cholesterol / DMG-PEG2000 (50:10:38.5:1.5 mol / mol), and encapsulated with an N / P ratio of 6 (the ratio of positively charged lipid amine (N=nitrogen) groups to negatively charged nucleic acid phosphate (P) groups). The LNP was frozen at -80°C. LNP was prepared, wherein the ionizable cationic lipid was one of compounds A-2, A-11, A-12, A-13, A-14 or A-15. The diameter of the nanoparticles was measured by dynamic light scattering using a Zetasizer Nano ZS (Malvern Instruments Ltd., Malvern, UK) instrument. Size measurements were performed in Tris buffer at pH 7.4 at 25° C. in associated disposable capillary cuvettes. Size measurements were performed using a non-invasive backscattering system (NIBS) with a scattering angle of 173°.
[0472] Table 7. Physicochemical properties of LNP
[0473]
[0474] *Polydispersity index
[0475] All of these ionizable cationic lipids formed LNPs with generally acceptable sizes and good encapsulation efficiencies. Compound A-13 LNPs showed the greatest size uniformity.
[0476] Example 36. Transfection of HEK293F cells
[0477] The LNPs formed in the previous examples were evaluated for their ability to transfect HEK293F cells (a human embryonic kidney cell derived cell line) with mCherry mRNA. Virus producer cells (Gibco catalog number: A35347) are a derivative of the HEK 293F cell line adapted to chemically defined serum-free and protein-free medium (LV-MAX TM Production medium; Gibco catalog number: A3583401), which was grown in suspension, settled, and cultured at approximately 1×10 6 The cells / mL were resuspended, and 200 μL were assigned to the wells of 96-well U-bottom plates. Frozen LNPs were thawed and diluted to 100 μg mRNA / mL with sterile water for injection. Appropriate volume of LNP was added to provide 0, 0.3, 0.6 or 2 μg RNA per well, in duplicate, and mixed by pipetting again. The cells were then incubated at 37 °C for 1 hour in a CO2 incubator, washed three times with phosphate buffered saline, resuspended in 400 μL culture medium in a deep well 96-well plate, and incubated at 37 °C in a CO2 incubator on an orbital shaker at 900 RPM.
[0478] 24 hours after adding LNPs to cells, they were stained with Aqua Live / Dead (Thermo: Cat. L34965) to assess cell viability. Transfection efficiency and expression levels in transfected cells were assessed by flow cytometry based on mCherry fluorescence. Figure 5A As can be seen in the Figures, except for compound A-11, all LNPs caused a reduction in cell number compared to untransfected cells even at the lowest dose tested, and some LNPs caused almost complete cell killing at higher doses. Compound A-11 caused only a small reduction in cell number even at the highest dose tested.
[0479] exist Figure 5BAs can be seen in Figure 12, all LNPs achieve a robust transfection frequency of ≥80% in live cells, except for compound A-11, which is close to 50% transfection rate only at the highest dose tested. Expression levels are variable and there is no definite pattern (Figure 12C). LNPs containing compounds A-2, A-12, A-13, A-14, and A-15 are all more basic (more positively charged) than A-11, which is related to their different abilities to transfect HEK293F cells.
[0480] Example 37. Incorporation of ionizable lipids into tLNPs
[0481] Each of compounds A-2 and A-11 to A-15 and benchmark lipids 10a, 10f and 10p was incorporated into tLNPs packaging mRNA encoding fluorescent protein mCherry and the physicochemical properties were measured. The results are presented in Table 6 below.
[0482] mCherry 5-methoxyuridine (5moU) mRNA (L-7203) was purchased from Trilink. mRNA was encapsulated in LNPs using a self-assembly method, in which an aqueous solution of mRNA at pH = 3.5 was quickly mixed with a lipid solution dissolved in ethanol, followed by gradual dilution of phosphate and Tris buffers and TFF purification. The LNP composition in this study was: ionizable cationic lipids / distearoylphosphatidylcholine / cholesterol / DMG-PEG2000 / distearoylphosphatidylethanolamine (DSPE)-PEG2000-maleimide (50:10:38.5:1.4:0.1mol / mol), and encapsulated with an N / P ratio of 6 (the ratio of positively charged polymer amine (N = nitrogen) groups to negatively charged nucleic acid phosphate (P) groups). The hydrodynamic diameter of the nanoparticles was measured by dynamic light scattering using a Zetasizer Nano ZS (Malvern Instruments Ltd., Malvern, UK) instrument.
[0483] Next, anti-CD5 mAb was conjugated to the above LNPs to produce tLNPs. Purified rat anti-mouse CD5 antibody clone 53-7.3 (Biolegend) was coupled to LNPs via N-succinimidyl S-acetylthioacetate (SATA)-maleimide conjugation chemistry. In brief, LNPs incorporating DSPE-PEG (2000)-maleimide were prepared and stored at 4 °C on the day of conjugation. Antibodies were modified with SATA (Sigma-Aldrich) to introduce sulfhydryl groups at accessible lysine residues, thereby allowing conjugation to maleimide. SATA was deprotected using 0.5M hydroxylamine, and unreacted components were then removed by G-25 Sephadex Quick Spin Protein columns (Roche Applied Science, Indianapolis, IN). The reactive sulfhydryl groups on the antibody were then conjugated to the maleimide moieties on the LNPs using thioether conjugation chemistry. Purification was performed using a Sepharose CL-4B gel filtration column (Sigma-Aldrich). The tLNP (LNP conjugated to the targeting antibody) was frozen at -80°C. Others have conjugated antibodies to free functionalized PEG-lipids and then incorporated the conjugated lipids into preformed LNPs. However, we have found that this method is more controllable and produces more consistent results.
[0484] Using Quant-iT TM RiboGreen RNA Assay Kit (Invitrogen TM ) The mRNA content was determined by measuring the fluorescence intensity (Fi) when the RiboGreen reagent was added to the LNPs and comparing this value with the total fluorescence intensity (Ft) of the RNA content obtained by lysing the LNPs with 1% Triton X-100, where % encapsulation = (Ft-Fi) / Ft×100), thereby calculating the encapsulation efficiency.
[0485] The particle size (hydrodynamic diameter) and polydispersity index of the target lipid nanoparticles were determined using dynamic light scattering (DLS) on a Malvern Zetasizer Nano ZS (Malvern Instruments, Worcestershire, UK). Size measurements were performed in a Tris buffer at pH 7.4 at 25°C in a relevant disposable capillary sample cell. Size measurements were performed using a non-invasive backscattering system (NIBS) with a scattering angle of 173°.
[0486] The apparent pKa of ionizable lipids in lipid nanoparticles was determined using 6-(p-toluidinyl)-2-naphthalenesulfonic acid sodium salt (TNS salt, Toronto Research Chemicals, Toronto, ON, Canada). The lipid nanoparticles were diluted to a concentration of 1 mM total lipid in 1x Dulbecco's PBS. The TNS salt was prepared as a 1 mg / mL stock solution in DMSO and then further diluted to a working solution of 60 μg / mL (179 mM) using distilled water. The diluted lipid nanoparticle sample was further diluted to 90 μM total lipid in 165 μL of a buffer solution containing 10 mM HEPES, 10 mM MES, 10 mM ammonium acetate, 130 mM NaCl, and the final TNS concentration was 1.33 μg / mL (4 μM) with a pH range of 3.5 to 12.2. After pipetting mixing and incubation for 15 min at room temperature in the dark, fluorescence intensity was measured at room temperature in a BioTek Synergy H1 plate reader using excitation and emission wavelengths of 321 and 445 nm, respectively. The fluorescence signal was blank-subtracted and plotted as a function of pH and then analyzed using nonlinear (Boltzmann) regression analysis, and the apparent pKa was determined as the pH that produced half-maximal fluorescence intensity, which was calculated by the Henderson-Hasselbalch equation.
[0487] The tLNP prepared in this example is based on a reasonable conventional lipid composition, plus a functionalized PEG-lipid for conjugating a targeting moiety and an ionizable cationic lipid disclosed herein. Conventional compositions provide a good platform for evaluating the contribution of ionizable lipids to tLNP properties and a baseline for evaluating further optimization of the overall composition. As seen in Table 7, all tLNPs incorporating compounds A-2 or A-11 to A-15 have a hydrodynamic diameter and polydispersity index within an acceptable range of 50-150nm, and PDI≤0.2. It is acceptable when the encapsulation rate is ≥80%, although ≥85% and ≥90% are preferred. All test compounds exceed the ≥90% threshold (although 10a of one of the benchmark lipids is not exceeded).
[0488] Table 8. Physicochemical properties of LNP
[0489]
[0490] *Journal of Medicinal Chemistry 63:12992-13012,2020
[0491] **Polydispersity index
[0492] Example 38. In vitro targeted transfection of T cells
[0493] To evaluate the performance of the tLNPs described in Example 35, they were used to transfect mouse T cells in tissue culture. Mouse spleen T cells were isolated from mechanically dissociated mouse spleens using a standard T cell isolation kit (Stem Cell Technologies #19851). The isolated T cells were cultured in complete RPMI medium supplemented with mouse interleukin-2 in the presence of CD3 / CD28 T cell activation beads (Gibco #11453D) for 3 days. After activation, the T cells were magnetically separated from the activation beads and cultured at 2×10 5 The concentration of cells / well was transferred to 100 μL complete RPMI medium in a 96-well plate. The tLNP formulation described in Example 35 (above) was diluted to 100 μg / mL, and 6 μL (0.6 μg) of tLNP was added to each well of the cells to be tested. The cells were incubated with tLNP at 37°C for 1 hour, and then the tLNP was washed away by centrifuging the plate, removing the supernatant and replacing fresh culture medium. The transfected cells were then returned to the incubator overnight. The next day, the cells were washed and resuspended in a staining buffer containing fluorescently labeled antibodies for T cell markers for 30 minutes before the last wash. After washing, the cells were resuspended in staining buffer and run on a Novocyte Quanteon flow cytometer to detect mCherry expression and mouse T cell markers. CD3 + T cell results Figure 6 shown.
[0494] exist Figure 6 As can be seen in the Figures, tLNPs incorporating compound A-11 and benchmark lipid 10p gave robust and comparable results, with transfection efficiencies of about or exceeding 80% and high expression levels. Transfection with tLNPs incorporating compounds A-12 to A-15 or benchmark lipids 10a and 10f all resulted in similar expression levels, lower than A-11 and 10p, but still significant. The transfection efficiency varied between about 20% and about 60%. By comparison, the results of tLNPs incorporating compound A-2 were poorer, but still positive. The excellent performance of compound A-11 among the disclosed compounds tested herein is related to the fact that it is the only one of those compounds with a measured pKa of 6 to 7. However, the performance of the other compounds was not associated with the size outside the preferred range of their measured pKa, indicating that other factors dominate outside this range.
[0495] Example 39. In vivo targeted transfection of T cells
[0496] In order to evaluate the performance of the tLNP described in Example 35, they are used to transfect mouse T cells by injecting tLNP into live mice, and evaluate their ability to produce mouse T cells expressing mCherry reporter genes in vivo. All tLNP test products were thawed at room temperature for 30 minutes, and then diluted with sterile water for injection at 1:2 to achieve a final dose concentration of 100 μg / mL. Each test product of 100 μL (10 μg) was then injected into 8-week-old female C57B1 / 6 mice via the tail vein. All treated mice were then killed 24 hours after treatment and their spleens were collected. Each spleen was then dissociated into a single cell suspension and stained with antibodies to identify T cells, B cells, monocytes and non-hematopoietic cells. The mCherry expression of the stained samples in immune cell subsets and non-hematopoietic cells was then analyzed by flow cytometry. Data analysis was performed using FlowJo (version 10.8.1) and GraphPad Prism (9.4.1).
[0497] exist Figure 7 As can be seen in the Figure, compared with in vitro, the transfection rate and the level of mCherry expression are greatly reduced. Compared with adding tLNP to the wells of the tissue culture plate, this can be expected from the lower effective dose after applying tLNP to the live animal. The tLNP mixed with compound A-11 performs significantly better than any other tLNP, with a transfection rate of about 7%, and the MFI is significantly higher than other tLNP. The tLNP mixed with three benchmark lipids performs comparable to each other with a transfection rate of about 2%, while the tLNP mixed with other test compounds is not significantly different from the background. Surprisingly, among the compounds tested in this article, only compound A-11 has a measured pKa of 6 to 7, but in view of this, the poor performance of compounds A-2 and A-12 to A-15 is not unexpected. The tLNP mixed with compound A-11 performs significantly better than the tLNP mixed with benchmark lipids (whose measured pKa is indeed 6 to 7), which confirms that pKa is not the only performance determining factor.
[0498] Example 40. Further embodiments
[0499] Further embodiments are disclosed herein.
[0500] Embodiment 1. An ionizable cationic lipid having a structure of Formula 1,
[0501]
[0502] wherein Y is O, NH, N-CH3 or CH2,
[0503] n is an integer from 0 to 4,
[0504] X is
[0505]
[0506] m is an integer from 1 to 3,
[0507] o is an integer from 1 to 4,
[0508] p is an integer from 1 to 4,
[0509] When p=1, each R is independently C6 to C 16 Straight chain alkyl; C6 to C 16 Branched alkyl; C6 to C 16 Straight chain alkenyl; C6 to C 16 Branched alkenyl; C9 to C 16 Cycloalkyl-alkyl, wherein the cycloalkyl is a C3 to C8 cycloalkyl located at the end of the alkyl chain or within the alkyl chain; or a C8 to C 18 Aryl-alkyl, wherein the aryl group is phenyl or naphthyl and is located at the end of the alkyl chain or within the alkyl chain,
[0510] When p=2, each R is independently C6 to C 14 Straight chain alkyl; C6 to C 14 Straight chain alkenyl; C6 to C 14 Branched alkyl; C6 to C 14 Branched alkenyl; C9 to C 14 Cycloalkyl-alkyl, wherein the cycloalkyl is a C3 to C8 cycloalkyl located at the end of the alkyl chain or within the alkyl chain; a C8 to C 16 Aryl-alkyl, wherein the aryl group is phenyl or naphthyl and is located at the end of the alkyl chain or within the alkyl chain,
[0511] When p=3, each R is independently C6 to C 12 Straight chain alkyl; C6 to C 12 Straight chain alkenyl; C6 to C 12 Branched alkyl; C6 to C 12 Branched alkenyl; C9 to C 12 Cycloalkyl-alkyl, wherein the cycloalkyl is a C3 to C8 cycloalkyl located at the end of the alkyl chain or within the alkyl chain; a C8 to C 14 Aryl-alkyl, wherein the aryl group is phenyl or naphthyl and is located at the end of the alkyl chain or within the alkyl chain, and
[0512] When p=4, each R is independently C6 to C 10 Straight chain alkyl; C6 to C 10 Straight chain alkenyl; C6 to C 10 Branched alkyl; C6 to C 10 Branched alkenyl; C9 to C 10Cycloalkyl-alkyl, wherein the cycloalkyl is a C3 to C8 cycloalkyl located at the end of the alkyl or within the alkyl; C8 to C 12 Aryl-alkyl, wherein the aryl group is phenyl or naphthyl and is located at the end of the alkyl chain or within the alkyl chain.
[0513] Embodiment 2. An ionizable cationic lipid having a structure of Formula 2,
[0514]
[0515] wherein Y is O, NH, N-CH3 or CH2,
[0516] n is an integer from 0 to 4,
[0517] X is
[0518]
[0519] m is an integer from 1 to 3,
[0520] o is an integer from 1 to 4,
[0521] p is an integer from 1 to 4,
[0522] When p=1, each R is independently C6 to C 16 Straight chain alkyl; C6 to C 16 Straight chain alkenyl; C6 to C 16 Branched alkyl; C6 to C 16 Branched alkenyl; C9 to C 16 Cycloalkyl-alkyl, wherein the cycloalkyl is a C3 to C8 cycloalkyl located at the end of the alkyl chain or within the alkyl chain; or a C8 to C 18 Aryl-alkyl, wherein the aryl group is phenyl or naphthyl and is located at the end of the alkyl chain or within the alkyl chain,
[0523] When p=2, each R is independently C6 to C 14 Straight chain alkyl; C6 to C 14 Straight chain alkenyl; C6 to C 14 Branched alkyl; C6 to C 14 Branched alkenyl; C9 to C 14 Cycloalkyl-alkyl, wherein the cycloalkyl is a C3 to C8 cycloalkyl located at the end of the alkyl chain or within the alkyl chain; or a C8 to C 16 Aryl-alkyl, wherein the aryl group is phenyl or naphthyl and is located at the end of the alkyl chain or within the alkyl chain,
[0524] When p=3, each R is independently C6 to C 12 Straight chain alkyl; C6 to C 12 Straight chain alkenyl; C6 to C 12Branched alkyl; branched C6 to C 12 Alkenyl; C9 to C 12 Cycloalkyl-alkyl, wherein the cycloalkyl is a C3 to C8 cycloalkyl located at the end of the alkyl chain or within the alkyl chain; or a C8 to C 14 Aryl-alkyl, wherein the aryl group is phenyl or naphthyl and is located at the end of the alkyl chain or within the alkyl chain, and
[0525] When p=4, each R is independently C6 to C 10 Straight chain alkyl; Straight chain C6 to C 10 Alkenyl; C6 to C 10 Branched alkyl; C6 to C 10 Branched alkenyl; C9 to C 10 Cycloalkyl-alkyl, wherein the cycloalkyl is a C3 to C8 cycloalkyl located at the end of the alkyl or within the alkyl; or a C8 to C 12 Aryl-alkyl, wherein the aryl group is phenyl or naphthyl and is located at the end of the alkyl chain or within the alkyl chain.
[0526] Embodiment 3. An ionizable cationic lipid having a structure of Formula 3,
[0527]
[0528] Wherein W is C=O or CH2,
[0529] n is an integer from 0 to 4,
[0530] X is
[0531]
[0532] m is an integer from 1 to 3,
[0533] o is an integer from 1 to 4,
[0534] p is an integer from 1 to 4,
[0535] When p = 1, each R c Independently C8 to C 18 Straight chain alkyl; C8 to C 18 Straight chain alkenyl; C8 to C 18 Branched alkyl; C8 to C 18 Branched alkenyl; C 11 To C 18 Cycloalkyl-alkyl, wherein the cycloalkyl is a C3 to C8 cycloalkyl located at the end of the alkyl chain or within the alkyl chain; or C 10 To C 20 Aryl-alkyl, wherein the aryl group is phenyl or naphthyl and is located at the end of the alkyl chain or within the alkyl chain,
[0536] When p = 2, each R c Independently C8 to C 16 Straight chain alkyl; C8 to C 16 Straight chain alkenyl; C8 to C 16 Branched alkyl; C8 to C 16 Branched alkenyl; C 11 To C 16 Cycloalkyl-alkyl, wherein the cycloalkyl is a C3 to C8 cycloalkyl located at the end of the alkyl chain or within the alkyl chain; or C 10 To C 18 Aryl-alkyl, wherein the aryl group is phenyl or naphthyl and is located at the end of the alkyl chain or within the alkyl chain,
[0537] When p = 3, each R c Independently C8 to C 14 Straight chain alkyl; C8 to C 14 Straight chain alkenyl; C8 to C 14 Branched alkyl; C8 to C 14 Branched alkenyl; C 11 To C 14 Cycloalkyl-alkyl, wherein the cycloalkyl is a C3 to C8 cycloalkyl located at the end of the alkyl chain or within the alkyl chain; or C 10 To C 16 Aryl-alkyl, wherein the aryl group is phenyl or naphthyl and is located at the end of the alkyl chain or within the alkyl chain, and
[0538] When p = 4, each R c Independently C8 to C 12 Straight chain alkyl; C8 to C 12 Straight chain alkenyl; C8 to C 12 Branched alkyl; C8 to C 12 Branched alkenyl; C 11 To C 12 Cycloalkyl-alkyl, wherein the cycloalkyl is a C3 to C8 cycloalkyl located at the end of the alkyl or within the alkyl; or C 10 To C 14 Aryl-alkyl, wherein the aryl group is phenyl or naphthyl and is located at the end of the alkyl chain or within the alkyl chain.
[0539] Embodiment 4. The ionizable cationic lipid of embodiment 1 or 2, wherein Y is O.
[0540] Embodiment 5. The ionizable cationic lipid of embodiment 1 or 2, wherein Y is NH.
[0541] Embodiment 6. An ionizable cationic lipid as described in embodiment 1 or 2, wherein Y is N-CH3.
[0542] Embodiment 7. An ionizable cationic lipid as described in embodiment 1 or 2, wherein Y is CH2.
[0543] Embodiment 8. The ionizable cationic lipid of embodiment 1 or 2, wherein X is
[0544] Embodiment 9. The ionizable cationic lipid of embodiment 3, wherein W is C═O.
[0545] Embodiment 10. An ionizable cationic lipid as described in any one of embodiments 1 to 9, which comprises R or R being a linear alkyl group c .
[0546] Embodiment 11. An ionizable cationic lipid as described in any one of embodiments 1 to 9, comprising R or R being a linear alkenyl group. c .
[0547] Embodiment 12. An ionizable cationic lipid as described in any one of embodiments 1 to 9, which comprises R or R being a branched alkyl group. c .
[0548] Embodiment 13. The ionizable cationic lipid of any one of embodiments 1 to 9, comprising R which is a branched alkenyl group.
[0549] Embodiment 14. An ionizable cationic lipid as described in any one of embodiments 1 to 9, comprising R or R being a cycloalkyl-alkyl group. c .
[0550] Embodiment 15. An ionizable cationic lipid as described in any one of embodiments 1 to 9, comprising R or R being an aryl-alkyl group. c .
[0551] Embodiment 16. An ionizable cationic lipid as described in any one of embodiments 1 to 9, wherein each R or R c The groups are the same.
[0552] Embodiment 17. An ionizable cationic lipid as described in any one of embodiments 1 to 15, wherein R or R derived from the first branch point c The groups are the same and originate from R or R at the second branch point c Same group, but originating from the first branch point R or R c The group is different from R or R originating from the second branch point c Group.
[0553] Embodiment 18. A lipid nanoparticle (LNP) comprising the ionizable cationic lipid of any one of embodiments 1 to 17.
[0554] Embodiment 19. The LNP of embodiment 18, further comprising one or more of phospholipids, sterols, co-lipids and PEG-lipids, or a combination thereof.
[0555] Embodiment 20. The LNP of embodiment 18, wherein the phospholipid comprises dioleoylphosphatidylethanolamine (DOPE), dimyristoylphosphatidylcholine (DMPC), distearoylphosphatidylcholine (DSPC), dimyristoylphosphatidylglycerol (DMPG), dipalmitoylphosphatidylcholine (DPPC) or 1,2-arachidonoylphosphatidylcholine (DAPC) or a combination thereof.
[0556] Embodiment 21. The LNP of embodiment 18 or 19, wherein the sterol comprises cholesterol, campesterol, sitosterol, or stigmasterol, or a combination thereof.
[0557] Embodiment 22. The LNP of any one of embodiments 18 to 21, wherein the co-lipid comprises cholesterol hemisuccinate (CHEMS) or a lipid containing a quaternary ammonium head group.
[0558] Embodiment 23. An LNP as described in embodiment 22, wherein the lipid containing a quaternary ammonium head group comprises 1,2-dioleoyl-3-trimethylammonium propane (DOTAP), N-(1-(2,3-dioleoyloxy)propyl)-N,N,N-trimethylammonium (DOTMA) or 3β-(N-(N',N'-dimethylaminoethane)carbamoyl)cholesterol (DC-Chol) or a combination thereof.
[0559] Embodiment 24. The LNP of any one of embodiments 18 to 23, wherein the PEG-lipid comprises a PEG portion having a molecular weight (MW) of 1000-5000 Da.
[0560] Embodiment 25. An LNP as described in any one of embodiments 18 to 24, wherein the PEG-lipid comprises a 14 -C 18 Fatty acids with a fatty acid chain length.
[0561] Embodiment 26. The LNP of any one of embodiments 18 to 25, wherein the PEG-lipid comprises DMG-PEG2000 (1,2-dimyristoyl-glycerol-3-methoxypolyethylene glycol-2000), DPG-PEG2000 (1,2-dipalmitoyl-glycerol-3-methoxypolyethylene glycol-2000), DSG-PEG2000 (1,2-distearoyl-glycerol-3-methoxypolyethylene glycol-2000), DOG-PEG2000 (1,2-dioleoyl-glycerol-3-methoxypolyethylene glycol-2000) , DMPE-PEG200 (1,2-dimyristoyl-glycero-3-phosphoethanolamine-3-methoxypolyethylene glycol-2000), DPPE-PEG2000 (1,2-dipalmitoyl-glycero-3-phosphoethanolamine-3-methoxypolyethylene glycol-2000), DSPE-PEG2000 (1,2-distearoyl-glycero-3-phosphoethanolamine-3-methoxypolyethylene glycol-2000), DOPE-PEG2000 (1,2-dioleoyl-glycero-3-phosphoethanolamine-3-methoxypolyethylene glycol-2000) or a combination thereof.
[0562] Embodiment 27. The LNP of any one of embodiments 18 to 26, wherein the PEG-lipid comprises an optically pure glycerol moiety.
[0563] Embodiment 28. The LNP of any one of embodiments 18 to 27, further comprising a functionalized PEG-lipid.
[0564] Embodiment 29. The LNP of embodiment 28, wherein the functionalized PEG-lipid has been conjugated to a binding moiety.
[0565] Embodiment 30. The LNP of Embodiment 29, wherein the binding moiety comprises an antigen binding domain of an antibody.
[0566] Embodiment 31. An LNP as described in any one of embodiments 28 to 30, wherein the functionalized PEG-lipid comprises a C 16 -C 18 Fatty acids with a fatty acid chain length.
[0567] Embodiment 32. The LNP of embodiment 31, wherein the functionalized PEG-lipid comprises a dipalmitoyl lipid or a distearoyl lipid.
[0568] Embodiment 33. The LNP of any one of embodiments 18 to 32, comprising 40 to 60 mol% of ionizable cationic lipids.
[0569] Embodiment 34. The LNP of any one of embodiments 19 to 33, comprising 7 to 30 mol% phospholipids.
[0570] Embodiment 35. The LNP of any one of embodiments 19 to 34, comprising 20 to 45 mol% sterol.
[0571] Embodiment 36. The LNP of any one of embodiments 19 to 35, comprising 1 to 30 mol% of co-lipids.
[0572] Embodiment 37. The LNP of any one of embodiments 19 to 36, comprising 0 to 5 mol% PEG-lipid.
[0573] Embodiment 38. The LNP of any one of embodiments 19 to 37, comprising 0.1 to 5 mol% of the functionalized PEG-lipid.
[0574] Embodiment 39. The LNP of any one of embodiments 18 to 38, further comprising a nucleic acid.
[0575] Embodiment 40. The LNP of embodiment 39, wherein the weight ratio of total lipid to nucleic acid is 10:1 to 50:1.
[0576] Embodiment 41. The LNP of embodiment 39 or 40, comprising mRNA.
[0577] Embodiment 42. A method of delivering a nucleic acid into a cell, comprising contacting the cell with the LNP of any one of embodiments 39 to 41.
Claims
1. An ionizable cationic lipid having a structure of formula 1, wherein Y is O, NH, N-CH3 or CH2, n is an integer from 0 to 4, X is m is an integer from 1 to 3, o is an integer from 1 to 4, p is an integer from 1 to 4, When p=1, each R is independently C6 to C 16 Straight chain alkyl; C6 to C 16 Branched alkyl; C6 to C 16 Straight chain alkenyl; C6 to C 16 Branched alkenyl; C9 to C 16 Cycloalkyl-alkyl, wherein the cycloalkyl is a C3 to C8 cycloalkyl located at the end of the alkyl chain or within the alkyl chain; or a C8 to C 18 Aryl-alkyl, wherein the aryl group is phenyl or naphthyl and is located at the end of the alkyl chain or within the alkyl chain, When p=2, each R is independently C6 to C 14 Straight chain alkyl; C6 to C 14 Straight chain alkenyl; C6 to C 14 Branched alkyl; C6 to C 14 Branched alkenyl; C9 to C 14 Cycloalkyl-alkyl, wherein the cycloalkyl is a C3 to C8 cycloalkyl located at the end of the alkyl chain or within the alkyl chain; a C8 to C 16 Aryl-alkyl, wherein the aryl group is phenyl or naphthyl and is located at the end of the alkyl chain or within the alkyl chain, When p=3, each R is independently C6 to C 12 Straight chain alkyl; C6 to C 12 Straight chain alkenyl; C6 to C 12 Branched alkyl; C6 to C 12 Branched alkenyl; C9 to C 12 Cycloalkyl-alkyl, wherein the cycloalkyl is a C3 to C8 cycloalkyl located at the end of the alkyl chain or within the alkyl chain; a C8 to C 14 Aryl-alkyl, wherein the aryl group is phenyl or naphthyl and is located at the end of the alkyl chain or within the alkyl chain, and When p=4, each R is independently C6 to C 10 Straight chain alkyl; C6 to C 10 Straight chain alkenyl; C6 to C 10 Branched alkyl; C6 to C 10 Branched alkenyl; C9 to C 10 Cycloalkyl-alkyl, wherein the cycloalkyl is a C3 to C8 cycloalkyl located at the end of the alkyl or within the alkyl; a C8 to C 12 Aryl-alkyl, wherein the aryl group is phenyl or naphthyl and is located at the end of the alkyl chain or within the alkyl chain.
2. An ionizable cationic lipid having a structure of formula 2, wherein Y is O, NH, N-CH3 or CH2, n is an integer from 0 to 4, X is m is an integer from 1 to 3, o is an integer from 1 to 4, p is an integer from 1 to 4, When p=1, each R is independently C6 to C 16 Straight chain alkyl; C6 to C 16 Straight chain alkenyl; C6 to C 16 Branched alkyl; C6 to C 16 Branched alkenyl; C9 to C 16 Cycloalkyl-alkyl, wherein the cycloalkyl is a C3 to C8 cycloalkyl located at the end of the alkyl chain or within the alkyl chain; or a C8 to C 18 Aryl-alkyl, wherein the aryl group is phenyl or naphthyl and is located at the end of the alkyl chain or within the alkyl chain, When p=2, each R is independently C6 to C 14 Straight chain alkyl; C6 to C 14 Straight chain alkenyl; C6 to C 14 Branched alkyl; C6 to C 14 Branched alkenyl; C9 to C 14 Cycloalkyl-alkyl, wherein the cycloalkyl is a C3 to C8 cycloalkyl located at the end of the alkyl chain or within the alkyl chain; or a C8 to C 16 Aryl-alkyl, wherein the aryl group is phenyl or naphthyl and is located at the end of the alkyl chain or within the alkyl chain, When p=3, each R is independently C6 to C 12 Straight chain alkyl; C6 to C 12 Straight chain alkenyl; C6 to C 12 Branched alkyl; branched C6 to C 12 Alkenyl; C9 to C 12 Cycloalkyl-alkyl, wherein the cycloalkyl is a C3 to C8 cycloalkyl located at the end of the alkyl chain or within the alkyl chain; or a C8 to C 14 Aryl-alkyl, wherein the aryl group is phenyl or naphthyl and is located at the end of the alkyl chain or within the alkyl chain, and When p=4, each R is independently C6 to C 10 Straight chain alkyl; Straight chain C6 to C 10 Alkenyl; C6 to C 10 Branched alkyl; C6 to C 10 Branched alkenyl; C9 to C 10 Cycloalkyl-alkyl, wherein the cycloalkyl is a C3 to C8 cycloalkyl located at the end of the alkyl or within the alkyl; or a C8 to C 12 Aryl-alkyl, wherein the aryl group is phenyl or naphthyl and is located at the end of the alkyl chain or within the alkyl chain.
3. An ionizable cationic lipid having a structure of formula 3, Wherein W is C=O or CH2, n is an integer from 0 to 4, X is m is an integer from 1 to 3, o is an integer from 1 to 4, p is an integer from 1 to 4, When p = 1, each R c Independently C8 to C 18 Straight chain alkyl; C8 to C 18 Straight chain alkenyl; C8 to C 18 Branched alkyl; C8 to C 18 Branched alkenyl; C 11 To C 18 Cycloalkyl-alkyl, wherein the cycloalkyl is a C3 to C8 cycloalkyl located at the end of the alkyl chain or within the alkyl chain; or C 10 To C 20 Aryl-alkyl, wherein the aryl group is phenyl or naphthyl and is located at the end of the alkyl chain or within the alkyl chain, When p = 2, each R c Independently C8 to C 16 Straight chain alkyl; C8 to C 16 Straight chain alkenyl; C8 to C 16 Branched alkyl; C8 to C 16 Branched alkenyl; C 11 To C 16 Cycloalkyl-alkyl, wherein the cycloalkyl is a C3 to C8 cycloalkyl located at the end of the alkyl chain or within the alkyl chain; or C 10 To C 18 Aryl-alkyl, wherein the aryl group is phenyl or naphthyl and is located at the end of the alkyl chain or within the alkyl chain, When p = 3, each R c Independently C8 to C 14 Straight chain alkyl; C8 to C 14 Straight chain alkenyl; C8 to C 14 Branched alkyl; C8 to C 14 Branched alkenyl; C 11 To C 14 Cycloalkyl-alkyl, wherein the cycloalkyl is a C3 to C8 cycloalkyl located at the end of the alkyl chain or within the alkyl chain; or C 10 To C 16 Aryl-alkyl, wherein the aryl group is phenyl or naphthyl and is located at the end of the alkyl chain or within the alkyl chain, and When p = 4, each R c Independently C8 to C 12 Straight chain alkyl; C8 to C 12 Straight chain alkenyl; C8 to C 12 Branched alkyl; C8 to C 12 Branched alkenyl; C 11 To C 12 Cycloalkyl-alkyl, wherein the cycloalkyl is a C3 to C8 cycloalkyl located at the end of the alkyl or within the alkyl; or C 10 To C 14 Aryl-alkyl, wherein the aryl group is phenyl or naphthyl and is located at the end of the alkyl chain or within the alkyl chain.
4. The ionizable cationic lipid of claim 1 or 2, wherein Y is O.
5. The ionizable cationic lipid of claim 1 or 2, wherein Y is NH.
6. The ionizable cationic lipid of claim 1 or 2, wherein Y is N-CH3.
7. The ionizable cationic lipid of claim 1 or 2, wherein Y is CH2.
8. The ionizable cationic lipid of claim 1 or 2, wherein X is 9. The ionizable cationic lipid of claim 3, wherein W is C=O.
10. The ionizable cationic lipid according to any one of claims 1 to 9, comprising R or R being a straight chain alkyl group c .
11. The ionizable cationic lipid according to any one of claims 1 to 9, comprising R or R being a straight chain alkenyl group. c .
12. The ionizable cationic lipid according to any one of claims 1 to 9, comprising R or R being a branched alkyl group c .
13. The ionizable cationic lipid according to any one of claims 1 to 9, comprising R which is a branched alkenyl group.
14. The ionizable cationic lipid of any one of claims 1 to 9, comprising R or R being a cycloalkyl-alkyl group. c .
15. The ionizable cationic lipid of any one of claims 1 to 9, comprising R or R being an aryl-alkyl group. c .
16. The ionizable cationic lipid of any one of claims 1 to 15, wherein each R or R c The groups are the same.
17. The ionizable cationic lipid of any one of claims 1 to 15, wherein R or R derived from the first branch point c The groups are the same and originate from R or R at the second branch point c The groups are the same, but originate from the R or R c A group different from the R or R derived from the second branch point c Group.
18. A lipid nanoparticle (LNP) comprising the ionizable cationic lipid of any one of claims 1 to 17.
19. The LNP of claim 18, further comprising one or more of a phospholipid, a sterol, a co-lipid, and a PEG-lipid, or a combination thereof.
20. The LNP of claim 18, wherein the phospholipid comprises dioleoylphosphatidylethanolamine (DOPE), dimyristoylphosphatidylcholine (DMPC), distearoylphosphatidylcholine (DSPC), dimyristoylphosphatidylglycerol (DMPG), dipalmitoylphosphatidylcholine (DPPC) or 1,2-arachidonoylphosphatidylcholine (DAPC), or a combination thereof.
21. The LNP of claim 18 or 19, wherein the sterol comprises cholesterol, campesterol, sitosterol, or stigmasterol, or a combination thereof.
22. The LNP of any one of claims 18 to 21, wherein the co-lipid comprises cholesterol hemisuccinate (CHEMS) or a lipid containing a quaternary ammonium head group.
23. The LNP of claim 22, wherein the lipid containing a quaternary ammonium head group comprises 1,2-dioleoyl-3-trimethylammonium propane (DOTAP), N-(1-(2,3-dioleoyloxy)propyl)-N,N,N-trimethylammonium (DOTMA), or 3β-(N-(N',N'-dimethylaminoethane)carbamoyl)cholesterol (DC-Chol), or a combination thereof.
24. The LNP of any one of claims 18 to 23, wherein the PEG-lipid comprises a PEG moiety having a molecular weight (MW) of 1000-5000 Da.
25. The LNP of any one of claims 18 to 24, wherein the PEG-lipid comprises a 14 -C 18 Fatty acids with a fatty acid chain length.
26. The LNP of any one of claims 18 to 25, wherein the PEG-lipid comprises DMG-PEG2000 (1,2-dimyristoyl-glycerol-3-methoxypolyethylene glycol-2000), DPG-PEG2000 (1,2-dipalmitoyl-glycerol-3-methoxypolyethylene glycol-2000), DSG-PEG2000 (1,2-distearoyl-glycerol-3-methoxypolyethylene glycol-2000), DOG-PEG2000 (1,2-dioleoyl-glycerol-3-methoxypolyethylene glycol-2000), D MPE-PEG200 (1,2-dimyristoyl-glycero-3-phosphoethanolamine-3-methoxypolyethylene glycol-2000), DPPE-PEG2000 (1,2-dipalmitoyl-glycero-3-phosphoethanolamine-3-methoxypolyethylene glycol-2000), DSPE-PEG2000 (1,2-distearoyl-glycero-3-phosphoethanolamine-3-methoxypolyethylene glycol-2000), DOPE-PEG2000 (1,2-dioleoyl-glycero-3-phosphoethanolamine-3-methoxypolyethylene glycol-2000) or a combination thereof.
27. The LNP of any one of claims 18 to 26, wherein the PEG-lipid comprises an optically pure glycerol moiety.
28. The LNP of any one of claims 18 to 27, further comprising a functionalized PEG-lipid.
29. The LNP of claim 28, wherein the functionalized PEG-lipid has been conjugated to a binding moiety.
30. The LNP of claim 29, wherein the binding moiety comprises an antigen binding domain of an antibody.
31. The LNP of any one of claims 28 to 30, wherein the functionalized PEG-lipid comprises a C 16 -C 18 Fatty acids with a fatty acid chain length.
32. The LNP of claim 31 , wherein the functionalized PEG-lipid comprises a dipalmitoyl lipid or a distearoyl lipid.
33. The LNP of any one of claims 18 to 32, comprising 40 to 60 mol% ionizable cationic lipids.
34. The LNP of any one of claims 19 to 33 comprising 7 to 30 mol% phospholipids.
35. The LNP of any one of claims 19 to 34 comprising 20 to 45 mol% sterol.
36. The LNP of any one of claims 19 to 35, comprising 1 to 30 mol% of co-lipids.
37. The LNP of any one of claims 19 to 36, comprising 0 to 5 mol% PEG-lipid.
38. The LNP of any one of claims 19 to 37 comprising 0.1 to 5 mol% of functionalized PEG-lipid.
39. The LNP of any one of claims 18 to 38, further comprising a nucleic acid.
40. The LNP of claim 39, wherein the weight ratio of total lipid to nucleic acid is 10:1 to 50:
1.
41. The LNP of claim 39 or 40, comprising mRNA.
42. A method of delivering a nucleic acid into a cell comprising contacting the cell with the LNP of any one of claims 39 to 41.
Citation Information
Cited By
Synthesis method of DOTAP lysolipid
CN121800658A
